Prevalence of Hypertrophic Cardiomyopathy in a Gener

Circulation

92, 785-789

DOI: 10.1161/01.cir.92.4.785

Citation Report

#	Article	IF	Citations
1	Dyskinesia Associated with Chronic Antihistamine Use. New England Journal of Medicine, 1976, 294, 113-113.	27.0	13
2	TRIGGERS FOR SUDDEN CARDIAC DEATH IN THE ATHLETE. Cardiology Clinics, 1996, 14, 195-210.	2.2	46
4	The Cardiovascular Complications of Vigorous Physical Activity. Archives of Internal Medicine, 1996, 156, 2297.	3.8	65
5	Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families.. Heart, 1997, 77, 130-132.	2.9	252
6	Training Related Left Ventricular Hypertrophy in a Soldier. Journal of the Royal Army Medical Corps, 1997, 143, 118-121.	0.8	0
7	Sudden death from cardiovascular disease in young athletes: fact or fiction?. British Journal of Sports Medicine, 1997, 31, 269-276.	6.7	41
8	Epidemiology of Idiopathic Cardiomyopathies in Children and Adolescents: A Nationwide Study in Finland. American Journal of Epidemiology, 1997, 146, 385-393.	3.4	212
9	RISK PROFILES AND CARDIOVASCULAR PREPARTICIPATION SCREENING OF COMPETITIVE ATHLETES. Cardiology Clinics, 1997, 15, 473-483.	2.2	13
10	OUTER LIMITS OF THE ATHLETE'S HEART, THE EFFECT OF GENDER, AND RELEVANCE TO THE DIFFERENTIAL DIAGNOSIS WITH PRIMARY CARDIAC DISEASES. Cardiology Clinics, 1997, 15, 381-396.	2.2	76
11	The Management of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1997, 336, 775-785.	27.0	945
12	Hypertrophic cardiomyopathy. Lancet, The, 1997, 350, 127-133.	13.7	412
13	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 229-232.	1.0	1
14	Molecular Genetic Basis of Hypertrophic Cardiomyopathy:.. Journal of Cardiovascular Electrophysiology, 1998, 9, 88-99.	1.7	97
15	Heart disease and other causes of sudden death in young athletes. Current Problems in Cardiology, 1998, 23, 477-529.	2.4	20
16	Cardiac Myosin-Binding Protein C and Hypertrophic Cardiomyopathy. Trends in Cardiovascular Medicine, 1998, 8, 151-157.	4.9	11
17	Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic Research in Cardiology, 1998, 93, s013-s016.	5.9	85
18	A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated Î²-myosin heavy chain genes. Human Genetics, 1998, 102, 299-304.	3.8	68
20	Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. Journal of Molecular Medicine, 1998, 76, 208-214.	3.9	130

#	Article	IF	Citations
21	Genes and disease expression in hypertrophic cardiomyopathy. Lancet, The, 1998, 352, 1162-1163.	13.7	28
22	Hypertrophic cardiomyopathy. Evidence-based Cardiovascular Medicine, 1998, 2, 89-91.	0.0	1
23	Screening for Hypertrophic Cardiomyopathy in Young Athletes. New England Journal of Medicine, 1998, 339, 364-369.	27.0	890
24	Prevention of Cardiac Hypertrophy in Mice by Calcineurin Inhibition. Science, 1998, 281, 1690-1693.	12.6	421
25	Mutations in the Gene for Cardiac Myosin-Binding Protein C and Late-Onset Familial Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1998, 338, 1248-1257.	27.0	701
26	Sudden death in hypertrophic cardiomyopathy: potential importance of altered autonomic control of vasculature. Heart, 1998, 79, 538-540.	2.9	7
27	Cardiovascular Risks to Young Persons on the Athletic Field. Annals of Internal Medicine, 1998, 129, 379.	3.9	105
28	Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovascular Research, 1999, 44, 20-36.	3.8	163
29	Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart, 1999, 81, 141-147.	2.9	77
30	Screening for hypertrophic cardiomyopathy. Journal of Medical Screening, 1999, 6, 159-162.	2.3	0
31	Sudden cardiac death in familial hypertrophic cardiomyopathy: an Australian experience. Australian and New Zealand Journal of Medicine, 1999, 29, 368-370.	0.5	12
32	The Inheritance of Hypertrophic Cardiomyopathy. Pediatric Cardiology, 1999, 20, 313-316.	1.3	24
34	Preventing sudden death in student athletes. Comprehensive Therapy, 1999, 25, 151-154.	0.2	4
35	The Origins of Hypertrophic Cardiomyopathyâ€“Causing Mutations in Two South African Subpopulations: A Unique Profile of Both Independent and Founder Events. American Journal of Human Genetics, 1999, 65, 1308-1320.	6.2	106
36	The prevalence of left ventricular hypertrophy in elite professional footballers. International Journal of Cardiology, 1999, 71, 129-134.	1.7	20
37	SUDDEN CARDIAC DEATH IN INFANTS, CHILDREN, AND ADOLESCENTS. Pediatric Clinics of North America, 1999, 46, 221-234.	1.8	48
38	Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities11Each of the of the submitted manuscript.. Journal of the American College of Cardiology, 1999, 33, 1590-1595.	2.8	114
39	Editorial. Journal of the American College of Cardiology, 1999, 34, 1633-1636.	2.8	23

#	Article	IF	Citations
40	Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Europace, 1999, 1, 77-84.	1.7	53
41	Epidural Anesthesia for Cesarean Section in Patients with Hypertrophic CardiomyopathyÂ. Anesthesiology, 1999, 90, 1205-1207.	2.5	67
42	Genetic aspects of heart failure. European Journal of Heart Failure, 1999, 1, 121-126.	7.1	17
43	New treatment methods for patients with hypertrophic obstructive cardiomyopathy. Current Opinion in Cardiology, 2000, 15, 172-177.	1.8	18
44	Animal models of hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2000, 15, 189-196.	1.8	52
45	Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. American Journal of Medical Genetics Part A, 2000, 95, 108-117.	2.4	214
46	Electromyographic evidence of subclinical myopathy in hypertrophic cardiomyopathy. Muscle and Nerve, 2000, 23, 1856-1861.	2.2	10
47	Time-Frequency Analysis of the RT and RR Variability to Stratify Hypertrophic Cardiomyopathy Patients. Journal of Biomedical Informatics, 2000, 33, 416-430.	0.7	10
48	Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?. , 2000, 1, 41.		6
49	Molecular genetics of card iomyopathies*1. Journal of Nuclear Cardiology, 2000, 7, 159-170.	2.1	4
50	Unusual Myocardial Hypertrophy in a Young Woman. Echocardiography, 2000, 17, 451-451.	0.9	0
51	Pearls for Practice. Recognizing Young People at Risk For Sudden Cardiac Death in Preparticipation Sports Physicals. Journal of the American Academy of Nurse Practitioners, 2000, 12, 11-14.	1.4	1
52	Molecular genetics of hypertrophic cardiomyopathy. Current Cardiology Reports, 2000, 2, 134-140.	2.9	44
53	Natural history of hypertrophic cardiomyopathy. Current Cardiology Reports, 2000, 2, 141-147.	2.9	3
54	Percutaneous transluminal septal myocardial ablation. Current Cardiology Reports, 2000, 2, 160-165.	2.9	5
55	Athlete's heart and hypertrophic cardiomyopathy. Current Cardiology Reports, 2000, 2, 166-171.	2.9	23
56	Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy. Current Cardiology Reports, 2000, 2, 522-528.	2.9	11
57	Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2000, 342, 1778-1785.	27.0	998

#	Article	IF	Citations
58	Implantable Cardioverterâ€“Defibrillators in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2000, 343, 68-69.	27.0	1
59	Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?. European Heart Journal, 2000, 21, 1653-1665.	2.2	107
60	Altered Regulatory Properties of Human Cardiac Troponin I Mutants That Cause Hypertrophic Cardiomyopathy. Journal of Biological Chemistry, 2000, 275, 22069-22074.	3.4	136
61	Deletion in the Cardiac Troponin I Gene in a Family From Northern Sweden with Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2000, 32, 521-525.	1.9	35
62	Reversal of Cardiac Hypertrophy in Transgenic Disease Models by Calcineurin Inhibition. Journal of Molecular and Cellular Cardiology, 2000, 32, 697-709.	1.9	69
63	Homozygotes for a R869G Mutation in the Î² -myosin Heavy Chain Gene have a Severe Form of Familial Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2000, 32, 1575-1583.	1.9	59
64	FROM THESARCOMERE TO THENUCLEUS: Role of Genetics and Signaling in Structural Heart Disease. Annual Review of Genomics and Human Genetics, 2000, 1, 179-223.	6.2	67
66	PACING IN HYPERTROPHIC CARDIOMYOPATHY. Cardiology Clinics, 2000, 18, 67-79.	2.2	14
67	Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. Journal of the American College of Cardiology, 2000, 36, 852-855.	2.8	135
68	Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2001, 38, 322-330.	2.8	125
69	Beta-myosin Heavy Chain Gene Mutations and Hypertrophic Cardiomyopathy in Austrian Children. Journal of Molecular and Cellular Cardiology, 2001, 33, 141-148.	1.9	18
70	Manipulating the Contractile Apparatus: Genetically Defined Animal Models of Cardiovascular Disease. Journal of Molecular and Cellular Cardiology, 2001, 33, 9-25.	1.9	32
71	The Molecular Genetic Basis for Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2001, 33, 655-670.	1.9	394
72	A Polymorphic Modifier Gene Alters the Hypertrophic Response in a Murine Model of Familial Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2001, 33, 2055-2060.	1.9	59
73	Calcineurin inhibitors and the generalization of the presenting protein strategy. Advances in Protein Chemistry, 2001, 56, 253-291.	4.4	15
74	Molecular genetic basis of sudden cardiac death. Cardiovascular Pathology, 2001, 10, 283-295.	1.6	50
75	The Genetic Basis for Cardiomyopathy. Cell, 2001, 104, 557-567.	28.9	984
76	Cardiomyopathies: from genetics to the prospect of treatment. Lancet, The, 2001, 358, 1627-1637.	13.7	159

#	Article	IF	Citations
78	MiocardiopatÃa hipertrÃ³fica. Medicine, 2001, 8, 2487-2497.	0.0	0
80	Molecular Pathophysiology of Cardiomyopathies. , 2001, , 1045-1063.		2
81	Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2001, 16, 58-65.	1.8	9
82	Arrhythmia substrate and management in hypertrophic cardiomyopathy: from molecules to implantable card ioverter-defibrillators. European Heart Journal Supplements, 2001, 3, L15-L20.	0.1	4
83	Percutaneous transluminal septal myocardial ablation: A new catheter-based therapy for patients with hypertrophic obstructive cardiomyopathy. Heart Lung and Circulation, 2001, 10, 63-67.	0.4	0
84	Molecular medicine in the 21st century. Internal Medicine Journal, 2001, 31, 53-59.	0.8	18
85	Arrhythmogenic inherited heart muscle diseases in children. Journal of Electrocardiology, 2001, 34, 151-165.	0.9	12
86	Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2001, 22, 1374-1450.	2.2	699
87	Lack of Tacrolimus-Induced Cardiomyopathy. Annals of Pharmacotherapy, 2001, 35, 985-989.	1.9	21
88	A Simple Method for Assessing the Regression or Progression of Ventricular Hypertrophy in the Growing Child and Adult: the Value of Left Ventricular Wall-to-cavity Ratios. European Journal of Echocardiography, 2001, 2, 22-30.	2.3	7
89	Management strategies in hypertrophic cardiomyopathy: influence of age and morphology. European Heart Journal Supplements, 2001, 3, L10-L14.	0.1	2
90	Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations. Journal of Medical Genetics, 2001, 38, 43e-43.	3.2	70
91	Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management. European Heart Journal Supplements, 2001, 3, L43-L50.	0.1	10
92	Mutations in the gamma2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Human Molecular Genetics, 2001, 10, 1215-1220.	2.9	469
93	Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. British Heart Journal, 2002, 87, 126-130.	2.1	87
94	Apical Hypertrophic Cardiomyopathy: Clinical, Electrocardiographic, Scintigraphic, Echocardiographic, and Magnetic Resonance Imaging Findings of a Case. Journal of Cardiovascular Magnetic Resonance, 2002, 4, 291-295.	3.3	42
95	The need for European Registries in inherited cardiomyopathies. European Heart Journal, 2002, 23, 1972-1974.	2.2	3
96	Genes and their polymorphisms in mono- and multifactorial cardiomyopathies:. Pharmacogenomics, 2002, 3, 367-378.	1.3	12

#	Article	IF	Citations
97	Molecular Mechanisms of Inherited Cardiomyopathies. Physiological Reviews, 2002, 82, 945-980.	28.8	286
98	Molecular diagnosis of myocardial disease. Expert Review of Molecular Diagnostics, 2002, 2, 587-602.	3.1	18
99	Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. British Heart Journal, 2002, 87, 169-176.	2.1	183
100	Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2002, 287, 1308-20.	7.4	1,981
101	Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Cardiology in Review, 2002, 10, 173-181.	1.4	34
102	Modifier genes for hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2002, 17, 242-252.	1.8	124
103	Echocardiographic assessment of patients with hypertrophic and restrictive cardiomyopathy: imaging and echocardiography. Current Opinion in Cardiology, 2002, 17, 470-477.	1.8	14
104	The Athlete???s Heart: Remodeling, Electrocardiogram And Preparticipation Screening. Cardiology in Review, 2002, 10, 85-90.	1.4	53
105	Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochemical Journal, 2002, 362, 443.	3.7	27
106	Epidemiologic and Clinical Characteristics of Cardiomyopathies in Japan. Results From Nationwide Surveys.. Circulation Journal, 2002, 66, 323-336.	1.6	76
107	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2002, 39, 301-307.	2.8	329
108	Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin t genes in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2002, 39, 2042-2048.	2.8	222
109	Cardiomyopathies and Myofibril Abnormalities. , 2002, , 237-263.		1
111	The prevention of sudden death in hypertrophic cardiomyopathy. Expert Opinion on Pharmacotherapy, 2002, 3, 499-504.	1.8	4
112	Genetic Causes of Inherited Cardiac Hypertrophy: Robert L. Frye Lecture. Mayo Clinic Proceedings, 2002, 77, 1315-1319.	3.0	16
113	Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiological Genomics, 2002, 10, 31-44.	2.3	220
114	A reduÃ§Ã£o do gradiente na via de saÃda do ventrÃculo esquerdo pelo marcapasso DDD em pacientes com miocardiopatia hipertrÃ³fica obstrutiva. Brazilian Journal of Cardiovascular Surgery, 2002, 17, 248.	0.6	0
115	Two husbandsâ€"one disease: the broad clinical spectrum of hypertrophic cardiomyopathy. American Journal of Cardiology, 2002, 89, 899-900.	1.6	0

#	Article	IF	Citations
116	A novel TPM1 mutation in a family with hypertrophic cardiomyopathy and sudden cardiac death in childhood. American Journal of Cardiology, 2002, 90, 1123-1127.	1.6	36
118	Low-density DNA microarrays are versatile tools to screen for known mutations in hypertrophic cardiomyopathy. Human Mutation, 2002, 19, 560-569.	2.5	30
119	Paravertebral somatic nerve blocks for breast surgery in a patient with hypertrophic obstructive cardiomyopathy. Canadian Journal of Anaesthesia, 2002, 49, 571-574.	1.6	13
120	Hypertrophic Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 443-453.	0.9	84
121	Hypertrophic cardiomyopathy: Management issues in the new millennium. Current Cardiology Reports, 2002, 4, 226-232.	2.9	4
122	Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. European Journal of Human Genetics, 2002, 10, 741-748.	2.8	75
123	Sudden death in young athletes: HCM or ARVC?. Cardiovascular Drugs and Therapy, 2002, 16, 11-17.	2.6	27
124	Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot study. Journal of Medical Systems, 2002, 26, 293-300.	3.6	2
125	Arrhythmias and sudden death in hypertrophic cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 26-31.	1.0	8
126	Mechanisms of the Pathogenesis of Troponin T-Based Familial Hypertrophic Cardiomyopathy. Trends in Cardiovascular Medicine, 2003, 13, 232-237.	4.9	7
127	Screening for hypertrophic cardiomyopathy in a young male military population. American Journal of Cardiology, 2003, 91, 1021-1023.	1.6	51
128	Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clinical Genetics, 2003, 64, 339-349.	2.0	192
129	Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clinical Genetics, 2003, 63, 46-52.	2.0	46
130	Molecular Genetics of Arrhythmias and Cardiovascular Conditions Associated with Arrhythmias. Journal of Cardiovascular Electrophysiology, 2003, 14, 1259-1272.	1.7	50
131	Molecular Genetics of Arrhythmias and Cardiovascular Conditions Associated with Arrhythmias. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2194-2208.	1.2	15
132	Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Research, 2003, 13, 9-20.	12.0	66
134	Diastolic ventricular dysfunction as a marker for hypertrophic cardiomyopathy in a family with a novel alpha-tropomyosin mutation. Journal of the American Society of Echocardiography, 2003, 16, 698-702.	2.8	7
135	Sudden cardiac death. Clinics in Sports Medicine, 2003, 22, 51-66.	1.8	14

#	Article	IF	Citations
136	Doppler tissue imaging: Regional myocardial function in hypertrophic cardiomyopathy and in athlete's heart. Journal of the American Society of Echocardiography, 2003, 16, 223-232.	2.8	97
137	Cardiovascular Disease. New England Journal of Medicine, 2003, 349, 60-72.	27.0	382
138	On predictors of sudden cardiac death in hypertrophic cardiomyopathy**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 41, 994-996.	2.8	27
139	Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. Journal of the American College of Cardiology, 2003, 41, 1776-1782.	2.8	359
140	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 1687-1713.	2.8	1,444
141	Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. European Heart Journal, 2003, 24, 883-896.	2.2	131
142	The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. European Heart Journal, 2003, 24, 1848-1853.	2.2	127
143	Hypertrophic cardiomyopathy: two homozygous cases with â€œtypicalâ€•hypertrophic cardiomyopathy and three new mutations in cases with progression to dilated cardiomyopathy. Biochemical and Biophysical Research Communications, 2003, 309, 391-398.	2.1	76
144	Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. Journal of Molecular and Cellular Cardiology, 2003, 35, 841-849.	1.9	96
145	Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the Î²-Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients. Clinical Chemistry, 2003, 49, 1279-1285.	3.2	62
146	Comparison of fluorescent SSCP and denaturing HPLC analysis with direct sequencing for mutation screening in hypertrophic cardiomyopathy. Journal of Medical Genetics, 2003, 40, 59e-59.	3.2	40
147	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. European Heart Journal, 2003, 24, 1965-1991.	2.2	448
148	Sudden Cardiac Death in Athletes. Cardiology, 2003, 100, 186-195.	1.4	11
149	Hypertrophic cardiomyopathyâ€”the clinical challenge of managing a hereditary heart condition. European Heart Journal, 2003, 24, 496-498.	2.2	6
150	Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac Î²-myosin gene mutations. Cardiovascular Research, 2003, 57, 347-357.	3.8	38
151	Pathology of Sudden Death During Recreational Sports Activity. American Journal of Forensic Medicine and Pathology, 2003, 24, 9-16.	0.8	26
153	Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy: initial experience in the Federal District. Arquivos Brasileiros De Cardiologia, 2003, 80, 359-78.	0.8	7
154	Familial Hypertrophic Cardiomyopathy-linked Alterations in Ca2+ Binding of Human Cardiac Myosin Regulatory Light Chain Affect Cardiac Muscle Contraction. Journal of Biological Chemistry, 2004, 279, 3535-3542.	3.4	65

#	Article	IF	Citations
155	Effects of cardiomyopathic mutations on the biochemical and biophysical properties of the human Î±-tropomyosin. FEBS Journal, 2004, 271, 4132-4140.	0.2	18
156	The pathology of hypertrophic cardiomyopathy. Histopathology, 2004, 44, 412-427.	2.9	236
157	Myosin binding protein C: Structural abnormalities in familial hypertrophic cardiomyopathy. Cell Research, 2004, 14, 95-110.	12.0	53
158	Prevalence of hypertrophic cardiomyopathy in a Population-Based sample of American Indians aged 51 to 77 years (the Strong Heart Study)**The opinions expressed in this report are those of the authors and do not necessarily reflect the views of the Indian Health Service.. American Journal of Cardiology, 2004, 93, 1510-1514.	1.6	71
159	Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Molecular and Cellular Biochemistry, 2004, 263, 99-114.	3.1	60
160	Role of troponin T in disease. Molecular and Cellular Biochemistry, 2004, 263, 115-129.	3.1	60
161	Decreased interactions of mutant muscle LIM protein (MLP) with N-RAP and Î±-actinin and their implication for hypertrophic cardiomyopathy. Cell and Tissue Research, 2004, 317, 129-136.	2.9	56
162	Gelsolin superfamily proteins: key regulators of cellular functions. Cellular and Molecular Life Sciences, 2004, 61, 2614-2623.	5.4	353
163	Sudden cardiac death in the young in Sweden: electrocardiogram in relation to forensic diagnosis. Journal of Internal Medicine, 2004, 255, 213-220.	6.0	20
164	Cardiovascular disease in athletes. Clinics in Sports Medicine, 2004, 23, 455-471.	1.8	5
165	Molecular genetic basis of sudden cardiac death. Pediatric Clinics of North America, 2004, 51, 1229-1255.	1.8	26
166	Hypertrophic cardiomyopathy in childhood. Pediatric Clinics of North America, 2004, 51, 1305-1346.	1.8	57
167	Exercise recommendations and risk factors for sudden cardiac death. Pediatric Clinics of North America, 2004, 51, 1401-1420.	1.8	14
168	Risk of sudden cardiac death in young athletes: which screening strategies are appropriate?. Pediatric Clinics of North America, 2004, 51, 1421-1441.	1.8	20
169	Hypertrophic Cardiomyopathy: From â€œHeart Tumourâ€•to a Complex Molecular Genetic Disorder. Heart Lung and Circulation, 2004, 13, 15-25.	0.4	17
170	Hypertrophic Cardiomyopathy. Heart Lung and Circulation, 2004, 13, S48-S55.	0.4	4
171	Comprehensive Analysis of the Beta-Myosin Heavy Chain Gene in 389 Unrelated Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 602-610.	2.8	178
172	Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2315-2325.	2.8	124

#	Article	IF	Citations
173	New treatment strategies for hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2054-2055.	2.8	62
174	Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2125-2132.	2.8	176
175	Mortality from hypertrophic cardiomyopathy in England and Wales: clinical and screening implications. International Journal of Cardiology, 2004, 97, 479-484.	1.7	8
176	Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. American Journal of Medicine, 2004, 116, 14-18.	1.5	225
177	Hypertrophic cardiomyopathy: an important global disease. American Journal of Medicine, 2004, 116, 63-65.	1.5	157
178	Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 1903-1910.	2.8	403
179	Subaortic myectomy for patients with hypertrophic obstructive cardiomyopathy. Operative Techniques in Thoracic and Cardiovascular Surgery, 2004, 9, 254-260.	0.3	2
180	Hypertrophic cardiomyopathy. Lancet, The, 2004, 363, 1881-1891.	13.7	558
181	The use of Tissue Doppler Imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies. European Journal of Echocardiography, 2005, 6, 243-250.	2.3	23
182	ACC/ESC Recommendations for the Clinical Management of Hypertrophic Cardiomyopathy: A Practical Perspective. , 2005, , 267-277.		0
184	Parasympathetic dysfunction in hypertrophic cardiomyopathy assessed by heart rate variability: comparison between short-term and 24-h measurements. Clinical Physiology and Functional Imaging, 2005, 25, 90-99.	1.2	21
185	Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5â€ƒyears after kidney transplant in a 6-year-old recipient. Pediatric Transplantation, 2005, 9, 117-121.	1.0	24
186	Amyloid heart disease mimicking hypertrophic cardiomyopathy*. Journal of Internal Medicine, 2005, 258, 225-230.	6.0	47
187	One third of Danish hypertrophic cardiomyopathy patients have mutations in MYH7 rod region. European Journal of Human Genetics, 2005, 13, 161-165.	2.8	42
188	Cardiomyopathie hypertrophique. EMC - Cardiologie-Angeiologie, 2005, 2, 103-119.	0.8	3
189	Sudden Cardiac Death in Young Athletes. Clinical Pediatric Emergency Medicine, 2005, 6, 194-199.	0.4	12
190	Hypertrophic Cardiomyopathy and Arrhythmogenic Right Ventricular Dysplasia in Young Patients. Seminars in Pediatric Neurology, 2005, 12, 25-31.	2.0	2
191	ThePTPN11gene is not implicated in nonsyndromic hypertrophic cardiomyopathy. , 2005, 132A, 333-334.		10

#	Article	IF	Citations
194	Male Sex Aggravates the Phenotype in Mouse Models of Hypertrophic Cardiomyopathy. Herz, 2005, 30, 405-408.	1.1	3
195	Weaning failure from mechanical ventilation due to hypertrophic obstructive cardiomyopathy. Intensive Care Medicine, 2005, 31, 734-737.	8.2	24
196	Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Clinical Research in Cardiology, 2005, 94, 328-335.	1.1	31
197	Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies. Physiological Genomics, 2005, 21, 131-143.	2.3	34
198	Taking a bite out of hypertrophic cardiomyopathy: soy diet and disease. Journal of Clinical Investigation, 2005, 116, 16-19.	8.2	1
199	Medicolegal Issues in Sports Medicine. Clinical Orthopaedics and Related Research, 2005, &NA;, 38-49.	1.5	4
201	Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. Journal of Medical Genetics, 2005, 42, e59-e59.	3.2	327
202	The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice. Journal of Cell Science, 2005, 118, 3675-3683.	2.0	63
203	Gene-specific modifying effects of pro-LVH polymorphisms involving the reninâ€“angiotensinâ€“aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. European Heart Journal, 2005, 26, 2457-2462.	2.2	90
204	Ambulatory monitoring of aborted sudden cardiac death related to hypertrophic cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 659-662.	3.3	0
205	Recent advances in genetics and treatment of hypertrophic cardiomyopathy. Future Cardiology, 2005, 1, 341-353.	1.2	4
206	Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. European Heart Journal, 2005, 26, 516-524.	2.2	1,037
207	Sarcomeric Genotyping in Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2005, 80, 463-469.	3.0	145
208	Hypertrophic cardiomyopathy linked to homozygosity for a new mutation in the myosin-binding protein C gene (A627V) suggests a dosage effect. International Journal of Cardiology, 2005, 102, 501-507.	1.7	24
209	MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Biochemical and Biophysical Research Communications, 2005, 329, 796-799.	2.1	14
210	Characterization and functional significance of myotrophin: A gene with multiple transcripts. Gene, 2005, 353, 31-40.	2.2	9
211	Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. Journal of Molecular and Cellular Cardiology, 2005, 38, 387-393.	1.9	44
212	Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy. Molecular Genetics and Metabolism, 2005, 85, 280-285.	1.1	20

#	Article	IF	Citations
214	Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil. American Heart Journal, 2005, 149, 1099-1105.	2.7	31
215	The Italian registry for hypertrophic cardiomyopathy: A nationwide survey. American Heart Journal, 2005, 150, 947-954.	2.7	56
216	Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. Journal of the American College of Cardiology, 2005, 45, 1340-1345.	2.8	238
217	Frequency of Cardiac Troponin I Mutations in Families With Hypertrophic Cardiomyopathy in China. Journal of the American College of Cardiology, 2005, 46, 180-181.	2.8	2
219	Impact of Carvedilol Before Angiotensin-Converting Enzyme Inhibitor Therapy on Cardiac Function. Journal of the American College of Cardiology, 2005, 46, 181-182.	2.8	0
220	Dilated-Hypokinetic Evolution of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 1543-1550.	2.8	199
222	Use of Echocardiography in Patients with Hypertrophic Cardiomyopathy: Clinical Implications of Massive Hypertrophy. Journal of the American Society of Echocardiography, 2006, 19, 788-795.	2.8	60
223	Genetic basis of hypertrophic cardiomyopathy. Expert Review of Cardiovascular Therapy, 2006, 4, 927-934.	1.5	49
224	Congenital Coronary Artery Anomalies With Origin in the Contralateral Sinus of Valsalva: Which Approach Should We Take?. Revista Espanola De Cardiologia (English Ed), 2006, 59, 360-370.	0.6	15
225	Hypertrophyc Cardiomyopathy: Infrequent Mutation of the Cardiac Beta-Myosin Heavy-Chain Gene. Revista Espanola De Cardiologia (English Ed), 2006, 59, 846-849.	0.6	3
228	Genomics and Cardiac Arrhythmias. Journal of the American College of Cardiology, 2006, 47, 9-21.	2.8	86
229	Implantable Cardioverter- Defibrillator Therapy in Clinical Practice. Journal of the American College of Cardiology, 2006, 47, 1507-1517.	2.8	28
230	The Genetic Bases of Cardiomyopathies. Journal of the American College of Cardiology, 2006, 48, A79-A89.	2.8	92
231	A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. Biochemical and Biophysical Research Communications, 2006, 345, 998-1003.	2.1	88
232	Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2006, 41, 934-948.	1.9	64
233	Identification of a metavinculin missense mutation, R975W, associated with both hypertrophic and dilated cardiomyopathyâˆ†. Molecular Genetics and Metabolism, 2006, 87, 169-174.	1.1	97
234	Genotypeâ€“phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Molecular Genetics and Metabolism, 2006, 88, 78-85.	1.1	174
235	The diagnosis and management of hypertrophic cardiomyopathy. British Journal of Cardiac Nursing, 2006, 1, 225-231.	0.1	3

#	Article	IF	Citations
236	Mutation of Arg723Gly in Î²-myosin heavy chain gene in five Chinese families with hypertrophic cardiomyopathy. Chinese Medical Journal, 2006, 119, 1785-1789.	2.3	4
238	Becoming a cardiomyopathy nurse specialist. British Journal of Cardiac Nursing, 2006, 1, 188-190.	0.1	0
239	Postmortem Analysis for Inherited Ion Channelopathies. , 2006, , 15-37.		0
240	Cardiovascular Disorders. , 2006, , 317-543.		0
241	Hypertrophic cardiomyopathy: A care study. British Journal of Cardiac Nursing, 2006, 1, 81-85.	0.1	0
242	Commentary: The Value of the ECG in the Preparticipation Sports Physical Examination: The Italian Experience: Table.. Pediatrics in Review, 2006, 27, e75-e76.	0.4	2
244	Usefulness and Cost Effectiveness of Cardiovascular Screening of Young Adolescents. Medicine and Science in Sports and Exercise, 2006, 38, 2-6.	0.4	89
245	Electrocardiography and the Preparticipation Physical Examination. Current Sports Medicine Reports, 2006, 5, 67-73.	1.2	6
246	The athleteÊ¼s heart and hypertrophic cardiomyopathy: two conditions which may be misdiagnosed and coexistent. Which parameters should be analysed to distinguish one disease from the other?. Journal of Cardiovascular Medicine, 2006, 7, 257-266.	1.5	12
247	A molecular screening strategy based on Î²-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 601-607.	1.5	64
248	Combined Effects of Low-Dose Spironolactone and Captopril Therapy in a Rat Model of Genetic Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology, 2006, 48, 265-273.	1.9	31
249	GENES, CALCIUM AND MODIFYING FACTORS IN HYPERTROPHIC CARDIOMYOPATHY. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 139-145.	1.9	41
250	Sudden cardiac death associated with sports in young individuals: is screening the way to avoid it ?. Scandinavian Journal of Medicine and Science in Sports, 2006, 16, 1-3.	2.9	9
251	Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nature Reviews Drug Discovery, 2006, 5, 425-439.	46.4	234
252	Treatment of athletes with cardiac disease or arrhythmias. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 353-361.	0.9	2
253	Determinants for Clinical Diagnosis of Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2006, 98, 1507-1511.	1.6	61
254	Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. European Heart Journal, 2006, 27, 2196-2200.	2.2	164
255	Genetic testing in cardiac disease: from bench to bedside. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 462-463.	3.3	11

#	Article	IF	Citations
256	Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart, 2006, 92, 1447-1451.	2.9	102
257	Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease. Expert Review of Molecular Diagnostics, 2006, 6, 65-78.	3.1	24
258	Sudden cardiac death in athletes: the Lausanne Recommendations. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 859-875.	2.8	200
260	Hypertrophic Cardiomyopathy: Role of Echocardiography in Diagnosis and Management. The American Heart Hospital Journal, 2007, 5, 184-188.	0.2	1
261	Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace, 2007, 9, 817-822.	1.7	63
262	Exercise and Acute Cardiovascular Events. Medicine and Science in Sports and Exercise, 2007, 39, 886-897.	0.4	58
263	Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish. Heart, 2007, 94, 1326-1330.	2.9	66
264	Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart, 2007, 94, 1276-1281.	2.9	58
265	Cardiovascular Risk Reduction in High-Risk Pediatric Patients*. Journal of Cardiovascular Nursing, 2007, 22, 218-253.	1.1	51
266	Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy. Cardiovascular & Hematological Disorders Drug Targets, 2007, 7, 174-187.	0.7	6
267	Long-term cardio-respiratory consequences of heart disease in childhood. Paediatric Respiratory Reviews, 2007, 8, 313-322.	1.8	7
268	Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. Journal of Molecular and Cellular Cardiology, 2007, 42, 1026-1035.	1.9	165
269	Cardiac Hypertrophy. , 2007, , 1177-1188.		0
270	The Role of Cardiovascular MRI in Heart Failure and the Cardiomyopathies. Cardiology Clinics, 2007, 25, 71-95.	2.2	51
271	Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 667-676.	3.3	21
272	Assessment of Left Atrial Ejection Force in Hypertrophic Cardiomyopathy Using Real-time Three-dimensional Echocardiography. Journal of the American Society of Echocardiography, 2007, 20, 744-748.	2.8	33
273	Medical Management of the Athlete: Evaluation and Treatment of Important Issues in Sports Medicine. Clinics in Podiatric Medicine and Surgery, 2007, 24, 127-158.	0.6	7
274	Hypertrophic Cardiomyopathy and Other Causes of Sudden Cardiac Death in Young Competitive Athletes, with Considerations for Preparticipation Screening and Criteria for Disqualification. Cardiology Clinics, 2007, 25, 399-414.	2.2	88

#	Article	IF	Citations
275	The Role of Cardiovascular MRI in Heart Failure and the Cardiomyopathies. Magnetic Resonance Imaging Clinics of North America, 2007, 15, 541-564.	1.1	15
276	The â€œAthlete's Heartâ€: Relation to Gender and Race. Cardiology Clinics, 2007, 25, 383-389.	2.2	18
278	GFP-Tagged Regulatory Light Chain Monitors Single Myosin Lever-Arm Orientation in a Muscle Fiber. Biophysical Journal, 2007, 93, 2226-2239.	0.5	22
279	High-Risk Hypertrophic Cardiomyopathy Associated With a Novel Mutation in Cardiac Myosin-Binding Protein C. Revista Espanola De Cardiologia (English Ed), 2007, 60, 311-314.	0.6	2
280	Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications. Journal of the American College of Cardiology, 2007, 49, 1251-1264.	2.8	95
281	ACCF/AHA/SCAI 2007 Update of the Clinical Competence Statement on Cardiac Interventional Procedures. Journal of the American College of Cardiology, 2007, 50, 82-108.	2.8	73
282	Genetic Testing in Cardiovascular Disease. Journal of the American College of Cardiology, 2007, 50, 727-737.	2.8	59
283	Molecular Pathogenic Mechanisms of Cardiomyopathies Caused by Mutations in Cardiac Troponin T. , 2007, 592, 227-239.		10
284	Troponin Mutations in Cardiomyopathies. , 2007, 592, 201-226.		2
286	InfluÃªncia da gestaÃ§Ã£o na evoluÃ§Ã£o clÃnica materno-fetal de portadoras de cardiomiopatia hipertrÃ³fica. Arquivos Brasileiros De Cardiologia, 2007, 88, 480-485.	0.8	35
288	The role of the pathologist in the diagnosis of cardiomyopathy: a personal view. , 0, , 101-134.		0
289	Homozygosity for a novel splice site mutation in the cardiac myosinâ€binding protein C gene causes severe neonatal hypertrophic cardiomyopathy. American Journal of Medical Genetics, Part A, 2007, 143A, 2662-2667.	1.2	60
290	Resynchronization or Dyssynchronization?Successful Treatment with Biventricular Stimulation of a Child with Obstructive Hypertrophic Cardiomyopathy without Dyssynchrony. Journal of Cardiovascular Electrophysiology, 2007, 18, 542-544.	1.7	14
291	Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics. Journal of Cardiovascular Electrophysiology, 2008, 19, 104-110.	1.7	299
292	Syncope and Sudden Death in the Athlete. Clinical Pediatric Emergency Medicine, 2007, 8, 54-58.	0.4	3
293	Barry Joel Maron, MD: A Conversation With the EditorâŽâŽThis series of interviews was underwritten by an unrestricted grant from Bristol-Myers Squibb.. American Journal of Cardiology, 2007, 99, 1334-1349.	1.6	1
294	Cardiomyopathy: An Overview. Journal for Nurse Practitioners, 2007, 3, 248-258.	0.8	4
295	Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwanâ€”a tertiary center experience. Clinical Cardiology, 2007, 30, 177-182.	1.8	28

#	Article	IF	Citations
296	Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy. Netherlands Heart Journal, 2007, 15, 161-163.	0.8	7
297	Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience. Netherlands Heart Journal, 2007, 15, 184-190.	0.8	35
298	ESCAPE-HCM study: Evaluation of SCreening of Asymptomatic PatiEnts with Hypertrophic CardioMyopathy. Netherlands Heart Journal, 2007, 15, 216-220.	0.8	1
299	Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy. Heart and Vessels, 2007, 22, 322-327.	1.2	9
300	An integrated approach to determine left atrial volume, mass and function in hypertrophic cardiomyopathy by two-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2007, 24, 45-52.	1.5	39
301	RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Human Genetics, 2007, 122, 515-523.	3.8	36
302	Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up. Clinical Research in Cardiology, 2007, 96, 851-855.	3.3	1
303	Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Current Cardiology Reports, 2007, 9, 51-56.	2.9	26
304	The genetics of cardiomyopathies: What clinicians should know. Current Heart Failure Reports, 2007, 4, 229-235.	3.3	2
305	When the Third Degree Is Necessary: Do Pediatricians Obtain Enough Information to Detect Patients at Risk for HCM?. Pediatric Cardiology, 2008, 29, 589-596.	1.3	2
307	The genetic basis of cardiomyopathy. Current Cardiovascular Risk Reports, 2008, 2, 468-475.	2.0	1
308	Expression of cTnI-R145G affects shortening properties of adult rat cardiomyocytes. Pflugers Archiv European Journal of Physiology, 2008, 457, 17-24.	2.8	8
309	Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3gene. BMC Medical Genetics, 2008, 9, 95.	2.1	60
310	Evaluation of left ventricular outflow tract gradient during treadmill exercise and in recovery period in orthostatic position, in patients with hypertrophic cardiomyopathy. Cardiovascular Ultrasound, 2008, 6, 19.	1.6	46
311	A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Human Mutation, 2008, 29, 879-885.	2.5	70
312	Evaluation of nonischemic cardiomyopathies using cardiovascular magnetic resonance. Journal of Nuclear Cardiology, 2008, 15, 400-416.	2.1	8
313	Molecular genetics of sudden cardiac death. Forensic Science International, 2008, 182, 1-12.	2.2	77
314	Substrate and Procedural Predictors of Outcomes After Catheter Ablation for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2008, 19, 1009-1014.	1.7	105

#	Article	IF	Citations
315	Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. European Journal of Human Genetics, 2008, 16, 1201-1207.	2.8	94
316	Significance of Left Atrial Volume in Patients < 20 Years of Age With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2008, 102, 1390-1393.	1.6	33
317	Psychiatric disorders in hypertrophic cardiomyopathy. General Hospital Psychiatry, 2008, 30, 49-54.	2.4	32
318	Cardiomyopathy: Magnetic Resonance Imaging Evaluation. Seminars in Roentgenology, 2008, 43, 204-222.	0.6	4
319	Family History: An Essential Tool for Cardiovascular Genetic Medicine. Congestive Heart Failure, 2008, 14, 37-45.	2.0	56
320	Sudden Cardiac Death in Athletes. Progress in Cardiovascular Diseases, 2008, 51, 44-57.	3.1	21
321	Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 158-168.	3.3	165
322	Prevalence of Hypertrophic Cardiomyopathy in Highly Trained Athletes. Journal of the American College of Cardiology, 2008, 51, 1033-1039.	2.8	171
323	Ethnic Differences in Left Ventricular Remodeling in Highly-Trained Athletes. Journal of the American College of Cardiology, 2008, 51, 2256-2262.	2.8	291
325	Pre-Participation Screening of Young Competitive Athletes for Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2008, 52, 1981-1989.	2.8	240
326	Genetics and pathogenic mechanisms of cardiomyopathies in the Drosophila model. Drug Discovery Today: Disease Models, 2008, 5, 125-134.	1.2	7
327	Identification of Myofilament Mutations: Its Role in the Diagnosis and Management of Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2008, 83, 626-627.	3.0	0
328	Clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy with latent obstruction. American Heart Journal, 2008, 156, 342-347.	2.7	53
329	Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutants. Journal of Molecular and Cellular Cardiology, 2008, 44, 891-904.	1.9	39
330	Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. Journal of Molecular and Cellular Cardiology, 2008, 45, 281-288.	1.9	111
331	The ubiquitinâ€“proteasome system in cardiac dysfunction. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 749-763.	3.8	129
332	Heart rate variability analysis based on timeâ€“frequency representation and entropies in hypertrophic cardiomyopathy patients. Physiological Measurement, 2008, 29, 401-416.	2.1	17
333	Prevalence of the Myosin-Binding Protein C Mutation in Maine Coon Cats. Journal of Veterinary Internal Medicine, 2008, 22, 893-896.	1.6	42

#	Article	IF	Citations
334	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure â€“ 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Canadian Journal of Cardiology, 2008, 24, 21-40.	1.7	93
335	Genetic Basis of Ventricular Arrhythmias. Cardiology Clinics, 2008, 26, 335-353.	2.2	20
336	A Comprehensive Approach to Management of Ventricular Arrhythmias. Cardiology Clinics, 2008, 26, 481-496.	2.2	4
337	Anesthetic Considerations in the Patient With Valvular Heart Disease Undergoing Noncardiac Surgery. Seminars in Cardiothoracic and Vascular Anesthesia, 2008, 12, 33-59.	1.0	35
338	Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Human Molecular Genetics, 2008, 17, 2753-2765.	2.9	142
339	Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genetics in Medicine, 2008, 10, 117-120.	2.4	102
340	Utilities and limitations of genetic testing for hypertropic cardiomyopathy. Expert Opinion on Medical Diagnostics, 2008, 2, 539-546.	1.6	2
341	Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. European Heart Journal, 2008, 29, 1160-1167.	2.2	95
342	Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. European Heart Journal, 2008, 30, 139-151.	2.2	74
343	Efficacy of personal symptom and family history questionnaires when screening for inherited cardiac pathologies: the role of electrocardiography. British Journal of Sports Medicine, 2008, 42, 207-211.	6.7	136
344	Thick hearts, high stakes, great uncertainties: screening athletes for hypertrophic cardiomyopathy. Heart, 2008, 95, 345-347.	2.9	4
345	Troponin T and Î²-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovascular Research, 2008, 77, 687-694.	3.8	17
346	A novel mouse model of X-linked cardiac hypertrophy. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2701-H2711.	3.2	10
347	Molecular Mechanisms of Inherited Arrhythmias. Current Genomics, 2008, 9, 160-168.	1.6	21
348	Cardiac myosin-binding protein C decorates F-actin: Implications for cardiac function. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18360-18365.	7.1	107
349	Physical Examination and ECG Screening in Relation to Echocardiography Findings in Young Healthy Adults. Cardiology, 2008, 109, 202-207.	1.4	5
350	Influence of the pattern of hypertrophy on left ventricular twist in hypertrophic cardiomyopathy. Heart, 2008, 95, 657-661.	2.9	49
351	Identification of Myofilament Mutations: Its Role in the Diagnosis and Management of Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2008, 83, 626-627.	3.0	2

#	Article	IF	Citations
352	Genetic determinants of cardiac hypertrophy. Current Opinion in Cardiology, 2008, 23, 199-205.	1.8	78
353	Imaging studies in patients with heart failure: Current and evolving technologies. Critical Care Medicine, 2008, 36, S28-S39.	0.9	2
354	Hypertrophic Cardiomyopathy. Cardiology in Review, 2008, 16, 172-180.	1.4	32
355	Valvular Heart Disease in Critical Care. , 2008, , 677-707.		1
356	An Unusual Type of Hypertrophic Cardiomyopathy. Korean Circulation Journal, 2009, 39, 213.	1.9	0
357	Pathological and physiological left ventricular hypertrophy: echocardiography for differentiation. Future Cardiology, 2009, 5, 495-502.	1.2	6
358	Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy. Genetic Testing and Molecular Biomarkers, 2009, 13, 647-650.	0.7	6
359	Advances in the prevention of sudden cardiac death in the young. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 145-155.	2.1	14
360	Muscle Lim Protein Interacts with Cofilin 2 and Regulates F-Actin Dynamics in Cardiac and Skeletal Muscle. Molecular and Cellular Biology, 2009, 29, 6046-6058.	2.3	51
361	Epidemiology and clinical management of cardiomyopathies and heart failure in China. Heart, 2009, 95, 1727-1731.	2.9	68
362	Hypertrophic cardiomyopathy: current understanding and treatment objectives. Journal of Clinical Pathology, 2009, 62, 226-235.	2.0	42
363	Electrocardiographic screening in athletes: the time is now for universal screening. British Journal of Sports Medicine, 2009, 43, 663-668.	6.7	43
364	Sudden cardiac death: history, aetiology and management. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, 89-94.	0.5	3
365	Implications of Hypertrophic Cardiomyopathy Transmitted by Sperm Donation. JAMA - Journal of the American Medical Association, 2009, 302, 1681.	7.4	43
366	Letters to the Editor. Journal of the American Veterinary Medical Association, 2009, 235, 263-265.	0.5	0
367	Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. European Heart Journal, 2009, 30, 2593-2598.	2.2	80
368	Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management. European Journal of Echocardiography, 2009, 10, iii9-iii14.	2.3	72
369	Incidence and aetiology of sudden cardiac death in young athletes: an international perspective. British Journal of Sports Medicine, 2009, 43, 644-648.	6.7	81

#	Article	IF	Citations
370	Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A crossâ€sectional cohort study. American Journal of Medical Genetics, Part A, 2009, 149A, 602-612.	1.2	110
371	Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: The patients' perspective. American Journal of Medical Genetics, Part A, 2009, 149A, 1444-1451.	1.2	56
373	Familial hypertrophic cardiomyopathy: Basic concepts and future molecular diagnostics. Clinical Biochemistry, 2009, 42, 755-765.	1.9	26
374	The genetics of cardiomyopathy: Genotyping and genetic counseling. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 433-446.	0.9	11
375	Insights into Human Î²-Cardiac Myosin Function from Single Molecule and Single Cell Studies. Journal of Cardiovascular Translational Research, 2009, 2, 426-440.	2.4	24
376	Evolving Anatomic, Functional, and Molecular Imaging in the Early Detection and Prognosis of Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 398-406.	2.4	4
377	Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?. Journal of Cardiovascular Translational Research, 2009, 2, 392-397.	2.4	7
378	Sudden Death in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 368-380.	2.4	32
380	Prognostic Factors in Chronic Heart Failure. Herz, 2009, 34, 141-147.	1.1	26
381	Hypertrophic cardiomyopathy as a cause of sudden death. Herz, 2009, 34, 305-314.	1.1	18
382	Identification of high risk patients with hypertrophic cardiomyopathy in a northern Greek population. Cardiovascular Ultrasound, 2009, 7, 37.	1.6	8
383	Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nature Methods, 2009, 6, 507-510.	19.0	56
384	Hypertrophic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S23-31.	1.2	30
385	A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy. Clinical Genetics, 2009, 76, 91-101.	2.0	39
386	Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity?. Netherlands Heart Journal, 2009, 17, 458-463.	0.8	16
387	Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Netherlands Heart Journal, 2009, 17, 464-469.	0.8	8
388	ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians task Force on Clinical Competence and Training (writing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	2
389	Cardiovascular Interventions, 2009, , NA-NA. A Novel Mutation of the Beta Myosin Heavy Chain Gene Responsible for Familial Hypertrophic Cardiomyopathy. Clinical Cardiology, 2009, 32, E16-21.	1.8	9

#	Article	IF	Citations
390	Hypertrophic cardiomyopathy due to beta-myosin heavy chain mutation with extreme phenotypic variability within a family. International Journal of Cardiology, 2009, 134, e87-e93.	1.7	1
391	Use of Genetics in the Clinical Evaluation of Cardiomyopathy. JAMA - Journal of the American Medical Association, 2009, 302, 2471.	7.4	50
392	Mutations in Sarcomeric Genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in Patients With Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2009, 62, 48-56.	0.6	19
393	The Genetic Basis of Malignant Arrhythmias and Cardiomyopathies. Revista Espanola De Cardiologia (English Ed), 2009, 62, 422-436.	0.6	1
395	Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations. Heart Rhythm, 2009, 6, S18-S24.	0.7	12
396	Prevention of sudden cardiac death: return to sport considerations in athletes with identified cardiovascular abnormalities. British Journal of Sports Medicine, 2009, 43, 685-689.	6.7	15
397	Involvement of hypertrophic cardiomyopathy genes in sudden infant death syndrome (SIDS). Forensic Science International: Genetics Supplement Series, 2009, 2, 495-496.	0.3	13
398	MiocardiopatÃas. Concepto. Tipos. ClasificaciÃ³n. Medicine, 2009, 10, 2815-2819.	0.0	0
399	Espectro mutacional de los genes sarcomÃ©ricos MYH7, MYBPC3, TNNT2, TNNI3 y TPM1 en pacientes con miocardiopatÃa hipertrÃ³fica. Revista Espanola De Cardiologia, 2009, 62, 48-56.	1.2	51
400	Bases genÃ©ticas de las arritmias malignas y las miocardiopatÃas. Revista Espanola De Cardiologia, 2009, 62, 422-436.	1.2	5
402	Athleteâ€™s heart or hypertrophic cardiomyopathy?. Clinical Research in Cardiology, 2009, 98, 80-88.	3.3	66
403	Delayed Left Ventricular Untwisting in Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2009, 22, 1320-1326.	2.8	31
404	Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. Heart Rhythm, 2009, 6, 1366-1369.	0.7	54
405	The Role of Genetic Testing In Paediatric Syndromes of Sudden Death: State Of The Art and Future Considerations. Cardiology in the Young, 2009, 19, 54-65.	0.8	5
406	Preparticipation Exam to Identify Risk for Sudden Cardiac Death. Athletic Therapy Today, 2009, 14, 13-16.	0.2	4
407	Left Ventricular Outflow Tract Obstruction by a Bioprosthetic Mitral Valve. Journal of Thoracic Imaging, 2009, 24, 132-135.	1.5	5
408	Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest double-heterozygosity?. Netherlands Heart Journal, 2010, , 1.	0.8	0
409	Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Netherlands Heart Journal, 0, , 1.	0.8	0

#	Article	IF	Citations
410	Genetics of hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2010, 25, 205-209.	1.8	112
411	Myocardial scar as arrhythmia risk in patients with hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2010, 25, 276-281.	1.8	3
412	Cost-Effectiveness of Preparticipation Screening for Prevention of Sudden Cardiac Death in Young Athletes. Annals of Internal Medicine, 2010, 152, 276.	3.9	211
413	Sudden Cardiac Death in a 20-Year-Old Male Swimmer. Southern Medical Journal, 2010, 103, 464-466.	0.7	5
414	Sudden Arrhythmic Death Syndrome. , 2010, , .		0
415	Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Netherlands Heart Journal, 2010, 18, 248-254.	0.8	68
416	Longâ€Term Outcome of 4 Korean Families With Hypertrophic Cardiomyopathy Caused by 4 Different Mutations. Clinical Cardiology, 2010, 33, 430-438.	1.8	15
417	Parental Knowledge and Attitudes Toward Hypertrophic Cardiomyopathy Genetic Testing. Pediatric Cardiology, 2010, 31, 195-202.	1.3	16
418	Sarcomere Gene Mutations in Hypertrophy and Heart Failure. Journal of Cardiovascular Translational Research, 2010, 3, 297-303.	2.4	29
419	Dr. Gunnar Thor Gunnarsson and Hypertrophic Cardiomyopathy: What â€œGiving Backâ€•Means. American Journal of Cardiology, 2010, 105, 277-278.	1.6	2
420	Apical Hypertrophic Cardiomyopathy in an Adolescent. Congenital Heart Disease, 2010, 5, 182-187.	0.2	4
421	Prevalence of suspected hypertrophic cardiomyopathy or left ventricular hypertrophy based on race and gender in teenagers using screening echocardiography. Cardiovascular Ultrasound, 2010, 8, 54.	1.6	15
422	Hypertrophic cardiomyopathy in childhood and adolescence â€“ strategies to prevent sudden death. Fundamental and Clinical Pharmacology, 2010, 24, 637-652.	1.9	55
423	Population characteristics and survival in 127 referred cats with hypertrophic cardiomyopathy (1997) Tj ETQq1 1 0.784314 rgBT /Ove	1.2	101
424	Emotional Stress Triggers Symptoms in Hypertrophic Cardiomyopathy: A Survey of the Hypertrophic Cardiomyopathy Association. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 1047-1053.	1.2	9
425	Implantable Cardioverterâ€Defibrillator in Patients With Hypertrophic Cardiomyopathy: Efficacy and Complications of the Therapy in Longâ€Term Followâ€up. Journal of Cardiovascular Electrophysiology, 2010, 21, 883-889.	1.7	67
426	Understanding hypertrophic cardiomyopathy: implications of diagnosis for the patient and family. International Journal of Clinical Practice, 2010, 64, 1699-1704.	1.7	0
427	Hypertrophic cardiomyopathy: from genetics to treatment. European Journal of Clinical Investigation, 2010, 40, 360-369.	3.4	99

#	Article	IF	Citations
428	Obtaining insurance after DNA diagnostics: a survey among hypertrophic cardiomyopathy mutation carriers. European Journal of Human Genetics, 2010, 18, 251-253.	2.8	16
429	Impact of Mendelian inheritance in cardiovascular disease. Annals of the New York Academy of Sciences, 2010, 1214, 122-137.	3.8	13
431	Hypertrophic cardiomyopathy and sudden cardiac death. World Journal of Cardiology, 2010, 2, 289.	1.5	25
432	Percutaneous transluminal septal myocardial ablation (PTSMA) of hypertrophic cardiomyopathy: Indonesian initial experience. Medical Journal of Indonesia, 0, , 164.	0.5	0
433	Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy. Circulation, 2010, 122, 2441-2450.	1.6	128
435	Genetic variations of Î²-MYH7 in hypertrophic cardiomyopathy and dilated cardiomyopathy. Indian Journal of Human Genetics, 2010, 16, 67.	0.7	13
436	Echocardiographic deformation imaging reveals preserved regional systolic function in endurance athletes with left ventricular hypertrophy. British Journal of Sports Medicine, 2010, 44, 872-878.	6.7	12
437	Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Review of Molecular Diagnostics, 2010, 10, 329-351.	3.1	29
438	The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovascular Research, 2010, 85, 330-338.	3.8	73
439	Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genetics in Medicine, 2010, 12, 655-667.	2.4	223
440	The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. European Heart Journal, 2010, 31, 842-848.	2.2	68
441	Preparticipation Screening of Young Competitive Athletes for Cardiovascular Disorders. Physician and Sportsmedicine, 2010, 38, 54-63.	2.1	17
442	Cardiac Ischemia in Pediatric Patients. Pediatric Clinics of North America, 2010, 57, 1261-1280.	1.8	8
443	Genetic Basis of Ventricular Arrhythmias. Heart Failure Clinics, 2010, 6, 249-266.	2.1	7
444	Hypertrophic Cardiomyopathy. Heart Failure Clinics, 2010, 6, 141-159.	2.1	45
445	Hypertrophic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2010, 2, 587-598.	1.7	4
446	Genetic Testing for Cardiac Arrhythmias: Ready for Prime Time?. Cardiac Electrophysiology Clinics, 2010, 2, 611-621.	1.7	0
447	Genomics of Heart Failure. Heart Failure Clinics, 2010, 6, 115-124.	2.1	11

#	Article	IF	Citations
448	Sleep Quality and Quality of Life in Patients with Hypertrophic Cardiomyopathy. Cardiology, 2010, 117, 200-206.	1.4	27
449	Mutations in Alpha-Actinin-2 Cause Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 55, 1127-1135.	2.8	170
450	Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 56, 867-874.	2.8	720
451	Cardiomyopathy: A Systematic Review of Disease-Causing Mutations in Myosin Heavy Chain 7 and Their Phenotypic Manifestations. Cardiology, 2010, 115, 49-60.	1.4	106
452	Cardiovascular Magnetic Resonance Imaging of Non-ischaemic Heart Disease: Established and Emerging Applications. Heart Lung and Circulation, 2010, 19, 117-132.	0.4	12
453	Feline Hypertrophic Cardiomyopathy: An Update. Veterinary Clinics of North America - Small Animal Practice, 2010, 40, 685-700.	1.5	52
454	Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. European Journal of Medical Genetics, 2010, 53, 261-267.	1.3	130
455	A mutation in the Î²-myosin rod associated with hypertrophic cardiomyopathy has an unexpected molecular phenotype. Biochemical and Biophysical Research Communications, 2010, 391, 352-356.	2.1	13
456	Differential protein expression profiling of myocardial tissue in a mouse model of hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2010, 48, 1014-1022.	1.9	15
457	Malignant and benign mutations in familial cardiomyopathies: Insights into mutations linked to complex cardiovascular phenotypes. Journal of Molecular and Cellular Cardiology, 2010, 48, 899-909.	1.9	69
458	Sudden cardiac death: An 11-year postmortem analysis in the region of Epirus, Greece. Pathology Research and Practice, 2010, 206, 690-694.	2.3	27
459	Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2010, 363, 552-563.	27.0	566
460	Obstructive Sleep Apnea Is Common and Independently Associated With Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Chest, 2010, 137, 1078-1084.	0.8	78
461	Multi-scale computational models of familial hypertrophic cardiomyopathy: genotype to phenotype. Journal of the Royal Society Interface, 2011, 8, 1550-1561.	3.4	30
462	Cost and yield of adding electrocardiography to history and physical in screening Division I intercollegiate athletes: A 5-year experience. Heart Rhythm, 2011, 8, 721-727.	0.7	54
463	Echocardiography: A Requisite Friend of the Cardiac Geneticist. Journal of the American Society of Echocardiography, 2011, 24, 790-791.	2.8	0
464	Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy: Do We Need to Stand to Be Counted. Journal of the American Society of Echocardiography, 2011, 24, 83-85.	2.8	5
465	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2011, 58, e212-e260.	2.8	984

#	Article	IF	Citations
466	Mortality Risk of Untreated Myosin-Binding Protein Câ€“Related Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2011, 58, 2406-2414.	2.8	27
467	Percutaneous Radiofrequency Septal Reduction for Hypertrophic Obstructive Cardiomyopathy in Children. Journal of the American College of Cardiology, 2011, 58, 2501-2510.	2.8	46
468	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2703-2738.	2.8	252
469	Time to Significant Gradient Reduction Following Septal Balloon Occlusion Predicts the Magnitude of Final Gradient Response During Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. JACC: Cardiovascular Interventions, 2011, 4, 1030-1034.	2.9	11
470	Hypertrophic obstructive cardiomyopathy and the mitral valve. , 2011, , 67-79.		0
471	Heart Failure as a Consequence of Restrictive Cardiomyopathy. , 2011, , 395-407.		0
472	Novel frameshift mutation in Troponin C (TNNC1) associated with hypertrophic cardiomyopathy and sudden death. Cardiology in the Young, 2011, 21, 345-348.	0.8	27
473	PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: Summary of the literature and implications for genetic testing. American Heart Journal, 2011, 161, 165-171.	2.7	54
474	Imaging hypertrophic heart diseases with cardiovascular MR. Clinical Radiology, 2011, 66, 176-186.	1.1	8
475	Imaging spectrum of sudden athlete cardiac death. Clinical Radiology, 2011, 66, 203-223.	1.1	14
476	Natural history of genotype positiveâ€“phenotype negative patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2011, 152, 258-259.	1.7	61
477	Human Cardiac Myosin Binding Protein C: Structural Flexibility within an Extended Modular Architecture. Journal of Molecular Biology, 2011, 414, 735-748.	4.2	37
478	Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: Mechanisms and therapeutic opportunities. Journal of Molecular and Cellular Cardiology, 2011, 50, 613-620.	1.9	96
479	Left atrial size and left ventricular hypertrophy correlate with myocardial fi brosis in patients with hypertrophic cardiomyopathy. Acta Cardiologica, 2011, 66, 153-157.	0.9	8
480	Is There Evidence for Mandating Electrocardiogram as Part of the Pre-Participation Examination?. Clinical Journal of Sport Medicine, 2011, 21, 13-17.	1.8	31
481	Effect of Cardiac Resynchronization on Gradient Reduction in Patients with Obstructive Hypertrophic Cardiomyopathy: Preliminary Study. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1544-1552.	1.2	17
482	Longitudinal Left Ventricular Strain in Hypertrophic Cardiomyopathy: Correlation with Nonsustained Ventricular Tachycardia. Echocardiography, 2011, 28, 709-714.	0.9	32
483	Respective Prevalence of the Different Carpentier Classes of Mitral Regurgitation: A Stepping Stone for Future Therapeutic Research and Development. Journal of Cardiac Surgery, 2011, 26, 385-392.	0.7	103

#	Article	IF	Citations
484	Clinical utility gene card for: hypertrophic cardiomyopathy (type 1â€“14). European Journal of Human Genetics, 2011, 19, 3-4.	2.8	9
485	Positron emission tomography for the evaluation and treatment of cardiomyopathy. Annals of the New York Academy of Sciences, 2011, 1228, 137-149.	3.8	11
486	Hypertrophic cardiomyopathy in the Amish community â€" What we may learn from it. Progress in Pediatric Cardiology, 2011, 31, 129-134.	0.4	5
487	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1303-1338.	0.8	73
488	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, e153-e203.	0.8	260
489	Cardiogenic Causes of Pediatric Syncope. Clinical Pediatric Emergency Medicine, 2011, 12, 266-277.	0.4	6
490	Exercise related ventricular arrhythmias are related to cardiac fibrosis in hypertrophic cardiomyopathy mutation carriers. Netherlands Heart Journal, 2011, 19, 168-174.	0.8	14
491	Unequal allelic expression of wild-type and mutated Î²-myosin in familial hypertrophic cardiomyopathy. Basic Research in Cardiology, 2011, 106, 1041-1055.	5.9	55
493	The Mitral Valve in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2011, 4, 757-766.	2.4	30
494	Role of echocardiography and cardiac MRI in depicting morphological and functional imaging findings useful for diagnosing hypertrophic cardiomyopathy. Radiologia Medica, 2011, 116, 197-210.	7.7	11
495	Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein C. BMC Cell Biology, 2011, 12, 18.	3.0	48
496	Unexpectedly low mutation rates in betaâ€myosin heavy chain and cardiac myosin binding protein genes in italian patients with hypertrophic cardiomyopathy. Journal of Cellular Physiology, 2011, 226, 2894-2900.	4.1	15
497	Developmental cardiac hypertrophy in a mouse model of prolidase deficiency. Birth Defects Research Part A: Clinical and Molecular Teratology, 2011, 91, 204-217.	1.6	7
498	A new strategy for septal ablation with transendocardial ethanol injection using a multifunctional intracardiac echocardiography catheter: A feasibility study in canines. Catheterization and Cardiovascular Interventions, 2011, 78, 316-323.	1.7	5
499	Overview of Sudden Cardiac Death in Young Athletes. Physician and Sportsmedicine, 2011, 39, 22-36.	2.1	9
500	Sudden Cardiac Deaths in Young British Army Personnel. Journal of the Royal Army Medical Corps, 2011, 157, 184-187.	0.8	4
501	Risk of sports: do we need a pre-participation screening for competitive and leisure athletes?. European Heart Journal, 2011, 32, 934-944.	2.2	193
502	Impact of polymorphisms in the reninâ€angiotensinâ€aldosterone system on hypertrophic cardiomyopathy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 521-530.	1.7	20

#	Article	IF	Citations
503	Junctophilin-2 Expression Silencing Causes Cardiocyte Hypertrophy and Abnormal Intracellular Calcium-Handling. Circulation: Heart Failure, 2011, 4, 214-223.	3.9	92
504	Genetics Primer for the General Cardiologist. Circulation, 2011, 123, 467-467.	1.6	3
505	Parentsâ€™ experiences of having an asymptomatic child diagnosed with hypertrophic cardiomyopathy through family screening. Cardiology in the Young, 2011, 21, 8-14.	0.8	13
506	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. European Heart Journal, 2011, 32, 177-183.	2.2	26
507	Prevalence of hypertrophic cardiomyopathy on an electrocardiogram-based pre-participation screening programme in a young male South-East Asian population: results from the Singapore Armed Forces Electrocardiogram and Echocardiogram screening protocol. Europace, 2011, 13, 883-888.	1.7	23
508	The bisferiens pulse. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, M189-M191.	0.5	3
509	Cellular mechanisms of cardiomyopathy. Journal of Cell Biology, 2011, 194, 355-365.	5.2	308
510	Edge of the world: practical considerations and a clinical perspective of next-generation sequencing for hereditary cardiac disease. Expert Opinion on Medical Diagnostics, 2011, 5, 5-8.	1.6	0
511	Hypertrophic cardiomyopathy: Prevalence, hypertrophy patterns, and their clinical and ECG findings in a hospital at Qatar. Heart Views, 2011, 12, 143.	0.2	13
512	Hypertrophic cardiomyopathy: from mutation to functional analysis of defective protein. Croatian Medical Journal, 2011, 52, 384-391.	0.7	5
513	Combined anterior mitral valve leaflet retention plasty and septal myectomy in patients with hypertrophic obstructive cardiomyopathy. European Journal of Cardio-thoracic Surgery, 2011, 40, 1515-20.	1.4	12
514	Identifying Sarcomere Gene Mutations in Hypertrophic Cardiomyopathy. Circulation Research, 2011, 108, 743-750.	4.5	234
515	Debate: challenges in sports cardiology; US versus European approaches. British Journal of Sports Medicine, 2012, 46, i9-i14.	6.7	12
516	Cardiomyopathy in Î±-Kinase 3 (ALPK3)â€“Deficient Mice. Veterinary Pathology, 2012, 49, 131-141.	1.7	37
517	Hypertrophic obstructive cardiomyopathy: a potential cause of loss of consciousness and sudden cardiac arrest in young adults. Emergency Medicine Journal, 2012, 29, 919-920.	1.0	0
518	In Vivo Cardiac Myosin Binding Protein C Gene Transfer Rescues Myofilament Contractile Dysfunction in Cardiac Myosin Binding Protein C Null Mice. Circulation: Heart Failure, 2012, 5, 635-644.	3.9	37
519	Cardiac Auscultation in Sports Medicine. Current Sports Medicine Reports, 2012, 11, 78-84.	1.2	5
520	A Mutation in TNNC1-encoded Cardiac Troponin C, TNNC1-A31S, Predisposes to Hypertrophic Cardiomyopathy and Ventricular Fibrillation. Journal of Biological Chemistry, 2012, 287, 31845-31855.	3.4	50

#	Article	IF	Citations
521	Polycystic Ovary Syndrome Is Associated with Higher Left Ventricular Mass Index: The CARDIA Women's Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4656-4662.	3.6	35
522	A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart, 2012, 98, 625-630.	2.9	119
523	Risk markers of sudden cardiac death in standard 12-lead electrocardiograms. Annals of Medicine, 2012, 44, 717-732.	3.8	10
524	The experience of being diagnosed with hypertrophic cardiomyopathy through family screening in childhood and adolescence. Cardiology in the Young, 2012, 22, 528-535.	0.8	10
525	Cardiac magnetic resonance imaging of non-ischaemic cardiomyopathy. Postgraduate Medical Journal, 2012, 88, 38-48.	1.8	4
526	Cardiac Structural and Sarcomere Genes Associated With Cardiomyopathy Exhibit Marked Intolerance of Genetic Variation. Circulation: Cardiovascular Genetics, 2012, 5, 602-610.	5.1	59
527	A Delta-Sarcoglycan Gene Polymorphism as a Risk Factor for Hypertrophic Cardiomyopathy. Genetic Testing and Molecular Biomarkers, 2012, 16, 855-858.	0.7	6
528	Hypertrophic Cardiomyopathy: A Real Risk Factor for Stroke. Scottish Medical Journal, 2012, 57, 1-3.	1.3	3
529	Cardiac Myosin Binding Protein C Insufficiency Leads to Early Onset of Mechanical Dysfunction. Circulation: Cardiovascular Imaging, 2012, 5, 127-136.	2.6	20
530	Electrocardiogram Screening for Disorders That Cause Sudden Cardiac Death in Asymptomatic Children: A Meta-analysis. Pediatrics, 2012, 129, e999-e1010.	2.1	73
531	Ventricular arrhythmias complicating hypertrophic cardiomyopathy. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 502-508.	0.5	2
532	Genetics of Hypertrophic and Dilated Cardiomyopathy. Current Pharmaceutical Biotechnology, 2012, 13, 2467-2476.	1.6	23
533	Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins. Current Molecular Medicine, 2012, 12, 507-518.	1.3	43
534	A variant of unknown significance in the GLA gene causing diagnostic uncertainty in a young female with isolated hypertrophic cardiomyopathy. Gene, 2012, 497, 320-322.	2.2	6
535	Inherited Cardiomyopathies. , 2012, , 211-229.		2
536	Interventional Treatments for Hypertrophic Cardiomyopathy. Cardiovascular Therapeutics, 2012, 30, e107-14.	2.5	4
537	Sarcomeric hypertrophic cardiomyopathy: Genetic profile in a Portuguese population. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 577-587.	0.2	18
538	Computing Myocardial Motion in 4-Dimensional Echocardiography. Ultrasound in Medicine and Biology, 2012, 38, 1284-1297.	1.5	14

#	Article	IF	Citations
539	Hypertrophic cardiomyopathy in children. Heart, 2012, 98, 1044-1054.	2.9	75
540	The Genetics of Cardiac Disease Associated with Sudden Cardiac Death. Journal of Molecular Diagnostics, 2012, 14, 424-436.	2.8	4
541	Sarcomeric hypertrophic cardiomyopathy: Genetic profile in a Portuguese population. Revista Portuguesa De Cardiologia, 2012, 31, 577-587.	0.5	41
542	Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. Journal of Molecular and Cellular Cardiology, 2012, 52, 1299-1307.	1.9	118
543	Cardiac Diseases. , 2012, , 28-74.		1
544	Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart, 2012, 98, 438-442.	2.9	61
545	Population-Based Variation in Cardiomyopathy Genes. Circulation: Cardiovascular Genetics, 2012, 5, 391-399.	5.1	126
546	Molecular characterization of a large MYBPC3 rearrangement in a cohort of 100 unrelated patients with hypertrophic cardiomyopathy. European Journal of Medical Genetics, 2012, 55, 163-166.	1.3	12
547	Management of Atrial Fibrillation in Patients With Structural Heart Disease. Circulation, 2012, 125, 945-957.	1.6	106
548	A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death. BMC Medical Genetics, 2012, 13, 105.	2.1	25
549	Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 86.	3.3	78
550	Genetics of Hypertrophic Cardiomyopathy After 20 Years. Journal of the American College of Cardiology, 2012, 60, 705-715.	2.8	614
551	Cell-Intrinsic Functional Effects of the Î±-Cardiac Myosin Arg-403-Gln Mutation in Familial Hypertrophic Cardiomyopathy. Biophysical Journal, 2012, 102, 2782-2790.	0.5	18
552	Hypertrophic cardiomyopathy - what is new?. Cor Et Vasa, 2012, 54, e300-e304.	0.1	2
553	Ethnic differences in ventricular hypertrabeculation on cardiac MRI in elite football players. Netherlands Heart Journal, 2012, 20, 389-395.	0.8	41
554	The role of reninâ€“angiotensinâ€“aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. European Journal of Human Genetics, 2012, 20, 1071-1077.	2.8	28
555	Functional characterization of the human Î±-cardiac actin mutations Y166C and M305L involved in hypertrophic cardiomyopathy. Cellular and Molecular Life Sciences, 2012, 69, 3457-3479.	5.4	52
556	In patients with hypertrophic cardiomyopathy myocardial fi brosis is associated with both left ventricular and left atrial dysfunction. Acta Cardiologica, 2012, 67, 187-193.	0.9	21

#	Article	IF	Citations
557	Management of Hypertrophic Obstructive Cardiomyopathy with a Focus on Alcohol Septal Ablation. , 2012, , .		0
558	Hypertrophic Cardiomyopathy in Infants and Children. , 0, , .		0
559	Familial Hypertrophic Cardiomyopathy-Related Troponin Mutations and Sudden Cardiac Death. , 0, , .		1
560	Dissociation of Structural and Functional Phenotypes in Cardiac Myosin-Binding Protein C Conditional Knockout Mice. Circulation, 2012, 126, 1194-1205.	1.6	26
561	Genetics of inherited cardiomyopathy. European Heart Journal, 2012, 33, 296-304.	2.2	146
562	Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging. International Journal of Cardiovascular Imaging, 2012, 28, 763-772.	1.5	17
563	New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy. Molecular Biology Reports, 2012, 39, 8777-8785.	2.3	13
564	Eugene Braunwald, MD and the Early Years of Hypertrophic Cardiomyopathy: A Conversation With Dr. Barry J. Maron. American Journal of Cardiology, 2012, 109, 1539-1547.	1.6	19
565	Hypertrophic Cardiomyopathy: Infants, Children, and Adolescents. Congenital Heart Disease, 2012, 7, 84-92.	0.2	15
566	Diversity of Mitral Valve Abnormalities in Obstructive Hypertrophic Cardiomyopathy. Progress in Cardiovascular Diseases, 2012, 54, 517-522.	3.1	48
567	Does Surgical Relief of Obstruction Improve Prognosis for Hypertrophic Cardiomyopathy?. Progress in Cardiovascular Diseases, 2012, 54, 529-534.	3.1	14
568	Anesthesia Management of Patients with Hypertrophic Obstructive Cardiomyopathy. Progress in Cardiovascular Diseases, 2012, 54, 503-511.	3.1	21
569	Can Pharmacologic Gradient Reduction Decrease Mortality in Hypertrophic Cardiomyopathy?. Progress in Cardiovascular Diseases, 2012, 54, 535-542.	3.1	5
570	Restrictive Physiology is Associated With Poor Outcomes in Children With Hypertrophic Cardiomyopathy. Pediatric Cardiology, 2012, 33, 141-149.	1.3	57
571	Prevalence and Spectrum Diseases Predisposing to Sudden Cardiac Death: Are They the Same for Both the Athlete and the Nonathlete?. Pediatric Cardiology, 2012, 33, 379-386.	1.3	3
572	Restricting Sports for Athletes With Heart Disease: Are We Saving Lives, Avoiding Lawsuits, or Just Promoting Obesity and Sedentary Living?. Pediatric Cardiology, 2012, 33, 407-416.	1.3	17
573	Uptake of Cardiac Screening and Genetic Testing Among Hypertrophic and Dilated Cardiomyopathy Families. Journal of Genetic Counseling, 2013, 22, 258-267.	1.6	61
574	Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genetics in Medicine, 2013, 15, 972-977.	2.4	110

#	Article	IF	Citations
575	Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. Journal of Molecular and Cellular Cardiology, 2013, 63, 189-198.	1.9	65
576	Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nature Reviews Cardiology, 2013, 10, 531-547.	13.7	763
577	Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine, 2013, 7, 505-516.	1.4	24
578	T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy: A preliminary study. European Journal of Radiology, 2013, 82, e225-e231.	2.6	30
579	Prediction and prevention of sudden death in young populations: the role of ECG screening. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 167-175.	1.3	6
580	Inherited Cardiomyopathies. , 2013, , 1-38.		0
581	Genetic Testing in the Contemporary Diagnosis of Cardiomyopathy. Current Heart Failure Reports, 2013, 10, 63-72.	3.3	13
583	Hypertrophic cardiomyopathy associated with an anomalous origin of right coronary artery. Herz, 2013, 38, 427-430.	1.1	5
584	Prolongation of the QTc Interval Predicts Appropriate Implantable Cardioverter-Defibrillator Therapies in Hypertrophic Cardiomyopathy. JACC: Heart Failure, 2013, 1, 149-155.	4.1	37
585	MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. Journal of Molecular and Cellular Cardiology, 2013, 65, 59-66.	1.9	49
586	Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy. American Heart Journal, 2013, 166, 775-782.	2.7	39
587	Fragmented QRS as a predictor of arrhythmic events in patients with hypertrophic obstructive cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 159-165.	1.3	42
588	Prognostic Indicators in Cats with Hypertrophic Cardiomyopathy. Journal of Veterinary Internal Medicine, 2013, 27, 1427-1436.	1.6	131
589	Inherited Cardiomyopathies. Journal of Molecular Diagnostics, 2013, 15, 158-170.	2.8	172
590	Cardiomyopathy and cardiac computed tomography: What the radiologist needs to know. Clinical Radiology, 2013, 68, e49-e58.	1.1	5
591	Familial hypertrophic cardiomyopathy: Functional effects of myosin mutation R723G in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2013, 57, 13-22.	1.9	72
593	Cardiac Imaging and Stress Testing Asymptomatic Athletes to Identify Those at Risk of Sudden Cardiac Death. JACC: Cardiovascular Imaging, 2013, 6, 993-1007.	5.3	90
594	Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human Î²-cardiac myosin motor function. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12607-12612.	7.1	144

#	Article	IF	Citations
595	Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. Cell Stem Cell, 2013, 12, 101-113.	11.1	584
596	Hypertrophic cardiomyopathy. Lancet, The, 2013, 381, 242-255.	13.7	946
597	Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study. International Journal of Cardiovascular Imaging, 2013, 29, 395-404.	1.5	8
598	Comparison of 3D Phase-Sensitive Inversion-Recovery and 2D Inversion-Recovery MRI at 3.0 T for the Assessment of Late Gadolinium Enhancement in Patients with Hypertrophic Cardiomyopathy. Academic Radiology, 2013, 20, 752-757.	2.5	18
599	Miocardiopatia hipertrÃ³fica associada a ventrÃculo esquerdo nÃ£o compactado e fÃstulas coronÃ¡rias â€“ a propÃ³sito de um caso clÃnico. Um genÃ³tipo, trÃªs fenÃ³tipos?. Revista Portuguesa De Cardiologia, 2013, 32, 919-924.	0.5	3
600	Echocardiographic Predictors of Mitral Regurgitation in High School and Collegiate Competitive Athletes. American Journal of Cardiology, 2013, 112, 1652-1656.	1.6	3
601	J wave is associated with increased risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy. Journal of International Medical Research, 2013, 41, 1281-1290.	1.0	8
602	Sudden Death in Marathon Runners. Cardiac Electrophysiology Clinics, 2013, 5, 43-51.	1.7	7
603	Heat shock protein 70 polymorphism in hypertrophic cardiomyopathy of South Indian cohort. Journal of Indian College of Cardiology, 2013, 3, 9-15.	0.1	2
604	Relation between left ventricular outflow tract obstruction and left ventricular shape in patients with hypertrophic cardiomyopathy: A cardiac magnetic resonance imaging study. Archives of Cardiovascular Diseases, 2013, 106, 440-447.	1.6	9
605	Hypertrophic cardiomyopathy associated with left ventricular noncompaction cardiomyopathy and coronary fistulae â€“ A case report. One genotype, three phenotypes?. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 919-924.	0.2	3
606	Dramatically Different Phenotypic Expressions of Hypertrophic Cardiomyopathy in Male Cousins Undergoing Cardiac Transplantation With Identical Disease-Causing Gene Mutation. American Journal of Cardiology, 2013, 111, 1818-1822.	1.6	7
607	Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program. Journal of Cardiovascular Translational Research, 2013, 6, 65-80.	2.4	31
608	A Clinical Approach to Inherited Hypertrophy. Circulation: Cardiovascular Genetics, 2013, 6, 118-131.	5.1	22
609	Antihypertensive Therapy in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2013, 111, 1040-1045.	1.6	28
610	Trends in cardiovascular engineering: Organizing the human heart. Trends in Cardiovascular Medicine, 2013, 23, 282-286.	4.9	9
611	Sudden Cardiac Death in Young Athletes. Journal of the American College of Cardiology, 2013, 61, 1027-1040.	2.8	191
612	Pericarditis, Myocarditis, and Other Cardiomyopathies. Primary Care - Clinics in Office Practice, 2013, 40, 213-236.	1.6	4

#	Article	IF	Citations
613	Obstructive sleep apnea and hypertrophic cardiomyopathy: A common and potential harmful combination. Sleep Medicine Reviews, 2013, 17, 201-206.	8.5	29
615	Focused Physicianâ€Performed Echocardiography in Sports Medicine. Journal of Ultrasound in Medicine, 2013, 32, 2101-2106.	1.7	10
616	Value of Electroâ€Vectorcardiogram in Hypertrophic Cardiomyopathy. Annals of Noninvasive Electrocardiology, 2013, 18, 311-326.	1.1	16
617	Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy. Cardiovascular Research, 2013, 100, 63-73.	3.8	86
618	Sudden Cardiac Death in Young Athletes: Preparticipation Screening for Underlying Cardiovascular Abnormalities and Approaches to Prevention. Physician and Sportsmedicine, 2013, 41, 81-93.	2.1	8
619	Screening athletes for cardiovascular disease in Africa: a challenging experience. British Journal of Sports Medicine, 2013, 47, 579-584.	6.7	17
620	Experience, outcomes and impact of delayed indication for video-assisted wide septal myectomy in 69 consecutive patients with hypertrophic cardiomyopathyâ€. European Journal of Cardio-thoracic Surgery, 2013, 44, e149-e155.	1.4	4
621	Focal Energy Deprivation Underlies Arrhythmia Susceptibility in Mice With Calcium-Sensitized Myofilaments. Circulation Research, 2013, 112, 1334-1344.	4.5	42
622	Hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2013, 28, 130-138.	1.8	7
623	Sudden cardiac death: detecting the warning signs. Clinical Medicine, 2013, 13, 614-617.	1.9	5
624	Perturbed Length-Dependent Activation in Human Hypertrophic Cardiomyopathy With Missense Sarcomeric Gene Mutations. Circulation Research, 2013, 112, 1491-1505.	4.5	191
625	Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. Cmaj, 2013, 185, 127-134.	2.0	34
626	E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction. Journal of General Physiology, 2013, 142, 241-255.	1.9	28
627	Syncope in patients with structural heart disease. Journal of Internal Medicine, 2013, 273, 336-344.	6.0	13
628	Emerging roles for cardiovascular magnetic resonance. Clinical Medicine, 2013, 13, s3-s8.	1.9	0
629	Rescue of cardiomyopathy through U7sn<scp>RNA</scp>â€mediated exon skipping in Mybpc3â€targeted knockâ€in mice. EMBO Molecular Medicine, 2013, 5, 1128-1145.	6.9	85
630	Advances of cardiovascular MRI in hypertrophic cardiomyopathy. Future Cardiology, 2013, 9, 697-709.	1.2	1
631	Somatic <i>MYH7</i>, <i>MYBPC3</i>, <i>TPM1</i>, <i>TNNT2</i> and <i>TNNI3</i> Mutations in Sporadic Hypertrophic Cardiomyopathy. Circulation Journal, 2013, 77, 2358-2365.	1.6	15

#	Article	IF	Citations
632	Impact of Systolic Dysfunction in Genotyped Hypertrophic Cardiomyopathy. Clinical Cardiology, 2013, 36, 160-165.	1.8	17
633	Lack of reliable clinical predictors to identify obstructive sleep apnea in patients with hypertrophic cardiomyopathy. Clinics, 2013, 68, 992-996.	1.5	15
635	Mimics of Hypertrophic Cardiomyopathy â€“ Diagnostic Clues to Aid Early Identification of Phenocopies. Arrhythmia and Electrophysiology Review, 2013, 2, 36.	2.4	30
636	Effects of Troponin T Cardiomyopathy Mutations on the Calcium Sensitivity of the Regulated Thin Filament and the Actomyosin Cross-Bridge Kinetics of Human Î²-Cardiac Myosin. PLoS ONE, 2013, 8, e83403.	2.5	53
637	Hypertrophic Cardiomyopathies. , 2013, , 572-586.		0
638	Disease Models for the Genetic Cardiac Diseases. , 0, , .		0
639	Hypertrophic cardiomyopathyâ€"genetic causes and ethical challenges for clinical care. British Journal of Cardiac Nursing, 2014, 9, 436-441.	0.1	0
640	Familial Hypertrophic Cardiomyopathy: New Insight on Mode of Inheritance among Egyptian Children. Journal of Clinical & Experimental Cardiology, 2014, 05, .	0.0	0
641	Assessment of Myocardial Function from Cine Cardiac MRI Using a Novel 4D Tracking Approach. Journal of Computer Science and Systems Biology, 2014, 07, .	0.0	17
643	Study of a Colombian Family with Hypertrophic Cardiomyopathy and Sudden Cardiac Death Associated with the Lys247arg Mutation in the Cardiac Troponin T (Tnnt2) Gene: Casual Relationship or Polymorphism?. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2014, 08, .	0.1	1
644	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. Expert Review of Cardiovascular Therapy, 2014, 12, 499-519.	1.5	33
645	Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. European Journal of Heart Failure, 2014, 16, 950-957.	7.1	53
646	Mechanochemotransduction During Cardiomyocyte Contraction Is Mediated by Localized Nitric Oxide Signaling. Science Signaling, 2014, 7, ra27.	3.6	128
647	Rare Variants in Genes Encoding MuRF1 and MuRF2 Are Modifiers of Hypertrophic Cardiomyopathy. International Journal of Molecular Sciences, 2014, 15, 9302-9313.	4.1	39
648	Reduction of left ventricular longitudinal global and segmental systolic functions in patients with hypertrophic cardiomyopathy: Study of two-dimensional tissue motion annular displacement. Experimental and Therapeutic Medicine, 2014, 7, 1457-1464.	1.8	11
649	Are We Missing Hypertrophic Cardiomyopathy in Pregnancy? Experience of a Tertiary Care Hospital. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, OC13-5.	0.8	5
650	Hypertrophic cardiomyopathy in the developing world: focus on India. European Heart Journal, 2014, 35, 2492-2495.	2.2	11
651	The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Open Heart, 2014, 1, e000176.	2.3	19

#	Article	IF	Citations
652	Deformation patterns in genotyped patients with hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2014, 15, 456-465.	1.2	23
653	Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nature Communications, 2014, 5, 5515.	12.8	131
654	Utility of coronary CT angiography in outpatients with hypertrophic cardiomyopathy presenting with angina symptoms. Journal of Cardiovascular Computed Tomography, 2014, 8, 429-437.	1.3	26
655	Î²-Myosin Heavy Chain Variant Val606Met Causes Very Mild Hypertrophic Cardiomyopathy in Mice, but Exacerbates HCM Phenotypes in Mice Carrying Other HCM Mutations. Circulation Research, 2014, 115, 227-237.	4.5	38
656	Therapeutic management of hypertrophic obstructive cardiomyopathy: alcohol septal ablation or surgical myomectomy?. Expert Review of Cardiovascular Therapy, 2014, 12, 1041-1044.	1.5	3
657	The Dilemma of Genotype Positive-Phenotype Negative Hypertrophic Cardiomyopathy. Current Sports Medicine Reports, 2014, 13, 94-99.	1.2	11
658	Pregnancy in Women With Hypertrophic Cardiomyopathy. Cardiology in Review, 2014, 22, 217-222.	1.4	33
660	Hypertrophic Cardiomyopathy: A Review. Clinical Medicine Insights: Cardiology, 2014, 8s1, CMC.S15717.	1.8	37
661	CMD in Myocardial Diseases. , 2014, , 115-143.		0
662	Clinical predictors of a positive genetic test in hypertrophic cardiomyopathy in the Brazilian population. BMC Cardiovascular Disorders, 2014, 14, 36.	1.7	6
663	Confusion Surrounding False-Positive Rates. Current Sports Medicine Reports, 2014, 13, 69-70.	1.2	0
664	Left ventricular noncompaction associated with hypertrophic cardiomyopathy: Echocardiographic diagnosis and genetic analysis of a new pedigree in China. International Journal of Cardiology, 2014, 174, 249-259.	1.7	22
665	Electrocardiography-inclusive screening strategies for detection of cardiovascular abnormalities in high school athletes. Heart Rhythm, 2014, 11, 442-449.	0.7	62
666	Optimization of Ultrasound Parameters of Myocardial Cavitation Microlesions for Therapeutic Application. Ultrasound in Medicine and Biology, 2014, 40, 1228-1236.	1.5	18
667	CT characterization of myocardial substrate in hypertrophic cardiomyopathy. Journal of Cardiovascular Computed Tomography, 2014, 8, 166-169.	1.3	1
668	Hypertrophic cardiomyopathy in the Saudi Arabian population: Clinical and echocardiographic characteristics and outcome analysis. Journal of the Saudi Heart Association, 2014, 26, 7-13.	0.4	5
669	The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 700-722.	2.6	137
670	Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genetics in Medicine, 2014, 16, 286-293.	2.4	83

#	Article	IF	Citations
671	Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases. Biophysical Journal, 2014, 106, 1236-1249.	0.5	226
672	Muscle dysfunction in hypertrophic cardiomyopathy: What is needed to move to translation?. Journal of Muscle Research and Cell Motility, 2014, 35, 37-45.	2.0	18
673	MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction. Pflugers Archiv European Journal of Physiology, 2014, 466, 215-223.	2.8	34
674	Cardiac myosin-binding protein C: hypertrophic cardiomyopathy mutations and structureâ€“function relationships. Pflugers Archiv European Journal of Physiology, 2014, 466, 201-206.	2.8	26
675	Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). Journal of Inherited Metabolic Disease, 2014, 37, 455-460.	3.6	47
676	Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart Journal, 2014, 66, S35-S45.	0.5	8
677	Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: The role of diagnostic electrocardiography. Journal of Cardiology, 2014, 64, 265-272.	1.9	32
678	Almanac 2014: cardiomyopathies. Heart, 2014, 100, 756-764.	2.9	8
679	Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy. Pflugers Archiv European Journal of Physiology, 2014, 466, 225-230.	2.8	14
680	MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25Âbp deletion mutation. Pflugers Archiv European Journal of Physiology, 2014, 466, 207-213.	2.8	21
681	DNA Sequence Capture and Next-Generation Sequencing for the Molecular Diagnosis of Genetic Cardiomyopathies. Journal of Molecular Diagnostics, 2014, 16, 32-44.	2.8	43
682	Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review. Future Cardiology, 2014, 10, 229-233.	1.2	2
683	Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy. Nature Communications, 2014, 5, 5326.	12.8	154
684	Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1594-H1604.	3.2	23
685	Early Screening for Cardiovascular Abnormalities With Preparticipation Echocardiography. Journal of Ultrasound in Medicine, 2014, 33, 307-313.	1.7	33
686	Genetics of hypertrophic cardiomyopathy in Norway. Clinical Genetics, 2014, 86, 355-360.	2.0	22
687	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
688	Exome Sequencing Identifies a Novel MYH7 p.G407C Mutation Responsible for Familial Hypertrophic Cardiomyopathy. DNA and Cell Biology, 2014, 33, 699-704.	1.9	4

#	Article	IF	Citations
689	Ablation of plasma membrane Ca2+-ATPase isoform 4 prevents development of hypertrophy in a model of hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2014, 77, 53-63.	1.9	10
690	Unveiling nonischemic cardiomyopathies with cardiac magnetic resonance. Expert Review of Cardiovascular Therapy, 2014, 12, 217-239.	1.5	0
691	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 64, 83-99.	2.8	541
692	Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 49.	3.3	73
693	Assessment of the 12-Lead Electrocardiogram asÂaÂScreening Test for Detection of Cardiovascular DiseaseÂinÂHealthy General Populations of Young PeopleÂ(12â€“25ÂYears of Age). Journal of the American College of Cardiology, 2014, 64, 1479-1514.	2.8	180
694	Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors. American Journal of Cardiology, 2014, 113, 1550-1555.	1.6	107
695	Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart, 2014, 100, 465-472.	2.9	248
696	Cardiovascular Magnetic Resonance Imaging of Myocardial Interstitial Expansion in Hypertrophic Cardiomyopathy. Current Cardiovascular Imaging Reports, 2014, 7, 9267.	0.6	19
697	Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H807-H815.	3.2	45
698	Inherited cardiomyopathies. Medicine, 2014, 42, 584-590.	0.4	0
699	Life threatening causes of syncope: Channelopathies and cardiomyopathies. Autonomic Neuroscience: Basic and Clinical, 2014, 184, 53-59.	2.8	3
700	Molecular Dynamics-Based Predictions of the Structural and Functional Effects of Disease-Causing Cardiac Troponin Mutations. Biophysical Journal, 2014, 106, 678a.	0.5	0
701	Isolated hypertrophy of the basal ventricular septum: Characteristics of patients with and without outflow tract obstruction. International Journal of Cardiology, 2014, 173, 487-493.	1.7	30
702	Echocardiography for Hypertrophic Cardiomyopathy. Progress in Cardiovascular Diseases, 2014, 57, 91-99.	3.1	6
703	The value of cardiac genetic testing. Trends in Cardiovascular Medicine, 2014, 24, 217-224.	4.9	37
704	Left ventricular apical aneurysm and systolic dysfunction in hypertrophic cardiomyopathy. Journal of Cardiology, 2014, 64, 253-255.	1.9	3
705	New Molecular Genetic Tests in the Diagnosis of Heart Disease. Clinics in Laboratory Medicine, 2014, 34, 137-156.	1.4	9
706	Early Changes in Apical Rotation in Genotype Positive Children with Hypertrophic Cardiomyopathy Mutations without Hypertrophic Changes on Two-Dimensional Imaging. Journal of the American Society of Echocardiography, 2014, 27, 215-221.	2.8	44

#	Article	IF	Citations
707	Nomenclature and systems of classification for cardiomyopathy in children. Cardiology in the Young, 2015, 25, 31-42.	0.8	13
708	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq1 1 0.784314 rgBT /Ov	7.1	114
709	Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing. Scientific Reports, 2015, 5, 11411.	3.3	27
710	Contractility parameters of human Î²-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. Science Advances, 2015, 1, e1500511.	10.3	102
711	Investigation of Pathogenic Genes in Chinese sporadic Hypertrophic Cardiomyopathy Patients by Whole Exome Sequencing. Scientific Reports, 2015, 5, 16609.	3.3	39
712	Nonobstructive septal hypertrophy in a young adult provoking recurrent polymorphic ventricular tachycardia successfully treated with transaortic and transventricular septal myectomy: A case report. HeartRhythm Case Reports, 2015, 1, 300-304.	0.4	0
713	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathologica Communications, 2015, 3, 68.	5.2	13
714	The Electrocardiogram Is a Poor Diagnostic Tool to Detect Left Ventricular Hypertrophy in Children: A Comparison with Echocardiographic Assessment of Left Ventricular Mass. Congenital Heart Disease, 2015, 10, E164-E171.	0.2	17
715	Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Pharmacotherapy, 2015, 35, 1164-1172.	2.6	18
716	Quality Control and Reproducibility in Mâ€Mode, Twoâ€Dimensional, and Speckle Tracking Echocardiography Acquisition and Analysis: The CARDIA Study, Year 25 Examination Experience. Echocardiography, 2015, 32, 1233-1240.	0.9	70
717	Role of imaging in evaluation of sudden cardiac death risk in hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2015, 30, 493-499.	1.8	7
718	Survival and Clinical Behavior of Hypertrophic Cardiomyopathy in a Latin American Cohort in Contrast to Cohorts from the Developed World. Journal of Cardiovascular Imaging, 2015, 23, 20.	0.8	6
719	Community Cardiovascular Screening to Identify Middle School Children at Risk of Sudden Cardiac Death: The Houston Early Age Risk Testing and Screening (HEARTS) Study. Journal of Child and Adolescent Behavior, 2015, 03, .	0.2	0
720	Association Between Genetic Variation in the <i>SCN10A</i> Gene and Cardiac Conduction Abnormalities in Patients With Hypertrophic Cardiomyopathy. International Heart Journal, 2015, 56, 421-427.	1.0	19
721	Morphological and Electrical Characteristics in Patient with Hypertrophic Cardiomyopathy: Quantitative Analysis of 864 Korean Cohort. Yonsei Medical Journal, 2015, 56, 1515.	2.2	1
722	Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. International Journal of Molecular Sciences, 2015, 16, 18894-18922.	4.1	41
723	Mechanical aberrations in hypetrophic cardiomyopathy: emerging concepts. Frontiers in Physiology, 2015, 6, 232.	2.8	1
724	Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies. Molecular and Cellular Probes, 2015, 29, 308-314.	2.1	44

#	Article	IF	Citations
725	Sudden Cardiac Death: A Modern Pathology Approach to Hypertrophic Cardiomyopathy. Archives of Pathology and Laboratory Medicine, 2015, 139, 413-416.	2.5	14
726	Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. European Heart Journal, 2015, 36, 1547-1554.	2.2	53
727	Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease. Journal of Cardiology, 2015, 65, 519-525.	1.9	4
728	Effects of lifestyle changes and high-dose Î²-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy. Cardiology in the Young, 2015, 25, 501-510.	0.8	7
730	General Practitionersâ€™ knowledge and use of genetic counselling in managing patients with genetic cardiac disease in non-specialised settings. Journal of Community Genetics, 2015, 6, 375-382.	1.2	4
731	Use of Theranostic Strategies in Myocardial Cavitation-Enabled Therapy. Ultrasound in Medicine and Biology, 2015, 41, 1865-1875.	1.5	14
732	Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiac magnetic resonance. European Heart Journal Cardiovascular Imaging, 2015, 16, 29-36.	1.2	22
733	Short-term beat-to-beat variability of the QT interval is increased and correlates with parameters of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Canadian Journal of Physiology and Pharmacology, 2015, 93, 765-772.	1.4	14
734	Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). Journal of Veterinary Cardiology, 2015, 17, S244-S257.	0.9	165
735	Hypertrophic cardiomyopathy: Past, presentâ€¦ and future. Trends in Cardiovascular Medicine, 2015, 25, 65-66.	4.9	6
737	The 20 advances that have defined contemporary hypertrophic cardiomyopathy. Trends in Cardiovascular Medicine, 2015, 25, 54-64.	4.9	17
738	Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 123-131.	11.4	104
739	Modest agreement in ECG interpretation limits the application of ECG screening in young athletes. Heart Rhythm, 2015, 12, 130-136.	0.7	48
740	How to effectively utilize genetic testing in the care of children with cardiomyopathies. Progress in Pediatric Cardiology, 2015, 39, 3-11.	0.4	4
741	Almanac 2014: cardiomyopathies. Cor Et Vasa, 2015, 57, e28-e38.	0.1	0
742	Magnetic Resonance Imaging of Hypertrophic Cardiomyopathy: Beyond Left Ventricular Wall Thickness. Canadian Association of Radiologists Journal, 2015, 66, 71-78.	2.0	7
743	Sex-dependent pathophysiological mechanisms in hypertrophic cardiomyopathy: Implications for rhythm disorders. Heart Rhythm, 2015, 12, 433-439.	0.7	12
744	Coexistence of Digenic Mutations in Both Thin (TPM1) and Thick (MYH7) Filaments of Sarcomeric Genes Leads to Severe Hypertrophic Cardiomyopathy in a South Indian FHCM. DNA and Cell Biology, 2015, 34, 350-359.	1.9	23

#	Article	IF	Citations
745	Variants in miRNA Regulating Cardiac Growth Are Not a Common Cause of Hypertrophic Cardiomyopathy. Cardiology, 2015, 130, 137-142.	1.4	3
746	The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy. Biochemical Society Transactions, 2015, 43, 64-72.	3.4	111
747	Systematic echocardiography is not efficacious when screening an ethnically diverse cohort of athletes in West Asia. European Journal of Preventive Cardiology, 2015, 22, 263-270.	1.8	29
748	The Genetic Landscape of Cardiomyopathy and Its Role in Heart Failure. Cell Metabolism, 2015, 21, 174-182.	16.2	106
749	Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genetics in Medicine, 2015, 17, 880-888.	2.4	344
750	<scp>TWEAK</scp> and <scp>NT</scp>â€pro<scp>BNP</scp> levels predict exercise capacity in hypertrophic cardiomyopathy. European Journal of Clinical Investigation, 2015, 45, 179-186.	3.4	5
751	Factors Associated with Uptake of Genetics Services for Hypertrophic Cardiomyopathy. Journal of Genetic Counseling, 2015, 24, 797-809.	1.6	12
753	Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. European Heart Journal Cardiovascular Imaging, 2015, 16, 280-280.	1.2	214
754	Parturients with hypertrophic cardiomyopathy: case series and review of pregnancy outcomes and anesthetic management of labor and delivery. International Journal of Obstetric Anesthesia, 2015, 24, 344-355.	0.4	21
755	Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs. Gene, 2015, 571, 153-166.	2.2	94
756	A Systematic Review of Phenotypic Features Associated With Cardiac Troponin I Mutations in Hereditary Cardiomyopathies. Canadian Journal of Cardiology, 2015, 31, 1377-1385.	1.7	37
757	Something Old, Something New. Clinics in Sports Medicine, 2015, 34, 517-537.	1.8	4
758	Decreased Exercise Capacity and Sleep-Disordered Breathing in Patients With Hypertrophic Cardiomyopathy. Chest, 2015, 147, 1574-1581.	0.8	20
759	Dextrocardia and symmetric hypertrophic cardiomyopathy with multiple mutations of genes encoding the sarcomere proteins. International Journal of Cardiology, 2015, 187, 581-584.	1.7	2
760	Detection of mutations in symptomatic patients with hypertrophic cardiomyopathy in Taiwan. Journal of Cardiology, 2015, 65, 250-256.	1.9	17
761	Atrial and Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 173-186.	1.7	23
762	Correlation of Precordial Voltages to Left Ventricular Mass on Echocardiogram in Adolescent Patients With Hypertrophic Cardiomyopathy Compared With that in Adolescent Athletes. American Journal of Cardiology, 2015, 115, 956-961.	1.6	9
763	Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovascular Research, 2015, 105, 397-408.	3.8	187

#	Article	IF	Citations
764	An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2015, 8, 232-243.	2.4	14
765	New Perspectives on the Prevalence ofÂHypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 1249-1254.	2.8	918
766	Mechanistic Heterogeneity in Contractile Properties of Î±-Tropomyosin (TPM1) Mutants Associated with Inherited Cardiomyopathies. Journal of Biological Chemistry, 2015, 290, 7003-7015.	3.4	41
767	Exercise Heart Rates in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 115, 1144-1150.	1.6	21
768	Elevated Ca‹sup›2+‹/sup› transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1086-H1095.	3.2	13
769	Hypertrophic cardiomyopathy associated with sleep apnea: serious implications and cogent management strategy. Expert Review of Cardiovascular Therapy, 2015, 13, 277-284.	1.5	6
770	Surgery for hypertrophic cardiomyopathy. Biophysical Reviews, 2015, 7, 117-125.	3.2	10
771	Regional Stress-Induced Ischemia in Non-fibrotic Hypertrophied Myocardium in Young HCM Patients. Pediatric Cardiology, 2015, 36, 1662-1669.	1.3	20
772	Imaging in Deciphering Histological Substrates in Hypertrophic Cardiomyopathy. Current Cardiovascular Imaging Reports, 2015, 8, 1.	0.6	0
773	At the Heart of the Matter. Journal of Diagnostic Medical Sonography, 2015, 31, 221-232.	0.3	1
774	Concise Review: Cardiac Disease Modeling Using Induced Pluripotent Stem Cells. Stem Cells, 2015, 33, 2643-2651.	3.2	39
775	The role of hemodynamic catheterization in the evaluation of hypertrophic obstructive cardiomyopathy: A case series. Catheterization and Cardiovascular Interventions, 2015, 86, 903-912.	1.7	5
776	Evolving Approaches to Genetic Evaluation of Specific Cardiomyopathies. Current Heart Failure Reports, 2015, 12, 339-349.	3.3	12
777	Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. Expert Opinion on Orphan Drugs, 2015, 3, 869-876.	0.8	54
778	Determined to Failâ€"the Role of Genetic Mechanisms in Heart Failure. Current Heart Failure Reports, 2015, 12, 333-338.	3.3	8
779	The Genetic Challenges and Opportunities in Advanced Heart Failure. Canadian Journal of Cardiology, 2015, 31, 1338-1350.	1.7	7
780	Cardiac sympathetic activity in hypertrophic cardiomyopathy and Tako-tsubo cardiomyopathy. Clinical and Translational Imaging, 2015, 3, 379-385.	2.1	11
781	The structural and functional effects of the familial hypertrophic cardiomyopathy-linked cardiac troponin C mutation, L29Q. Journal of Molecular and Cellular Cardiology, 2015, 87, 257-269.	1.9	18

#	Article	IF	Citations
782	Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene, 2015, 573, 188-197.	2.2	148
783	The E3 ubiquitin ligase Asb2Î² is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation. Journal of Molecular and Cellular Cardiology, 2015, 87, 214-224.	1.9	35
784	Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations. Journal of Muscle Research and Cell Motility, 2015, 36, 433-445.	2.0	31
785	Intrauterine Treatment of a Fetus with Familial Hypertrophic Cardiomyopathy Secondary to MYH7 Mutation. Pediatric Cardiology, 2015, 36, 1774-1777.	1.3	5
786	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes. Journal of the American College of Cardiology, 2015, 66, 2356-2361.	2.8	103
787	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: TaskÂForce 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis. Journal of the American College of Cardiology, 2015, 66, 2362-2371.	2.8	180
788	Manganeseâ€enhanced MRI detection of impaired calcium regulation in a mouse model of cardiac hypertrophy. NMR in Biomedicine, 2015, 28, 255-263.	2.8	7
789	Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. Journal of Molecular and Cellular Cardiology, 2015, 79, 234-243.	1.9	58
790	Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects. European Journal of Human Genetics, 2015, 23, 922-928.	2.8	70
791	Mitochondrial tRNA glutamine variant in hypertrophic cardiomyopathy. Herz, 2015, 40, 436-441.	1.1	4
793	Pregnancy in Hypertrophic Cardiomyopathy with Severe Left Ventricular Outflow Tract Obstruction. Journal of Cardiovascular Imaging, 2016, 24, 158.	0.8	1
794	Genetic Susceptibility in Biochemical and Physiological Traits. , 2016, , 177-217.		0
795	ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. Arrhythmia and Electrophysiology Review, 2016, 5, 188.	2.4	22
796	High-Throughput Diagnostic Assay for a Highly Prevalent Cardiomyopathy-Associated MYBPC3 Variant. Journal of Molecular Biomarkers & Diagnosis, 2016, 07, .	0.4	3
797	Clinical Characteristics and Treatment of Cardiomyopathies in Children. Current Cardiology Reviews, 2016, 12, 85-98.	1.5	15
798	The first cardioverter defibrillator implanted in Central Africa. Pan African Medical Journal, 2016, 23, 115.	0.8	1
799	A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies. Frontiers in Cardiovascular Medicine, 2016, 3, 21.	2.4	90
800	The Role of Genetic Testing in the Identification of Young Athletes with Inherited Primitive Cardiac Disorders at Risk of Exercise Sudden Death. Frontiers in Cardiovascular Medicine, 2016, 3, 28.	2.4	7

#	Article	IF	Citations
801	Drosophila in the Heart of Understanding Cardiac Diseases: Modeling Channelopathies and Cardiomyopathies in the Fruitfly. Journal of Cardiovascular Development and Disease, 2016, 3, 7.	1.6	16
802	A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. International Journal of Molecular Sciences, 2016, 17, 1239.	4.1	19
803	Sudden Cardiac Arrest in a Patient With Apical Hypertrophic Cardiomyopathy. American Journal of Therapeutics, 2016, 23, e276-e282.	0.9	6
804	Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 461-468.	0.8	58
805	Acute Medical Problems in the Adolescent Tennis Player. Contemporary Pediatric and Adolescent Sports Medicine, 2016, , 105-119.	0.0	0
806	High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. Journal of Cardiovascular Electrophysiology, 2016, 27, 779-784.	1.7	39
807	Effect of alcohol dosage on longâ€term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions, 2016, 88, 945-952.	1.7	5
808	Silent AF and Hypertrophic Stroke Risk: More Data, More Monitoring. Journal of Cardiovascular Electrophysiology, 2016, 27, 785-787.	1.7	1
809	QRS fragmentation: its role in sherlocking the arrhythmogenic heart. Journal of Community Hospital Internal Medicine Perspectives, 2016, 6, 31235.	0.8	3
810	Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy. Catheterization and Cardiovascular Interventions, 2016, 88, 971-977.	1.7	6
812	Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2016, 102, 1533-1543.	2.9	89
813	Clinical and Mechanistic Insights Into theÂGenetics of Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 2871-2886.	2.8	244
814	Genetics and Genomics of Single-Gene Cardiovascular Diseases. Journal of the American College of Cardiology, 2016, 68, 2831-2849.	2.8	43
815	Registry report of structural and functional cardiac abnormalities diagnosed by echocardiography in an asymptomatic population. Postgraduate Medical Journal, 2016, 92, 450-454.	1.8	2
816	The role of intraoperative transesophageal echocardiographic monitoring in a patient with hypertrophic cardiomyopathy undergoing laparoscopic surgery. Journal of Clinical Anesthesia, 2016, 34, 124-127.	1.6	1
817	Is There a Role for Limited Echocardiography During the Preparticipation Physical Examination?. PM and R, 2016, 8, S36-S44.	1.6	9
818	Acute Effects of Nasal CPAP in Patients With Hypertrophic Cardiomyopathy. Chest, 2016, 150, 1050-1058.	0.8	9
819	Effects of Cardiac Troponin I Mutation P83S on Contractile Properties and the Modulation by PKA-Mediated Phosphorylation. Journal of Physical Chemistry B, 2016, 120, 8238-8253.	2.6	15

#	Article	IF	Citations
820	Trends in the prevalence of heart diseases over a ten-year period from single-center observations based on a large echocardiographic database. Journal of Zhejiang University: Science B, 2016, 17, 54-59.	2.8	6
821	Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. Journal of the American Society of Echocardiography, 2016, 29, 622-639.	2.8	50
822	Comparison of Clinical Features in Blacks Versus Whites With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 1815-1820.	1.6	15
823	Troponins, intrinsic disorder, and cardiomyopathy. Biological Chemistry, 2016, 397, 731-751.	2.5	18
824	The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency. Archives of Biochemistry and Biophysics, 2016, 601, 133-140.	3.0	19
825	Electrocardiographic evaluation in athletes: â€˜Normalâ€™ changes in the athlete's heart and benefits and disadvantages of screening. Revista Portuguesa De Cardiologia, 2016, 35, 169-177.	0.5	7
826	Identification of novel mutations including a double mutation in patients with inherited cardiomyopathy by a targeted sequencing approach using the Ion Torrent PGM system. International Journal of Molecular Medicine, 2016, 37, 1511-1520.	4.0	9
827	Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy. JAMA Cardiology, 2016, 1, 324.	6.1	228
828	Stem Cell Proteomics. , 2016, , 123-153.		0
829	Anti-calreticulin antibodies and calreticulin in sera of patients diagnosed with dilated or hypertrophic cardiomyopathy. Autoimmunity, 2016, 49, 554-562.	2.6	4
830	Hypertrophic cardiomyopathy mutations in the calponin-homology domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation. Biochemical Journal, 2016, 473, 2485-2493.	3.7	42
831	Genetic Misdiagnoses and the Potential for Health Disparities. New England Journal of Medicine, 2016, 375, 655-665.	27.0	602
832	Extent of Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in Japanese Hypertrophic Cardiomyopathy Patients. Circulation Journal, 2016, 80, 950-957.	1.6	11
833	Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2016, 99, 197-206.	1.9	52
834	A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 1897-1907.	1.6	15
835	AMSSM Position Statement on Cardiovascular Preparticipation Screening in Athletes: Current Evidence, Knowledge Gaps, Recommendations and Future Directions. Current Sports Medicine Reports, 2016, 15, 359-375.	1.2	15
836	Sudden Cardiac Arrest in Pediatrics. Pediatric Emergency Care, 2016, 32, 630-636.	0.9	4
837	AMSSM Position Statement on Cardiovascular Preparticipation Screening in Athletes: Current Evidence, Knowledge Gaps, Recommendations, and Future Directions: Erratum.. Clinical Journal of Sport Medicine, 2018, 28, 324-324.	1.8	35

#	Article	IF	Citations
838	Causes of death and mortality in hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden. Journal of Cardiovascular Medicine, 2016, 17, 478-484.	1.5	9
839	The Case of â€œMissing Causal Genesâ€•and the Practice of Medicine. Circulation Research, 2016, 119, 21-24.	4.5	12
840	Multidimensional structure-function relationships in human Î²-cardiac myosin from population-scale genetic variation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6701-6706.	7.1	98
841	Recent advances in genetic testing and counseling for inherited arrhythmias. Journal of Arrhythmia, 2016, 32, 389-397.	1.2	27
842	Electrocardiographic evaluation in athletes: â€˜Normalâ€™ changes in the athlete's heart and benefits and disadvantages of screening. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 169-177.	0.2	4
843	Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. Journal of Molecular and Cellular Cardiology, 2016, 97, 82-92.	1.9	48
844	Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2016, 94, 65-71.	1.9	113
845	Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline. Current Cardiology Reports, 2016, 18, 70.	2.9	7
846	Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2016, 27, 953-960.	1.7	23
847	Now you see me, now you don't: The case of a vanishing outflow gradient in a patient with hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions, 2016, 88, 1006-1009.	1.7	0
848	Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human Î²-cardiac myosin. Journal of Experimental Biology, 2016, 219, 161-167.	1.7	60
849	Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. American Journal of Cardiology, 2016, 117, 1651-1654.	1.6	95
850	Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy. Heart, 2016, 102, 741-747.	2.9	88
853	A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science, 2016, 351, 617-621.	12.6	494
854	Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Archives of Biochemistry and Biophysics, 2016, 601, 11-21.	3.0	37
855	The Muscle-Bound Heart. Cardiac Electrophysiology Clinics, 2016, 8, 223-231.	1.7	6
856	Sudden Cardiac Death in the Young. Circulation, 2016, 133, 1006-1026.	1.6	115
857	Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. Radiographics, 2016, 36, 335-354.	3.3	83

#	Article	IF	Citations
858	Atomic resolution probe for allostery in the regulatory thin filament. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3257-3262.	7.1	53
859	Abnormal Mitral Valve Dimensions in Pediatric Patients with Hypertrophic Cardiomyopathy. Pediatric Cardiology, 2016, 37, 784-788.	1.3	3
860	MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients. Human Genetics, 2016, 135, 477-483.	3.8	26
862	The Ups and Downs of Genetic Diagnosis of Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2016, 69, 61-68.	0.6	7
863	Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. European Heart Journal, 2016, 37, 1815-1822.	2.2	63
864	Whole exome sequencing combined with integrated variant annotation prediction identifies a causative myosin essential light chain variant in hypertrophic cardiomyopathy. Journal of Cardiology, 2016, 67, 133-139.	1.9	14
865	Clinical and Prognostic Profiles of Cardiomyopathies Caused by Mutations in the Troponin T Gene. Revista Espanola De Cardiologia (English Ed), 2016, 69, 149-158.	0.6	17
866	The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. Journal of Cardiology, 2016, 68, 49-56.	1.9	42
867	Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score ofÂâ‰1 and without anticoagulant therapy. Heart and Vessels, 2016, 31, 1148-1153.	1.2	7
868	Misconceptions and Facts About Hypertrophic Cardiomyopathy. American Journal of Medicine, 2016, 129, 148-152.	1.5	17
869	Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. Journal of Medicinal Chemistry, 2016, 59, 2-15.	6.4	31
870	Phenotypeâ€driven molecular autopsy for sudden cardiac death. Clinical Genetics, 2017, 91, 22-29.	2.0	30
871	Familial hypertrophic cardiomyopathy caused by a de novo Gly716Arg mutation of the Î²-myosin heavy chain. Cardiology in the Young, 2017, 27, 467-472.	0.8	4
872	A Long Term Follow-up Study of Carriers of Hypertrophic Cardiomyopathy Mutations. Heart Lung and Circulation, 2017, 26, 18-24.	0.4	4
873	Animal Models of Congenital Cardiomyopathies Associated With Mutations in Z-Line Proteins. Journal of Cellular Physiology, 2017, 232, 38-52.	4.1	19
874	Limits of ventricular function: from athlete's heart to a failing heart. Clinical Physiology and Functional Imaging, 2017, 37, 549-557.	1.2	4
875	Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. European Heart Journal, 2017, 38, ehw603.	2.2	142
877	The current state of clinical interpretation of sequence variants. Current Opinion in Genetics and Development, 2017, 42, 33-39.	3.3	77

#	Article	IF	Citations
878	The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. American Heart Journal, 2017, 187, 145-155.	2.7	41
879	AMSSM Position Statement on Cardiovascular Preparticipation Screening in Athletes: Current evidence, knowledge gaps, recommendations and future directions. British Journal of Sports Medicine, 2017, 51, 153-167.	6.7	115
880	1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes. Radiologia Medica, 2017, 122, 265-272.	7.7	4
881	Cardiac gene therapy with adeno-associated virus-based vectors. Current Opinion in Cardiology, 2017, 32, 275-282.	1.8	42
882	Descending septal branch of right coronary artery: Rare, but important in hypertrophic cardiomyopathy. Cardiovascular Revascularization Medicine, 2017, 18, 23-25.	0.8	0
883	CMR in Phenotyping the Arrhythmic Substrate. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.6	0
884	Titin-Truncating Variants Increase the Risk of Cardiovascular Death in Patients With Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2017, 33, 1292-1297.	1.7	18
885	Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney International Reports, 2017, 2, 913-923.	0.8	42
886	Application of NGS in the Diagnosis of Cardiovascular Genetic Diseases. , 2017, , 243-286.		0
887	Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 243, 283-289.	1.7	25
888	Calcium Signaling and Cardiac Arrhythmias. Circulation Research, 2017, 120, 1969-1993.	4.5	368
889	Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. Journal of the American Heart Association, 2017, 6, .	3.7	38
890	Coronary Microcirculatory Dysfunction in Human Cardiomyopathies. Cardiology in Review, 2017, 25, 165-178.	1.4	12
891	Prevention of sudden cardiac death in children and young adults. Progress in Pediatric Cardiology, 2017, 45, 37-42.	0.4	13
892	Myocardial Extracellular Volume Is Not Associated With Malignant Ventricular Arrhythmias in High-risk Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2017, 70, 933-940.	0.6	2
893	Time and age dependent decrease of NT-proBNP after septal myectomy in hypertrophic obstructive cardiomyopathy. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1614-1620.	2.3	4
894	Sustained ventricular tachycardia as a first manifestation of hypertrophic cardiomyopathy with mid-ventricular obstruction and apical aneurysm in an elderly female patient. , 2017, 22, e12422.		7
895	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. Revista Espanola De Cardiologia (English Ed), 2017, 70, 105-114.	0.6	10

#	Article	IF	Citations
896	Hypertrophic cardiomyopathy with aortic dilation: a novel observation. European Heart Journal Cardiovascular Imaging, 2017, 18, 1398-1403.	1.2	8
897	Activation of Autophagy Ameliorates Cardiomyopathy in Mybpc3 -Targeted Knockin Mice. Circulation: Heart Failure, 2017, 10, .	3.9	53
898	Hypertrophic Cardiomyopathy Gene Testing. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	2
899	Population Burden of Sudden Death Associated With Hypertrophic Cardiomyopathy. Circulation, 2017, 136, 1665-1667.	1.6	29
900	Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Failure Reviews, 2017, 22, 879-888.	3.9	20
901	Relationship of cardiac troponin to systolic global longitudinal strain in hypertrophic cardiomyopathy. Echocardiography, 2017, 34, 1470-1477.	0.9	11
902	Hypertrophic Cardiomyopathy. Circulation Research, 2017, 121, 749-770.	4.5	790
903	The management of diagnosed heart failure in older people in primary care. Maturitas, 2017, 106, 26-30.	2.4	7
904	Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 481-488.	2.8	30
905	El volumen extracelular no se asocia a arritmias malignas en miocardiopatÃa hipertrÃ³fica de alto riesgo. Revista Espanola De Cardiologia, 2017, 70, 933-940.	1.2	2
906	Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 489-494.	2.8	35
907	Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2017, 19, 81.	2.9	18
908	Correction of a pathogenic gene mutation in human embryos. Nature, 2017, 548, 413-419.	27.8	781
909	The PRKAG2 gene and hypertrophic cardiomyopathy: an energetically imbalanced relationship. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H248-H250.	3.2	6
910	A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. Journal of Biological Chemistry, 2017, 292, 16571-16577.	3.4	136
911	Diversity and inclusion in genomic research: why the uneven progress?. Journal of Community Genetics, 2017, 8, 255-266.	1.2	236
912	Clinical Application of Genetic Testing in Heart Failure. Current Heart Failure Reports, 2017, 14, 543-553.	3.3	6
913	Autosomal dominant polycystic kidney disease combined with hypertrophic cardiomyopathy. Medicine (United States), 2017, 96, e8625.	1.0	1

#	Article	IF	Citations
914	Generalidades de las miocardiopatÃas. MiocardiopatÃa hipertrÃ³fica. Medicine, 2017, 12, 2548-2560.	0.0	0
915	Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H620-H630.	3.2	12
916	A comparative study of mutation screening of sarcomeric genes (MYBPC3 , MYH7 , TNNT2) using single gene approach versus targeted gene panel next generation sequencing in a cohort of HCM patients in Egypt. Egyptian Journal of Medical Human Genetics, 2017, 18, 381-387.	1.0	1
917	A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease. Journal of the American Society of Echocardiography, 2017, 30, 829-844.	2.8	17
918	Myofilament protein dynamics modulate EAD formation in human hypertrophic cardiomyopathy. Progress in Biophysics and Molecular Biology, 2017, 130, 418-428.	2.9	10
919	Alcohol Septal Ablation to Reduce Heart Failure. Interventional Cardiology Clinics, 2017, 6, 445-452.	0.4	2
920	ALPK3 gene mutation in a patient with congenital cardiomyopathy and dysmorphic features. Journal of Physical Education and Sports Management, 2017, 3, a001859.	1.2	20
921	Longâ€term survival after acute myocardial infarction in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 2017, 40, 26-31.	1.8	12
923	Exercise in patients with hypertrophic cardiomyopathy: A review of current evidence, national guideline recommendations and a proposal for a new direction to fitness. Journal of Science and Medicine in Sport, 2017, 20, 333-338.	1.3	17
924	Integrated Imaging in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 328-339.	1.6	13
925	Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart and Vessels, 2017, 32, 700-707.	1.2	13
926	Medico-legal perspectives on sudden cardiac death in young athletes. International Journal of Legal Medicine, 2017, 131, 393-409.	2.2	21
927	EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)â€"rationale and design: a prospective observational study on incidence of arrhythmias in Sweden. BMJ Open, 2017, 7, e019541.	1.9	2
929	Hypertrophic Cardiomyopathyâ€"Past, Present and Future. Journal of Clinical Medicine, 2017, 6, 118.	2.4	24
930	Hypertrophic cardiomyopathy in children. Annals of Cardiothoracic Surgery, 2017, 6, 376-385.	1.7	16
931	Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes. Clinical Epidemiology, 2017, Volume 9, 403-410.	3.0	25
932	Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results. Pilot and Feasibility Studies, 2017, 3, 53.	1.2	8
933	Septal alcoholization in hypertrophic cardiomyopathy: about 11 cases. Pan African Medical Journal, 2017, 27, 196.	0.8	2

#	Article	IF	Citations
934	Next-generation Sequencing in the Clinical Decision Making in Hypertrophic Cardiomyopathy. Journal of Next Generation Sequencing & Applications, 2017, 04, .	0.3	0
935	Hypertrophic Cardiomyopathy: Treatment, Risk Stratification, and Implantable Defibrillators. , 2017, , .		0
936	Inherited Cardiomyopathies: Genetics and Clinical Genetic Testing. Cardiovascular Innovations and Applications, 2017, 2, 297-308.	0.3	0
937	Left Ventricular Outflow Tract Obstructionâ€"be Prepared!. Anaesthesia and Intensive Care, 2017, 45, 12-20.	0.7	18
938	Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy. Journal of Genetic Counseling, 2018, 27, 1040-1048.	1.6	13
939	Usefulness of Serum Omentin-1 Levels for the Prediction of Adverse Cardiac Events in Patients with Hypertrophic Cardiomyopathy. Medical Principles and Practice, 2018, 27, 107-114.	2.4	12
940	Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy. European Journal of Medical Genetics, 2018, 61, 434-441.	1.3	11
941	Electrocardiography scar quantification correlates with scar size of hypertrophic cardiomyopathy seen by multidetector computed tomography. Clinical Cardiology, 2018, 41, 837-842.	1.8	7
942	Determinants of Reverse Remodeling of the Left Atrium After Transaortic Myectomy. Annals of Thoracic Surgery, 2018, 106, 447-453.	1.3	33
943	Update in Pediatric Cardiology. , 2018, , 61-81.		0
944	A new look into hypertrophic cardiomyopathy based on clinical evidence. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 11-13.	0.2	1
945	Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Cardiology in Review, 2018, 26, 145-151.	1.4	12
946	Novel Î±â€Actin Gene Mutation p.(Ala21Val) Causing Familial Hypertrophic Cardiomyopathy, Myocardial Noncompaction, and Transmural Crypts. Clinicalâ€Pathologic Correlation. Journal of the American Heart Association, 2018, 7, .	3.7	18
947	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia, 2018, 37, 1-10.	0.5	38
948	Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 117-124.	1.3	3
949	Genetic defects in mtDNA-encoded protein translation cause pediatric, mitochondrial cardiomyopathy with early-onset brain disease. European Journal of Human Genetics, 2018, 26, 537-551.	2.8	23
950	Disclosure of cardiac variants of uncertain significance results in an exome cohort. Clinical Genetics, 2018, 93, 1022-1029.	2.0	17
951	Hypertrophic obstructive cardiomyopathy: what, when, why, for whom?. European Journal of Cardio-thoracic Surgery, 2018, 53, 700-707.	1.4	11

#	Article	IF	Citations
952	Phenotypic diversity identified by cardiac magnetic resonance in a large hypertrophic cardiomyopathy family with a single MYH7 mutation. Scientific Reports, 2018, 8, 973.	3.3	17
953	Clinical, Radiographic, and Microbiologic Features of Infective Endocarditis in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 121, 480-484.	1.6	13
954	The Development of Left Ventricular Hypertrophy in Patients With Left-Sided Obstructive Lesions: Are Genetics at Play?. Heart Lung and Circulation, 2018, 27, 1-2.	0.4	1
955	Three-dimensional echocardiography for the assessment of left ventricular geometry and papillary muscle morphology in hypertrophic cardiomyopathy. Journal of Ultrasound, 2018, 21, 17-24.	1.3	8
956	Hypertrophic Cardiomyopathy in Liver Transplantation Patients. Transplantation Proceedings, 2018, 50, 1466-1469.	0.6	6
957	Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance. Magnetic Resonance in Medical Sciences, 2018, 17, 120-131.	2.0	38
958	Texture analysis and machine learning of non-contrast T1-weighted MR images in patients with hypertrophic cardiomyopathyâ€"Preliminary results. European Journal of Radiology, 2018, 102, 61-67.	2.6	97
959	Intraoperative Two- and Three-Dimensional Transesophageal Echocardiography in Combined Myectomy-Mitral Operations for Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2018, 31, 275-288.	2.8	35
960	Genetic Testing for Cardiomyopathies in Clinical Practice. Heart Failure Clinics, 2018, 14, 129-137.	2.1	18
961	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. Heart Failure Clinics, 2018, 14, 119-128.	2.1	32
962	Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap?. Progress in Pediatric Cardiology, 2018, 49, 31-37.	0.4	6
963	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 1-10.	0.2	13
964	Have We Reached the Apex?. JACC: Clinical Electrophysiology, 2018, 4, 351-354.	3.2	1
965	A new look into hypertrophic cardiomyopathy based on clinical evidence. Revista Portuguesa De Cardiologia, 2018, 37, 11-13.	0.5	1
966	Genetic cardiomyopathies. Current Opinion in Cardiology, 2018, 33, 354-362.	1.8	36
967	Hypertrophic Cardiomyopathy in the Era of Genomic Medicine. , 2018, , 103-126.		0
968	Successful knock-in of Hypertrophic Cardiomyopathy-mutation R723G into the MYH7 gene mimics HCM pathology in pigs. Scientific Reports, 2018, 8, 4786.	3.3	27
969	Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy. Heart Failure Clinics, 2018, 14, 139-146.	2.1	83

#	Article	IF	Citations
970	Prevalence and Impact of Coexistent Bicuspid Aortic Valve in Hypertrophic Cardiomyopathy. Heart Lung and Circulation, 2018, 27, 33-40.	0.4	11
971	Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction: Expecting the Unexpected. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 467-477.	1.3	12
972	A Unique Case of Type-1 Facioscapulohumeral Muscular Dystrophy and Sarcomeric Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2018, 71, 765-766.	0.6	0
973	Un caso Ãºnico de distrofia muscular facioscapulohumeral tipo 1 y miocardiopatÃa hipertrÃ³fica sarcomÃ©rica. Revista Espanola De Cardiologia, 2018, 71, 765-766.	1.2	2
974	Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. American Journal of Medicine, 2018, 131, 200.e1-200.e8.	1.5	31
975	Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy. Expert Review of Cardiovascular Therapy, 2018, 16, 21-26.	1.5	0
976	Structural destabilization of tropomyosin induced by the cardiomyopathyâ€linked mutation R21H. Protein Science, 2018, 27, 498-508.	7.6	8
977	Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 121, 349-355.	1.6	33
978	Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light. Biophysical Reviews, 2018, 10, 27-48.	3.2	115
979	Minimally Invasive versus Full-Sternotomy Septal Myectomy for Hypertrophic Cardiomyopathy. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2018, 13, 261-266.	0.9	4
980	Role of the Cardiac Pathologist in Evaluating Sudden Natural Deaths. , 2018, , 139-191.		0
981	Left Atrium as an Active Component of the Pathophysiology in HCM. International Heart Journal, 2018, 59, 906-908.	1.0	5
982	Impact of the Myosin Modulator Mavacamten on Force Generation and Crossâ€Bridge Behavior in a Murine Model of Hypercontractility. Journal of the American Heart Association, 2018, 7, e009627.	3.7	41
984	OBSOLETE: Athletes Heart. , 2018, , .		0
985	OBSOLETE: Ventricular Arrhythmias and Sudden Cardiac Death in Hypertrophic Cardiomyopathy. , 2018, , .		0
986	CardioXNet: Automated Detection for Cardiomegaly Based on Deep Learning. , 2018, 2018, 612-615.		31
987	Mutation profile of FLNC gene and its prognostic relevance in patients with hypertrophic cardiomyopathy. Molecular Genetics & Genomic Medicine, 2018, 6, 1104-1113.	1.2	34
988	Formins Emerge as a Cause of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2468-2470.	2.8	1

#	Article	IF	Citations
989	Stem Cells Therapy for Cardiomyopathy: An Emerging Paradigm. Stem Cells in Clinical Applications, 2018, , 115-128.	0.4	0
990	A Complete Absence of Missense Mutation in Myosin Regulatory and Essential Light Chain Genes of South Indian Hypertrophic and Dilated Cardiomyopathies. Cardiology, 2018, 141, 156-166.	1.4	4
991	Genetic Evaluation of Hypertrophic Cardiomyopathy. , 0, , .		1
992	Heterozygous junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause for HCM with heart failure. PLoS ONE, 2018, 13, e0203422.	2.5	32
993	The evaluation and management of decompensated hypertrophic cardiomyopathy in the emergency department. American Journal of Emergency Medicine, 2018, 36, 2286-2288.	1.6	1
994	Differential diagnosis of thickened myocardium: an illustrative MRI review. Insights Into Imaging, 2018, 9, 695-707.	3.4	10
995	Stress Echocardiography: the Role in Assessing Valvular Heart Diseases. Current Cardiovascular Imaging Reports, 2018, 11, 1.	0.6	1
996	Phenotypes of hypertrophic cardiomyopathy. An illustrative review of MRI findings. Insights Into Imaging, 2018, 9, 1007-1020.	3.4	26
997	Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management. Progress in Pediatric Cardiology, 2018, 51, 24-30.	0.4	3
998	Gene Therapy and Genomic Application in Heart Disease. Translational Bioinformatics, 2018, , 337-374.	0.0	0
999	Disparities in the Diagnosis of Hypertrophic Obstructive Cardiomyopathy: A Narrative Review of Current Literature. Cardiology Research and Practice, 2018, 2018, 1-6.	1.1	17
1000	Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1932-1938.	1.6	18
1001	Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential. Cardiovascular Research, 2018, 114, 1828-1842.	3.8	40
1002	Outcomes of patients with hypertrophic cardiomyopathy and acute myocardial infarction: a propensity score-matched, 15-year nationwide population-based study in Asia. BMJ Open, 2018, 8, e019741.	1.9	4
1003	Prevalence of clinically apparent hypertrophic cardiomyopathy in Germanyâ€"An analysis of over 5 million patients. PLoS ONE, 2018, 13, e0196612.	2.5	40
1004	Long-Term Outcomes of Acute Myocardial Infarction in Patients With Hypertrophic Cardiomyopathy. Angiology, 2018, 69, 900-908.	1.8	6
1006	Burst-Like Transcription of Mutant and Wildtype MYH7-Alleles as Possible Origin of Cell-to-Cell Contractile Imbalance in Hypertrophic Cardiomyopathy. Frontiers in Physiology, 2018, 9, 359.	2.8	39
1007	Ventricular Arrhythmias and Sudden Cardiac Death in Hypertrophic Cardiomyopathy. , 2018, , 654-663.		0

#	Article	IF	Citations
1008	Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7486-E7494.	7.1	109
1009	Acquired Cardiac Disease in the Pediatric Intensive Care Unit. Pediatric Annals, 2018, 47, e280-e285.	0.8	2
1010	Nonataxia symptoms in Friedreich Ataxia. Neurology, 2018, 91, e917-e930.	1.1	46
1011	Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. Journal of Atrial Fibrillation, 2018, 10, 1556.	0.5	44
1012	Hypertrophic Cardiomyopathy (HCM): New insights into Coronary artery remodelling and ischemia from FFRCT. Journal of Cardiovascular Computed Tomography, 2018, 12, 467-471.	1.3	17
1013	Exercise Training for Patients With HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 1157-1165.	2.8	39
1014	Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy. International Heart Journal, 2018, 59, 1096-1105.	1.0	13
1015	Athlete's Heart. , 2018, , 205-211.		0
1016	Opportunities in biotechnology. Journal of Biotechnology, 2018, 282, 38-45.	3.8	14
1017	Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. Archives of Cardiovascular Diseases, 2018, 111, 591-600.	1.6	11
1019	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genetics in Medicine, 2019, 21, 284-292.	2.4	54
1020	Identification of key proteins and lncRNAs in hypertrophic cardiomyopathy by integrated network analysis. Archives of Medical Science, 2019, 15, 484-497.	0.9	14
1021	In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica, 2019, 49, 718-733.	1.1	49
1022	Hypertrophic Cardiomyopathy Patients Undergoing Noncardiac Surgery: The Proverbial Pandoraâ€™s Box. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 115-117.	1.3	0
1023	Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?. Journal of Nuclear Cardiology, 2019, 26, 1125-1134.	2.1	11
1025	Histogram Analysis of Native T₁ Mapping and Its Relationship to Left Ventricular Late Gadolinium Enhancement, Hypertrophy, and Segmental Myocardial Mechanics in Patients With Hypertrophic Cardiomyopathy. Journal of Magnetic Resonance Imaging, 2019, 49, 668-677.	3.4	6
1026	Genetic basis of hypertrophic cardiomyopathy in children. Clinical Research in Cardiology, 2019, 108, 282-289.	3.3	22
1027	Cardiac MRI improves cardiovascular risk stratification in hazardous occupations. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 48.	3.3	1

#	Article	IF	Citations
1028	Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization. Journal of Arrhythmia, 2019, 35, 612-625.	1.2	12
1029	Rates of Actionable Genetic Findings in Individuals with Colorectal Cancer or Polyps Ascertained from a Community Medical Setting. American Journal of Human Genetics, 2019, 105, 526-533.	6.2	4
1030	Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians. Heart, 2019, 105, 1892-1897.	2.9	36
1031	The prognostic value of biventricular long axis strain using standard cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2019, 294, 43-49.	1.7	17
1032	Hypertrophic cardiomyopathy genetic test reports: A qualitative study of patient understanding of uninformative genetic test results. Journal of Genetic Counseling, 2019, 28, 1087-1097.	1.6	6
1033	Machine learning detection of obstructive hypertrophic cardiomyopathy using a wearable biosensor. Npj Digital Medicine, 2019, 2, 57.	10.9	39
1034	There is No Reason to Adopt ECGs and Abandon American Heart Association/American College of Cardiology History and Physical Screening for Detection of Cardiovascular Disease in the Young. Journal of the American Heart Association, 2019, 8, e013007.	3.7	16
1035	Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches. Current Cardiology Reports, 2019, 21, 75.	2.9	14
1036	Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2019, 12, 569-579.	2.4	17
1037	Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	3
1039	Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: A nationwide population-based cohort study. Scientific Reports, 2019, 9, 14565.	3.3	17
1041	Disease modeling of a mutation in Î±â€actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. EMBO Molecular Medicine, 2019, 11, e11115.	6.9	88
1042	Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2019, 297, 75-82.	1.7	3
1043	Novel Variations in Î²-Myosin Heavy-Chain Gene (Î²-MYH7) and Its Association in South Indian Women with Cardiomyopathies. Indian Journal of Cardiovascular Disease in Women WINCARS, 2019, 04, 072-078.	0.1	2
1044	Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center. Revista Portuguesa De Cardiologia, 2019, 38, 473-480.	0.5	11
1045	Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells. Expert Opinion on Biological Therapy, 2019, 19, 313-333.	3.1	6
1046	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circulation Genomic and Precision Medicine, 2019, 12, e002460.	3.6	267
1047	A Populationâ€wide study of electrocardiographic (ECG) norms and the effect of demographic and anthropometric factors on selected ECG characteristics in young, Southeast Asian malesâ€"results from the Singapore Armed Forces ECG (SAFE) study. Annals of Noninvasive Electrocardiology, 2019, 24, e12634.	1.1	17

#	Article	IF	Citations
1048	Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Science Translational Medicine, 2019, 11, .	12.4	133
1049	Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains. Pflugers Archiv European Journal of Physiology, 2019, 471, 683-699.	2.8	20
1050	Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. Circulation Research, 2019, 124, 1536-1550.	4.5	47
1051	Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PLoS ONE, 2019, 14, e0217612.	2.5	10
1052	From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies. Current Heart Failure Reports, 2019, 16, 157-167.	3.3	9
1053	Prognostic impact of mitral L-wave in patients with hypertrophic cardiomyopathy without risk factors for sudden cardiac death. Heart and Vessels, 2019, 34, 2002-2010.	1.2	4
1054	Bioinformatics analysis of the regulatory lncRNAâ€'miRNAâ€'mRNA network and drug prediction in patients with hypertrophic cardiomyopathy. Molecular Medicine Reports, 2019, 20, 549-558.	2.4	24
1055	The co-segregation of the MYL2 R58Q mutation in Chinese hypertrophic cardiomyopathy family and its pathological effect on cardiomyopathy disarray. Molecular Genetics and Genomics, 2019, 294, 1241-1249.	2.1	5
1056	Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.	30.5	347
1057	Variable and Limited Predictive Value of the European Society of Cardiology Hypertrophic Cardiomyopathy Sudden-Death Risk Model: A Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 1791-1799.	1.7	35
1058	Moving Beyond the Sarcomere to ExplainÂHeterogeneity in HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 1978-1986.	2.8	124
1059	Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy. Progress in Cardiovascular Diseases, 2019, 62, 212-216.	3.1	10
1060	Inherited cardiomyopathies. BMJ: British Medical Journal, 2019, 365, l1570.	2.3	12
1061	TNNT2 5â€¯bp deletion, sedentary lifestyle & abdominal adiposity accentuate the phenotypic severity in hypertrophic cardiomyopathy patients. Meta Gene, 2019, 20, 100567.	0.6	2
1062	Patient characteristics and incidence of childhood hospitalisation due to hypertrophic cardiomyopathy in the United States of America 2001â€"2014. Cardiology in the Young, 2019, 29, 344-354.	0.8	6
1063	Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA. Journal of the American Heart Association, 2019, 8, e012250.	3.7	33
1064	Microvascular Dysfunction in Hypertrophic Cardiomyopathy. Current Cardiovascular Imaging Reports, 2019, 12, 1.	0.6	0
1065	Low Left Atrial Strain Is Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy Patients. Journal of the American Society of Echocardiography, 2019, 32, 593-603.e1.	2.8	62

#	Article	IF	Citations
1066	The R249Q hypertrophic cardiomyopathy myosin mutation decreases contractility in Drosophila by impeding force production. Journal of Physiology, 2019, 597, 2403-2420.	2.9	9
1067	Epidemiology of Heart Failure. Cardiovascular Medicine, 2019, , 3-36.	0.0	1
1068	Measurement of Myofilament-Localized Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations. Circulation Research, 2019, 124, 1228-1239.	4.5	44
1069	Low Molecular Mass Myocardial Hyaluronan in Human Hypertrophic Cardiomyopathy. Cells, 2019, 8, 97.	4.1	13
1070	Different Clinical Presentation and Tissue Characterization in a Monozygotic Twin Pair with MYH7 Mutation-Related Hypertrophic Cardiomyopathy. International Heart Journal, 2019, 60, 477-481.	1.0	9
1071	Heart muscle disease management in aircrew. Heart, 2019, 105, s50-s56.	2.9	8
1072	Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovascular Diagnosis and Therapy, 2019, 9, S388-S415.	1.7	63
1073	A Review of the Emergence and Expansion of Cardiovascular Genetic Counseling. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	0
1074	Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules, 2019, 9, 878.	4.0	78
1075	Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. Scientific Reports, 2019, 9, 18152.	3.3	13
1076	Baseline Characteristics of the VANISH Cohort. Circulation: Heart Failure, 2019, 12, e006231.	3.9	10
1077	High-degree atrioventricular block revealing hypertrophic cardiomyopathy related to a mutation in MYBPC3 gene. Presse Medicale, 2019, 48, 68-71.	1.9	2
1078	MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2019, 127, 165-173.	1.9	48
1079	A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations. Stem Cell Reports, 2019, 12, 71-83.	4.8	82
1080	Fibrotic Signaling in Cardiomyopathies. Molecular and Translational Medicine, 2019, , 273-317.	0.4	1
1081	The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 661-677.	3.8	14
1082	Catecholamine response to exercise in patients with nonâ€obstructive hypertrophic cardiomyopathy. Journal of Physiology, 2019, 597, 1337-1346.	2.9	18
1083	Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genetics in Medicine, 2019, 21, 1576-1584.	2.4	44

#	Article	IF	Citations
1084	Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy. Circulation, 2019, 139, 1517-1529.	1.6	39
1085	Diagnosing and Managing Pulmonary and Right-Sided Heart Disease: Pulmonary Hypertension, Right Ventricular Outflow Pathology, and Sleep Apnea. , 2019, , 231-248.		0
1086	Natural History of Hypertrophic Cardiomyopathy. , 2019, , 9-21.		0
1087	Pathology and Pathophysiology. , 2019, , 23-39.		1
1088	Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity scoreâ€“matched cohort. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 306-315.e3.	0.8	77
1089	Inherited cardiomyopathies in veterinary medicine. Pflugers Archiv European Journal of Physiology, 2019, 471, 745-753.	2.8	23
1090	QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy. Acta Cardiologica, 2019, 74, 53-58.	0.9	27
1091	Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits. Antioxidants and Redox Signaling, 2019, 31, 318-358.	5.4	49
1092	Risk stratification in hypertrophic cardiomyopathy. Herz, 2020, 45, 50-64.	1.1	7
1093	Clinical and ECG variables to predict the outcome of genetic testing in hypertrophic cardiomyopathy. European Journal of Medical Genetics, 2020, 63, 103754.	1.3	9
1094	Heart Failure as a Consequence of Hypertrophic Cardiomyopathy. , 2020, , 311-321.e6.		0
1095	Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging. Journal of Cardiovascular Translational Research, 2020, 13, 238-244.	2.4	12
1096	Genetic Cardiomyopathies. , 2020, , 77-114.		1
1097	Three-dimensional Deep Convolutional Neural Networks for Automated Myocardial Scar Quantification in Hypertrophic Cardiomyopathy: A Multicenter Multivendor Study. Radiology, 2020, 294, 52-60.	7.3	58
1098	The role of echocardiography in management of hypertrophic cardiomyopathy. Journal of Echocardiography, 2020, 18, 77-85.	0.8	18
1099	Exome sequencing identifies a FHOD3 p.S527del mutation in a Chinese family with hypertrophic cardiomyopathy. Journal of Gene Medicine, 2020, 22, e3146.	2.8	8
1100	Electrocardiographic changes and long-term prognosis of children diagnosed with hypertrophic cardiomyopathy by the school screening program for heart disease in Japan. Journal of Cardiology, 2020, 75, 571-577.	1.9	8
1101	Multimodality imaging predictors of sudden cardiac death. Heart Failure Reviews, 2020, 25, 427-446.	3.9	9

#	Article	IF	Citations
1102	Sleep Disordered Breathing in Hypertrophic Cardiomyopathy. Sleep and Vigilance, 2020, 4, 3-9.	0.8	2
1103	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 83.	6.1	60
1104	Association of physical activity with all-cause and cardiovascular mortality in 7666 adults with hypertrophic cardiomyopathy (HCM): more physical activity is better. British Journal of Sports Medicine, 2021, 55, 1034-1040.	6.7	24
1105	Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy. Pharmacological Research, 2020, 160, 105176.	7.1	12
1106	Phenotyping of hypertensive heart disease and hypertrophic cardiomyopathy using personalized 3D modelling and cardiac cine MRI. Physica Medica, 2020, 78, 137-149.	0.7	6
1107	Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management. Critical Pathways in Cardiology, 2020, 19, 87-89.	0.5	2
1108	Cardiac implantable electronic device placement following alcohol septal ablation for hypertrophic cardiomyopathy in the United States. Journal of Cardiovascular Electrophysiology, 2020, 31, 2712-2719.	1.7	4
1110	Phenotypic expression and clinical outcomes in a South Asian PRKAG2 cardiomyopathy cohort. Scientific Reports, 2020, 10, 20610.	3.3	10
1111	Athleteâ€™s Heart in Elite Sport Climbers: Cardiac Adaptations Determined Using ECG and Echocardiography Data. Wilderness and Environmental Medicine, 2020, 31, 418-425.	0.9	6
1112	Early septal reduction therapy for patients with obstructive hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1502-1509.e5.	0.8	14
1113	Genetic study of pediatric hypertrophic cardiomyopathy in Egypt. Cardiology in the Young, 2020, 30, 1910-1916.	0.8	4
1114	Effects of mavacamten on Ca²⁺ sensitivity of contraction as sarcomere length varied in human myocardium. British Journal of Pharmacology, 2020, 177, 5609-5621.	5.4	36
1115	The Advantages of New Multimodality Imaging in Choosing the Optimal Management Strategy for Patients with Hypertrophic Cardiomyopathy. Diagnostics, 2020, 10, 719.	2.6	0
1116	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007230.	3.9	48
1117	Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23113-23124.	7.1	7
1118	Palpitation was associated with clinical outcomes in patients with hypertrophic cardiomyopathy. Scientific Reports, 2020, 10, 14935.	3.3	0
1119	Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do. Frontiers in Bioengineering and Biotechnology, 2020, 8, 972.	4.1	120
1120	Mid-cavitory hypertrophic obstructive cardiomyopathy with left ventricular apical thrombus and recurrent monomorphic ventricular tachycardia. IHJ Cardiovascular Case Reports (CVCR), 2020, 4, 126-129.	0.1	0

#	Article	IF	Citations
1121	Identification of Neuropsychiatric Copy Number Variants in a Health Care System Population. JAMA Psychiatry, 2020, 77, 1276.	11.0	46
1122	Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Cardiovascular Research, 2020, 116, 1585-1599.	3.8	40
1123	Danshen (Salvia miltiorhiza) inhibits Leu27 IGFâ€Ⅱ â€induced hypertrophy in H9c2 cells. Environmental Toxicology, 2020, 35, 1043-1049.	4.0	2
1124	Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. American Journal of Cardiology, 2020, 127, 139-141.	1.6	16
1125	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation, 2020, 142, 217-229.	1.6	129
1126	Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants. American Heart Journal, 2020, 225, 108-119.	2.7	25
1127	Novel frameshift variant in MYL2 reveals molecular differences between dominant and recessive forms of hypertrophic cardiomyopathy. PLoS Genetics, 2020, 16, e1008639.	3.5	16
1128	Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study. British Journal of Sports Medicine, 2020, 54, 1008-1012.	6.7	30
1129	Hypertrophic Cardiomyopathy: Sudden Death After Exercise. AAP Grand Rounds, 2020, 43, 16-16.	0.0	0
1130	Extracellular heat shock protein HSC70 protects against lipopolysaccharide-induced hypertrophic responses in rat cardiomyocytes. Biomedicine and Pharmacotherapy, 2020, 128, 110370.	5.6	10
1131	Radiomic Analysis of Native <scp>T₁</scp> Mapping Images Discriminates Between <scp>MYH7</scp> and <scp>MYBPC3</scp>â€Related Hypertrophic Cardiomyopathy. Journal of Magnetic Resonance Imaging, 2020, 52, 1714-1721.	3.4	23
1132	Artificial Intelligence-Enabled ECG: a Modern Lens on an Old Technology. Current Cardiology Reports, 2020, 22, 57.	2.9	23
1134	Reevaluation of the South Asian MYBPC3 ^{Î”25bp} Intronic Deletion in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002783.	3.6	31
1135	Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy. International Journal of Cardiovascular Imaging, 2020, 36, 1147-1156.	1.5	9
1136	The sex gap in hypertrophic cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2020, 73, 1018-1025.	0.6	2
1137	Cardiac Assessment of the Elite Athlete: Separating Structural Disease from Adaptive Changes. Structural Heart, 2020, 4, 389-396.	0.6	0
1138	The Hearts in Rhythm Organization: A Canadian National Cardiogenetics Network. CJC Open, 2020, 2, 652-662.	1.5	14
1139	Protein Thermodynamic Destabilization in the Assessment of Pathogenicity of a Variant of Uncertain Significance in Cardiac Myosin Binding Protein C. Journal of Cardiovascular Translational Research, 2020, 13, 867-877.	2.4	18

#	Article	IF	Citations
1140	Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides. Molecular Therapy - Nucleic Acids, 2020, 19, 1290-1298.	5.1	5
1141	Molecular Mechanisms of Pathologies of Skeletal and Cardiac Muscles Caused by Point Mutations in the Tropomyosin Genes. Biochemistry (Moscow), 2020, 85, 20-33.	1.5	15
1142	Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. Journal of the American College of Cardiology, 2020, 75, 722-733.	2.8	183
1143	Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca²⁺ flux caused by thin filament hypertrophic cardiomyopathy mutations. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H715-H722.	3.2	42
1144	RNA Splicing Defects in Hypertrophic Cardiomyopathy: Implications for Diagnosis and Therapy. International Journal of Molecular Sciences, 2020, 21, 1329.	4.1	15
1145	Exercise and hypertrophic cardiomyopathy: Two incompatible entities?. Clinical Cardiology, 2020, 43, 889-896.	1.8	10
1146	Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study. PLoS ONE, 2020, 15, e0227012.	2.5	28
1147	Texture signatures of native myocardial T₁ as novel imaging markers for identification of hypertrophic cardiomyopathy patients without scar. Journal of Magnetic Resonance Imaging, 2020, 52, 906-919.	3.4	26
1148	Hypertrophic Cardiomyopathy: Challenging the Status Quo?. Heart Lung and Circulation, 2020, 29, 556-565.	0.4	7
1149	Biventricular pacemaker therapy improves exercise capacity in patients with nonâ€obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise. European Journal of Heart Failure, 2020, 22, 1263-1272.	7.1	12
1151	Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis?. Forensic Science International: Genetics, 2020, 47, 102281.	3.1	20
1152	Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?. Journal of the American Heart Association, 2020, 9, e015473.	3.7	42
1153	The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy. Journal of Echocardiography, 2020, 18, 137-148.	0.8	17
1154	Hypertrophic cardiomyopathy. IJC Heart and Vasculature, 2020, 27, 100503.	1.1	35
1155	Special Article - Exercise-induced right ventricular injury or arrhythmogenic cardiomyopathy (ACM): The bright side and the dark side of the moon. Progress in Cardiovascular Diseases, 2020, 63, 671-681.	3.1	20
1156	Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. Keio Journal of Medicine, 2020, 69, 77-87.	1.1	4
1157	Sleep Disordered Breathing in Hypertrophic Cardiomyopathyâ€"Current State and Future Directions. Journal of Clinical Medicine, 2020, 9, 901.	2.4	1
1158	The Public Health Burden of Cardiomyopathies: Insights from a Nationwide Inpatient Study. Journal of Clinical Medicine, 2020, 9, 920.	2.4	11

#	Article	IF	Citations
1159	Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy. Global Heart, 2015, 10, 209.	2.3	7
1160	Diagnostic value of the novel CMR parameter â€œmyocardial transit-timeâ€•(MyoTT) for the assessment of microvascular changes in cardiac amyloidosis and hypertrophic cardiomyopathy. Clinical Research in Cardiology, 2021, 110, 136-145.	3.3	11
1161	Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring. Heart Rhythm, 2021, 18, 50-56.	0.7	7
1162	Fractal Analysis: Prognostic Value of Left Ventricular Trabecular Complexity Cardiovascular MRI in Participants with Hypertrophic Cardiomyopathy. Radiology, 2021, 298, 71-79.	7.3	18
1163	Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy. Archives of Cardiovascular Diseases, 2021, 114, 96-104.	1.6	20
1164	Targeting the population for gene therapy with MYBPC3. Journal of Molecular and Cellular Cardiology, 2021, 150, 101-108.	1.9	23
1165	Predicting the development of adverse cardiac events in patients with hypertrophic cardiomyopathy using machine learning. International Journal of Cardiology, 2021, 327, 117-124.	1.7	12
1166	Segmental longitudinal strain as the most accurate predictor of the patchy pattern late gadolinium enhancement in hypertrophic cardiomyopathy. Journal of Cardiology, 2021, 77, 475-481.	1.9	8
1167	Hypertrophic Cardiomyopathy in Pregnancy. Cardiology Clinics, 2021, 39, 143-150.	2.2	7
1168	Increased heart rate with sleep disordered breathing in hypertrophic cardiomyopathy. International Journal of Cardiology, 2021, 323, 155-160.	1.7	3
1169	Prevalence and Clinical Correlates of Aortic Dilation in Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2021, 34, 279-285.	2.8	6
1170	Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy. Heart, 2021, 107, 183-189.	2.9	12
1171	Cardiovascular Magnetic Resonance in Heritable Cardiomyopathies. Heart Failure Clinics, 2021, 17, 25-39.	2.1	2
1172	Implantable cardiac monitors in low risk hypertrophic cardiomyopathy: To protect and serve, or observe and report?. Journal of Cardiovascular Electrophysiology, 2021, 32, 136-137.	1.7	0
1173	Thromboembolism in Patients with Hypertrophic Cardiomyopathy. International Journal of Medical Sciences, 2021, 18, 727-735.	2.5	5
1174	Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior. Physiological Reviews, 2021, 101, 1083-1176.	28.8	87
1175	Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2021, 150, 77-90.	1.9	10
1176	Genetics, insurance and hypertrophic cardiomyopathy. Scandinavian Actuarial Journal, 2021, 2021, 54-81.	1.7	2

#	Article	IF	Citations
1177	Epidemiology of the inherited cardiomyopathies. Nature Reviews Cardiology, 2021, 18, 22-36.	13.7	117
1178	An Overview of the Cardiomyopathies. , 0, , .		0
1179	Gender-Related Differences in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Pulse, 2021, 9, 38-46.	1.9	6
1180	AS and HCM. , 2021, , 163-167.		0
1181	Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circulation Journal, 2021, 51, 797.	1.9	13
1183	Scope of genetic testing for inherited cardiovascular diseases in the clinical practice. Journal of Indian College of Cardiology, 2021, 11, 5.	0.1	0
1184	Clinical and laboratory reporting impact of ACMG-AMP and modified ClinGen variant classification frameworks in MYH7-related cardiomyopathy. Genetics in Medicine, 2021, 23, 1108-1115.	2.4	14
1185	Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity. Open Heart, 2021, 8, e001560.	2.3	8
1186	BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variantsâ€"design and status. Netherlands Heart Journal, 2021, 29, 318-329.	0.8	7
1187	Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics. Biology Open, 2021, 10, .	1.2	49
1188	4D flow MRI left atrial kinetic energy in hypertrophic cardiomyopathy is associated with mitral regurgitation and left ventricular outflow tract obstruction. International Journal of Cardiovascular Imaging, 2021, 37, 2755-2765.	1.5	3
1189	A simple algorithm for a clinical step-by-step approach in the management of hypertrophic cardiomyopathy. Future Cardiology, 2021, 17, 1395-1405.	1.2	0
1190	Septal myectomy in the era of genetic testing. Journal of Cardiac Surgery, 2021, 36, 1282-1288.	0.7	2
1191	Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nature Reviews Cardiology, 2021, 18, 465-478.	13.7	298
1192	Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Treatment Strategy, Characteristics of Consecutive Atrial Tachycardia and Longâ€Term Outcome. Journal of the American Heart Association, 2021, 10, e017451.	3.7	21
1193	Prognostic value of fast semi-automated left atrial long-axis strain analysis in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 36.	3.3	15
1194	Alcohol-induced right bundle branch block is associated with a benign outcome in HOCM after alcohol septum ablation (ASA). Clinical Research in Cardiology, 2022, 111, 175-185.	3.3	1
1195	Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	19

#	Article	IF	Citations
1196	Hypertrophic cardiomyopathy associated E22K mutation in myosin regulatory light chain decreases calciumâ€activated tension and stiffness and reduces myofilament Ca²⁺ sensitivity. FEBS Journal, 2021, 288, 4596-4613.	4.7	5
1197	Systolic anterior motion in hypertrophic cardiomyopathy: a fluidâ€“structure interaction computational model. Theoretical and Computational Fluid Dynamics, 2021, 35, 381-396.	2.2	7
1198	Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 612215.	2.4	11
1199	The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies. International Journal of Molecular Sciences, 2021, 22, 2955.	4.1	9
1200	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 951.	2.4	18
1201	Right ventricular involvement in hypertrophic cardiomyopathy: evidence and implications from current literature. Scandinavian Cardiovascular Journal, 2021, 55, 195-204.	1.2	8
1202	Concomitant Cox-Maze IV and Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy. Annals of Thoracic Surgery, 2022, 113, 109-117.	1.3	4
1204	Human pluripotent stem cellâ€“based cardiovascular disease modeling and drug discovery. Pflugers Archiv European Journal of Physiology, 2021, 473, 1087-1097.	2.8	5
1205	Variant Spectrum of Formin Homology 2 Domainâ€Containing 3 Gene in Chinese Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e018236.	3.7	10
1206	Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients. BMC Cardiovascular Disorders, 2021, 21, 126.	1.7	18
1207	Video-Assisted Thoracoscopic Transaortic Myectomy for Hypertrophic Obstructive Cardiomyopathy. Annals of Thoracic Surgery, 2021, 111, e217-e218.	1.3	2
1208	Early and late post-operative arrhythmias after surgical myectomy: 45Âyears of follow-up. International Journal of Cardiology, 2021, 328, 63-68.	1.7	6
1210	Evaluating the 12-Lead Electrocardiogram for Diagnosing ARVC in Young Populations: Implications for Preparticipation Screening of Athletes. CJC Open, 2021, 3, 498-503.	1.5	2
1211	Sex-related differences in symptomatic patients with hypertrophic obstructive cardiomyopathy â€“ Time for a new definition?. International Journal of Cardiology, 2021, 328, 117-121.	1.7	8
1212	The Role of Genetics in Cardiomyopaties: A Review. , 0, , .		0
1213	Efficacy of Novel Noncontrast Cardiac Magnetic Resonance Methods in Indicating Fibrosis in Hypertrophic Cardiomyopathy. Cardiology Research and Practice, 2021, 2021, 1-7.	1.1	7
1214	Molecular Diagnosis of Inherited Cardiac Diseases in the Era of Next-Generation Sequencing: A Single Centerâ€™s Experience Over 5 Years. Molecular Diagnosis and Therapy, 2021, 25, 373-385.	3.8	11
1215	A review of the underlying genetics and emerging therapies for canine cardiomyopathies. Journal of Veterinary Cardiology, 2022, 40, 2-14.	0.9	3

#	Article	IF	Citations
1216	Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography. Echo Research and Practice, 2021, 8, G61-G86.	2.5	13
1217	Prognostic significance of right ventricular function during exercise in asymptomatic/minimally symptomatic patients with nonobstructive hypertrophic cardiomyopathy. Echocardiography, 2021, 38, 916-923.	0.9	3
1218	Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circulation Research, 2021, 128, 1533-1553.	4.5	88
1219	Transgenic rabbit models for cardiac disease research. British Journal of Pharmacology, 2022, 179, 938-957.	5.4	13
1221	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2021, 23, 79.	2.9	17
1222	MiocardiopatÃa hipertrÃ³fica: mÃ¡s allÃ¡ de la hipertrofia ventricular izquierda. Revista Clinica Espanola, 2021, 221, 343-344.	0.6	0
1223	2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology, 2021, 26, 4541.	1.4	20
1224	Prevalencia de la miocardiopatÃa hipertrÃ³fica en una amplia muestra de la poblaciÃ³n laboral espaÃ±ola. Revista Clinica Espanola, 2021, 221, 315-322.	0.6	1
1225	Hypertrophic cardiomyopathy: Beyond left ventricular hypertrophy. Revista Clínica Espanõla, 2021, 221, 343-344.	0.5	0
1226	Characterization of atrial histology in a patient with hypertrophic cardiomyopathy: Possible evidence of a primary atrial myopathy. HeartRhythm Case Reports, 2021, 7, 413-417.	0.4	10
1227	Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy. Scientific Reports, 2021, 11, 13163.	3.3	17
1228	Prevalence of hypertrophic cardiomyopathy in a large sample of the Spanish working population. Revista Clínica Espanõla, 2021, 221, 315-322.	0.5	1
1229	NGHIÃŠN Cá»¨U XÃ,Y Dá»°NG QUY TRÃŒNH PHÃ,N TÃ€CH ÄA HÃŒNH rs36211723 TRÃŠN GEN MÃƒ HÃ“A PROTEIN C LIÃŠN Káº¾T MYOSIN á»ž NGÆ¯á»œI Bá»†NH CÆ TIM PHÌ Äại. Y Hoc Viet Nam, 2021, 500, .	0.0	0
1231	Cardiomyopathies: An Overview. International Journal of Molecular Sciences, 2021, 22, 7722.	4.1	57
1232	Sudden Cardiac Death Caused by a Fatal Association of Hypertrophic Cardiomyopathy (MYH7,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 18 Infection. Diagnostics, 2021, 11, 1229.	2.6	4
1233	Comprehensive Echocardiography of Left Atrium and Left Ventricle Using Modern Techniques Helps in Better Revealing Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy. Diagnostics, 2021, 11, 1288.	2.6	4
1234	ELAC2/RNaseZ-linked cardiac hypertrophy in Drosophila melanogaster. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	7
1235	The function of LncRNA-H19 in cardiac hypertrophy. Cell and Bioscience, 2021, 11, 153.	4.8	17

#	Article	IF	Citations
1236	Myocardial Bridge or Something Else?. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 332-337.	1.3	3
1237	JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies. Circulation Journal, 2021, 85, 1590-1689.	1.6	45
1238	Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes. Journal of Medical Genetics, 2022, 59, 768-775.	3.2	7
1239	Bioinformatics and Immune Infiltration Analyses Reveal the Key Pathway and Immune Cells in the Pathogenesis of Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 696321.	2.4	17
1240	Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG. Circulation Research, 2021, 129, 895-908.	4.5	20
1241	Surgery for Hypertrophic Obstructive Cardiomyopathy: Comprehensive LVOT Management beyond Septal Myectomy. Journal of Clinical Medicine, 2021, 10, 4397.	2.4	8
1242	Living with hypertrophic cardiomyopathy: a patientâ€™s perspective. Future Cardiology, 2022, 18, 43-50.	1.2	11
1243	Purkinje triggers of ventricular fibrillation in patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2021, 32, 2987-2994.	1.7	11
1244	The clinical utility of pediatric cardiomyopathy genetic testing: From diagnosis to a precision medicine-based approach to care. Progress in Pediatric Cardiology, 2021, 62, 101413.	0.4	9
1245	Enabling Autonomous Medical Image Data Annotation: A human-in-the-loop Reinforcement Learning Approach. , 0, , .		0
1246	Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	5
1247	Echocardiographic evaluation of hypertrophic cardiomyopathy: A review of upâ€toâ€date knowledge and practical tips. Echocardiography, 2021, 38, 1795-1808.	0.9	2
1248	Early and midterm results of extended septal myectomy: Indian experience. Journal of Cardiac Surgery, 2021, 36, 4465-4471.	0.7	4
1249	Detection of hypertrophic cardiomyopathy by an artificial intelligence electrocardiogram in children and adolescents. International Journal of Cardiology, 2021, 340, 42-47.	1.7	35
1250	The modified US heart allocation system improves transplant rates and decreases status upgrade utilization for patients with hypertrophic cardiomyopathy. Journal of Heart and Lung Transplantation, 2021, 40, 1181-1190.	0.6	9
1251	Cardiac-CT with the newest CT scanners: An incoming screening tool for competitive athletes?. Clinical Imaging, 2021, 78, 74-92.	1.5	2
1252	Cardiomiopatia hipertrÃ³fica associada a ventrÃculo esquerdo nÃ£o compactado: um relato de caso. Research, Society and Development, 2021, 10, e8910111500.	0.1	0
1253	Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification. Current Cardiology Reports, 2021, 23, 9.	2.9	11

#	Article	IF	Citations
1255	Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. Journal of Medical Economics, 2021, 24, 1115-1123.	2.1	11
1258	Implantable Defibrillator for Prevention of Sudden Death in Hypertrophic Cardiomyopathy. , 0, , 327-344.		1
1260	Essentials of Autopsy Practice. , 2013, , .		11
1261	Human Heart Failure: Dilated Versus Familial Hypertrophic Cardiomyopathy. Advances in Experimental Medicine and Biology, 2003, 538, 77-88.	1.6	2
1262	Inherited Cardiomyopathies. , 1998, , 127-132.		2
1266	The Genetic Landscape of Cardiomyopathies. Cardiac and Vascular Biology, 2019, , 45-91.	0.2	20
1268	Hypertrophische Kardiomyopathie (HCM). Spezielle Pathologische Anatomie, 2000, , 1055-1140.	0.0	1
1270	Kardiomyopathien â€" genetische Ursachen und Pathogenese. , 1998, , 61-110.		1
1271	Cardiovascular Causes and Pathology of Sudden Death in Athletes: The American Experience. Developments in Cardiovascular Medicine, 2000, , 31-48.	0.1	2
1272	Pathology of Sudden Death in Young Athletes: The European Experience. Developments in Cardiovascular Medicine, 2000, , 49-69.	0.1	4
1273	Cardiomyopathy. , 2006, , 981-993.		1
1275	Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2â€"Mediated COVID-19. Mayo Clinic Proceedings, 2020, 95, 1354-1368.	3.0	49
1276	Hemodynamic Benefits of Treatment Modalities for Hypertrophic Cardiomyopathy: A Case Study. Journal of Cardiovascular Nursing, 2001, 15, 33-40.	1.1	2
1277	Cardiovascular Preparticipation Screening of Competitive Athletes. Medicine and Science in Sports and Exercise, 1996, 28, 1445-1452.	0.4	10
1278	Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Medicine and Science in Sports and Exercise, 1997, 29, 1131-1138.	0.4	180
1279	Does preseason screening for cardiac disease really work?: the British perspective. Medicine and Science in Sports and Exercise, 1998, 30, S345-S350.	0.4	25
1280	Modifier genes for hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2002, 17, 242-52.	1.8	54
1281	The Preparticipation Athletic Exam Process. Southern Medical Journal, 2004, 97, 871-872.	0.7	2

#	Article	IF	Citations
1286	Hypertrophic Cardiomyopathy as an Oligogenic Disease: Transcriptomic Arguments. Molecular Biology, 2020, 54, 840-850.	1.3	8
1287	Acromegaly-induced cardiomyopathy with dobutamine-induced outflow tract obstruction. BMJ Case Reports, 2016, 2016, bcr2015213463.	0.5	1
1288	Preparticipation screening for cardiovascular abnormalities in young competitive athletes. BMJ: British Medical Journal, 2008, 337, a1596.	2.3	46
1289	Expression of HCM causing mutations: lessons learnt from genotype-phenotype studies of the South African founder MYH7 A797T mutation. Journal of Medical Genetics, 2000, 37, 951-956.	3.2	14
1290	Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy. Open Heart, 2020, 7, e001152.	2.3	8
1291	Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. JCI Insight, 2018, 3, .	5.0	33
1292	An abnormal Ca2+ response in mutant sarcomere proteinâ€“mediated familial hypertrophic cardiomyopathy. Journal of Clinical Investigation, 2000, 106, 1351-1359.	8.2	209
1293	Making matters worse for a broken heart. Journal of Clinical Investigation, 2000, 106, 1437-1439.	8.2	8
1294	The application of big data to cardiovascular disease: paths to precision medicine. Journal of Clinical Investigation, 2020, 130, 29-38.	8.2	74
1295	A transgenic rabbit model for human hypertrophic cardiomyopathy. Journal of Clinical Investigation, 1999, 104, 1683-1692.	8.2	171
1296	Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family. American Journal of Case Reports, 2017, 18, 766-776.	0.8	11
1297	Combinatorial Effects of Double Cardiomyopathy Mutant Alleles in Rodent Myocytes: A Predictive Cellular Model of Myofilament Dysregulation in Disease. PLoS ONE, 2010, 5, e9140.	2.5	11
1298	Myocardial Structural Alteration and Systolic Dysfunction in Preclinical Hypertrophic Cardiomyopathy Mutation Carriers. PLoS ONE, 2012, 7, e36115.	2.5	35
1299	In Hypertrophic Cardiomyopathy Reduction of Relative Resting Myocardial Blood Flow Is Related to Late Enhancement, T2-Signal and LV Wall Thickness. PLoS ONE, 2012, 7, e41974.	2.5	12
1300	Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C. PLoS ONE, 2013, 8, e59206.	2.5	19
1301	A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS ONE, 2016, 11, e0168407.	2.5	92
1302	Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy. PLoS ONE, 2017, 12, e0181465.	2.5	32
1303	Whole gene sequencing identifies deep-intronic variants with potential functional impact in patients with hypertrophic cardiomyopathy. PLoS ONE, 2017, 12, e0182946.	2.5	41

#	Article	IF	Citations
1304	Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records. PLoS ONE, 2018, 13, e0191214.	2.5	27
1305	Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. PLoS ONE, 2020, 15, e0239675.	2.5	14
1306	The mechanisms, diagnosis and management of mitral regurgitation in mitral valve prolapse and hypertrophic cardiomyopathy. Discoveries, 2016, 4, e61.	2.3	4
1307	Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion. Journal of Animal Science and Technology, 2015, 2, E1-E7.	2.5	6
1308	Abnormal His-Purkinje System Conduction Leading to Complete Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy: A Report of 3 Cases. International Heart Journal, 2004, 45, 347-352.	0.6	15
1309	Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. Arrhythmia and Electrophysiology Review, 2017, 6, 63.	2.4	10
1310	Risk Stratification in Hypertrophic Cardiomyopathy. European Cardiology Review, 2015, 10, 31.	2.2	19
1311	Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy. Interventional Cardiology Review, 2011, 9, 108.	1.6	3
1312	HYPERTROPHIC CARDIOMYOPATHY: GENETIC ALTERATIONS, PATHOGENESIS AND PATHOPHYSIOLOGY. Russian Journal of Cardiology, 2014, , 35-42.	1.4	8
1315	RessonÃ¢ncia magnÃ©tica cardiovascular na cardiomiopatia hipertrÃ³fica. Arquivos Brasileiros De Cardiologia, 2007, 88, 243-248.	0.8	10
1316	Caso 01/2008: paciente jovem do sexo feminino, portadora de forma familiar de cardiomiopatia hipertrÃ³fica que evoluiu com sÃncopes, arritmia ventricular complexa e choque cardiogÃªnico. Arquivos Brasileiros De Cardiologia, 2008, 90, 64-74.	0.8	2
1317	O diagnÃ³stico da obstruÃ§Ã£o da via de saÃda do ventrÃculo esquerdo na cardiomiopatia hipertrÃ³fica. Arquivos Brasileiros De Cardiologia, 2012, 99, 665-675.	0.8	6
1318	The modern view on the diagnosis and treatment of hypertrophic cardiomyopathy. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2019, 12, 38.	0.3	3
1319	Cardiovascular Screening in Young Athletes in Sarajevo Canton. Bosnian Journal of Basic Medical Sciences, 2010, 10, 227-233.	1.0	4
1320	Clinical dilemmas in predicting the progression of pre-clinical hypertrophic cardiomyopathyâ€"is MRI strain the solution?. Annals of Translational Medicine, 2019, 7, S177-S177.	1.7	2
1321	Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (Macaca mulatta). Comparative Medicine, 2020, 70, 348-357.	1.0	4
1322	Hypertrophic Obstructive Cardiomyopathy. Deutsches Ärzteblatt International, 2019, 116, 47-53.	0.9	18
1323	Cardiomiopatia HipertrÃ³fica â€“ RevisÃ£o. Arquivos Brasileiros De Cardiologia, 2020, 115, 927-935.	0.8	9

#	Article	IF	Citations
1324	Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia â€“ 2020. Arquivos Brasileiros De Cardiologia, 2020, 114, 849-942.	0.8	12
1325	Most Sudden Deaths in Adolescent Athletes Caused by Cardiac Conditions. Pediatric Annals, 2003, 32, 751-756.	0.8	3
1326	Epidemiology of cardiomyopathy - A clinical and genetic study of hypertrophic cardiomyopathy: The EPOCH-H study. Journal of the Practice of Cardiovascular Sciences, 2015, 1, 143.	0.1	6
1327	Cardiac transplantation for hypertrophic cardiomyopathy in the United States 2003â€“2011. International Journal of Critical Illness and Injury Science, 2020, 10, 129.	0.6	1
1328	Cardiac Arrest and Sudden Cardiac Death in the Pediatric Population. Journal of Clinical & Experimental Cardiology, 2012, 03, .	0.0	2
1329	Role of Modifying Genes on the Severity of Rare Mutation of MYH7 Gene in Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical & Experimental Cardiology, 2012, 03, .	0.0	5
1330	Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. World Journal of Cardiology, 2014, 6, 26.	1.5	35
1331	Pre-participation cardiovascular screening in athletes: when and how?. Cardiovascular Medicine(Switzerland), 2012, 15, 7-13.	0.0	1
1332	Survival after alcohol septal ablation versus conservative therapy in obstructive hypertrophic cardiomyopathy. Cardiology Journal, 2015, 22, 657-664.	1.2	4
1334	Endurance sport and cardiac injury. Kardiologia Polska, 2014, 72, 587-597.	0.6	15
1335	Pre-participation screening for the prevention of sudden cardiac death in athletes. World Journal of Methodology, 2013, 3, 1.	3.5	6
1336	Sudden Cardiac Death in Young Athletes; a Literature Review and Special Considerations in Asia. Asian Journal of Sports Medicine, 2011, 2, 1-15.	0.3	32
1337	ECG is an inefficient screening-tool for left ventricular hypertrophy in normotensive African children population. PeerJ, 2016, 4, e2439.	2.0	1
1338	A Review of Cardiac Complications in Coronavirus Disease 2019. Cureus, 2020, 12, e8034.	0.5	17
1339	Study of Cardiac Events Due to Hypertrophic Cardiomyopathy under School Management. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2015, 31, 240-245.	0.0	1
1340	Cardiomyopathy Management and In-Hospital Outcomes in a Tertiary Care Center: Clinical Components and Venues of Advanced Care. Cureus, 2021, 13, e19054.	0.5	0
1341	Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. Journal of Medicinal Chemistry, 2021, 64, 14142-14152.	6.4	74
1342	Hypertrophic Cardiomyopathy with a Twist. Indian Journal of Radiology and Imaging, 2021, 31, 751-753.	0.8	1

#	Article	IF	Citations
1343	Truncating Variants in OBSCN Gene Associated With Disease-Onset and Outcomes of Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003401.	3.6	5
1344	Ion Channel Impairment and Myofilament Ca2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy. Cells, 2021, 10, 2789.	4.1	11
1345	AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. Journal of Biological Engineering, 2021, 15, 24.	4.7	0
1346	Analysis of inherited causes of hypertrophic cardiomyopathy as part of clinical practice. , 2000, , 69-75.		0
1347	Familial Hypertrophic Cardiomyopathy Genetics. Developments in Cardiovascular Medicine, 2000, , 181-194.	0.1	0
1348	Pacemaker Treatment for Hypertrophic Obstructive Cardiomyopathy: Are Long-Term Results as Good as Short-Term Ones?. , 2000, , 514-521.		0
1351	Hypertrophic Cardiomyopathy and Coronary Arteries. , 2002, , 980-987.		1
1352	Kardiomyopathien. , 2003, , 30-55.		0
1353	Kardiomyopathien. , 2003, , 99-114.		0
1354	Arrhythmias Associated with Hypertrophic Cardiomyopathy. , 2005, , 601-612.		0
1356	What To Do with Hypertension and a Murmur Found During a Preparticipation Physical Evaluation?. , 2005, 9, 20-2.		0
1357	Arrhythmias and Sudden Cardiac Death. , 2006, , 171-194.		2
1358	Genetics and Heart Failure: Hypertrophic Cardiomyopathy. Fundamental and Clinical Cardiology, 2006, , 589-606.	0.0	0
1360	Toxicogenetics. , 2006, , 1087-1115.		0
1362	Echocardiography in the Evaluation and Management of Patients with Hypertrophic Cardiomyopathy. , 2007, , 653-678.		0
1363	Echocardiography in the Evaluation of the Cardiomyopathies. , 2007, , 1359-1378.		0
1364	Molecular genetics in hypertrophic cardiomyopathy. Cor Et Vasa, 2007, 49, 138-142.	0.1	2
1365	Toxicogenetics in Drug Abuse. , 2007, , 165-183.		0

#	Article	IF	Citations
1366		0.1	0
1367	Our initial experience with genetic testing of patients with hypertrophic cardiomyopathy: mutations of troponin T and troponin I genes. Cor Et Vasa, 2008, 50, 242-245.	0.1	0
1368	AvaliaÃ§Ã£o diagnÃ³stica da cardiomiopatia hipertrÃ³fica em fase clÃnica e prÃ©-clÃnica. Arquivos Brasileiros De Cardiologia, 2008, 91, 51-62.	0.8	10
1369	Cardiac Disorders. , 2010, , 2138-2167.		0
1371	Cardiomiopatia hipertrÃ³fica: ecocardiografia no diagnÃ³stico e prognÃ³stico. Experts in Ultrasound Reviews and Perspectives, 2010, 2, 112-116.	0.0	0
1375	Echocardiography and Advanced Cardiac Imaging in Athletes. , 2011, , 45-61.		0
1376	Long-Term Survival Following Cardiac Arrest Without Implantable Defibrillator Protection in a Hypertrophic Cardiomyopathy Patient. Cardiology Research, 2011, 2, 132-135.	1.1	0
1382	Septal Myectomy and Myotomy Attenuate Left Ventricular Hyper-Contractility in a Child with Hypertrophic Obstructive Cardiomyopathy. Annals of Thoracic and Cardiovascular Surgery, 2012, 18, 162-165.	0.8	2
1383	Cardiomyopathies and Heart Transplantation. , 2012, , 2459-2476.		0
1384	Sudden Cardiac Death and Preparticipation Sports Screening. , 2012, , 2399-2412.		1
1386	Krankheiten des Herzens. , 2012, , 335-393.		0
1388	Resultados a corto y mediano plazo del tratamiento de la obstrucciÃ³n al tracto de salida del ventrÃculo izquierdo mediante miectomÃa videoasistida. Revista Chilena De CardiologÃa, 2013, 32, 97-103.	0.0	0
1390	Spatio-temporal Registration of 2D US and 3D MR Images for the Characterization of Hypertrophic Cardiomyopathy. Lecture Notes in Computer Science, 2013, , 292-299.	1.3	2
1391	HYPERTROPHIC CARDIOMYOPATHY: FIBROSIS OR HYPERTROPHY. Arterial Hypertension (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	0
1392	The genetics of cardiomyopathy, new technologies and the path to personalised medicine. OA Genetics, 2013, 1, .	0.0	1
1393	Arrhythmias and Hypertrophic Cardiomyopathy. , 2014, , 253-264.		0
1394	Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy. Arquivos Brasileiros De Cardiologia - Imagem Cardiovascular, 2014, 27, .	0.0	0
1395	Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands*. , 2014, , 37-42.		0

#	Article	IF	Citations
1396	Contraceptive Management of Women with Cardiac Disease. , 2014, , 17-39.		0
1397	Bringing dead proteins back to life. ELife, 2014, 3, e02189.	6.0	1
1399	O acometimento isquÃªmico obstrutivo na cardiomiopatia hipertrÃ³fica do tipo septal assimÃ©trico com envolvimento da artÃ©ria descendente anterior. Arquivos Brasileiros De Cardiologia, 1997, 69, .	0.8	0
1400	Risk Stratification in Patients with Hypertrophic Cardiomyopathy. Developments in Cardiovascular Medicine, 1998, , 83-88.	0.1	0
1401	Clinical Aspects and Genetics of Cardiomyopathies. , 2015, , 501-521.		0
1402	Perfil clÃnico de pacientes con miocardiopatÃa hipertrÃ³fica en un hospital universitario. Revista Argentina De Cardiologia, 2014, 82, 366-372.	0.3	1
1403	Pathology and Pathophysiology. , 2015, , 23-38.		0
1404	Right ventricular cavity near obliteration in neonatal severe biventricular hypertrophic cardiomyopathy. BMJ Case Reports, 2014, 2014, bcr2014205041-bcr2014205041.	0.5	0
1406	Clinical Profile of Hypertrophic Cardiomyopathy in a Tertiary Level Hospital. Cardiovascular Journal, 2014, 7, 31-37.	0.0	0
1407	A Case of Mitral Valve Replacement for Left Ventricular Outflow Tract Obstruction due to Abnormal Papillary Muscle. Japanese Journal of Cardiovascular Surgery, 2015, 44, 92-96.	0.0	0
1408	Sport bei Kindern und Jugendlichen â€“ kinderkardiologische Aspekte. , 2015, , 129-148.		1
1410	Collapse in Athletes: Etiology and Management. , 2015, , 2981-2997.		0
1412	Comparison Between Clinical and Echocardiographic Findings in Infants and Children Diagnosed with Hypertrophic Cardiomyopathy. Acta Marisiensis - Seria Medica, 2015, 61, 83-86.	0.3	0
1413	Advanced Ngs Platforms in Molecular Diagnostics of Hypertrophic and Dilated Cardiomyopathies. Journal of Cardiology & Current Research, 2015, 3, .	0.1	0
1414	REPRODUCIBLE AND SHAREABLE QUANTIFICATIONS OF PATHOGENICITY. , 2016, , .		2
1415	Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications. International Cardiovascular Forum Journal, 0, 8, .	1.1	0
1416	Modern approaches to the problem of hypertrophic cardiomyopathy. Klinicheskaia Meditsina, 2016, 94, 754-763.	0.1	0
1417	Children and Exercise. , 2017, , 529-539.		0

#	Article	IF	Citations
1420	Sudden death on the playing field: Can we prevent it?. , 2017, 01, .		0
1421	Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatolian Journal of Cardiology, 2017, 18, 48-53.	0.9	28
1422	Epidemiology of cardiomyopathy â€“ A Clinical and Genetic Study of Restrictive Cardiomyopathy: The EPOCH-R Study. Journal of the Practice of Cardiovascular Sciences, 2017, 3, 143.	0.1	3
1424	Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies. , 2018, , 259-317.		0
1425	Inherited Arrhythmias: Brugada Syndrome and Early Repolarisation Syndrome. , 2018, , 437-480.		0
1427	Implantable cardioverter defibrillators in the context of hypertrophic cardiomyopathy: a lesson in patient autonomy. BMJ Case Reports, 2018, 2018, bcr-2017-223352.	0.5	0
1428	Hypertrophic
cardiomyopathy: forms and variants of the course, approaches to pharmacotherapy.. Klinicheskaia Meditsina, 2018, 95, 1061-1069.	0.1	1
1429	HOCM DIAGNOSTIC DILEMMA. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 1342-1344.	0.0	0
1430	Obstructive Hypertrophic Cardiomyopathy with Concomitant Mitral Regurgitation Treated with a Septal Myectomy and MV Repair: A Case Report. Serbian Journal of Experimental and Clinical Research, 2018, 19, 195-200.	0.1	0
1431	Hypertrophic cardiomyopathy with little hypertrophy and severe arrhythmia. Global Cardiology Science & Practice, 2018, 2018, 26.	0.4	1
1432	Progressive nature of myocardial fibrosis in pediatric hypertrophic cardiomyopathy: from mutation carrier to myocardial fibrosis. Annals of Translational Medicine, 2018, 6, S52-S52.	1.7	0
1433	Role of Cardiovascular Magnetic Resonance in Dilated Cardiomyopathy. , 2019, , 383-390.e4.		0
1434	Genetic Basis of Mitochondrial Cardiomyopathy. Cardiac and Vascular Biology, 2019, , 93-139.	0.2	1
1435	Genetics and Family Screening for Noncompaction Cardiomyopathy. , 2019, , 127-147.		0
1437	A Systematic review for sudden cardiac death in hypertrophic cardiomyopathy patients with Myocardial Fibrosis: A CMR LGE Study. Journal of Cardiology and Cardiovascular Medicine, 2019, 4, 187-191.	0.2	0
1438	ANESTHETIC NUANCES IN A HYPERTROPHIC CARDIOMYOPATHY PATIENT FOR LAPAROSCOPIC ABDOMINOPERINEAL RESECTION. Indian Journal of Case Reports, 2019, 05, 536-538.	0.0	0
1440	Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy. ESC Heart Failure, 2021, 8, 4791-4799.	3.1	3
1442	Current Knowledge of Hypertrophic Cardiomyopathy Among Health Care Providers in Sweden. Cureus, 2020, 12, e12220.	0.5	3

#	Article	IF	Citations
1444	Evaluation and Care of Common Pediatric Cardiac Disorders. , 2021, , .		0
1445	Genetic analysis of monoallelic double MYH7 mutations responsible for familial hypertrophic cardiomyopathy. Molecular Medicine Reports, 2019, 20, 5229-5238.	2.4	5
1447	Medical Evaluation of Athletes: Echocardiography. , 2020, , 135-151.		1
1448	Induced Pluripotent Stem Cells. , 2020, , 439-455.		0
1449	High-throughput digitization of analog human echocardiography data. MethodsX, 2020, 7, 101159.	1.6	0
1450	Inflammation, iron and vitamin D metabolism in different cardiomyopathy aetiologies. Pteridines, 2020, 31, 28-37.	0.5	1
1451	Use of peripheral nerve blocks in perioperative management of cases with hypertrophic cardiomyopathy undergoing lower limb orthopedic surgeries. Anesthesia: Essays and Researches, 2020, 14, 277.	0.5	1
1453	Differences in American Athletes Undergoing Preparticipation Examination by Sex, Participation Level, and Age. Clinical Journal of Sport Medicine, 2021, 31, e432-e441.	1.8	0
1454	Long-term Effect of Dual-chamber Pacing on Pressure Gradient at Left Ventricular Outflow Tract in Hypertrophic Obstructive Cardiomyopathy. Journal of Arrhythmia, 2011, 27, 226-230.	1.2	0
1455	Krankheiten des Herzens. , 2008, , 311-373.		0
1456	Kardiomyopathien. , 2007, , 173-190.		1
1457	Kardiomyopathien. , 2005, , 34-61.		0
1458	Sudden Cardiac Deaths in Young British Army Personnel. Journal of the Royal Army Medical Corps, 2011, 157, 184-187.	0.8	0
1459	Contraceptive Management of Women with Cardiac Disease. , 2014, , 17-39.		1
1460	Inherited Myocardial Diseases. , 2005, , 105-122.		0
1461	Inherited Cardiomyopathies. , 2006, , 98-104.		0
1463	Exercise Echocardiography following Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Thoracic and Cardiovascular Surgeon, 2020, , .	1.0	1
1464	Newer risk assessment strategies in hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2021, 36, 80-88.	1.8	2

#	Article	IF	Citations
1465	Prevalence of Risk Factors for Sudden Cardiac Death among Patients with Hypertrophic Cardiomyopathy in a Tertiary Care Centre in South India. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 2237-2241.	0.0	0
1466	Asymmetric Hypertrophic Cardiomyopathy in Athletes: Always a Higher Risk for Sudden Death?. Journal of Cardiac Arrhythmias, 2020, 33, 156-160.	0.1	0
1467	Epidemiology of cardiomyopathies: essential context knowledge for a tailored clinical work-up. European Journal of Preventive Cardiology, 2020, , .	1.8	3
1469	A Review of Sudden Cardiac Death in Young Athletes and Strategies for Preparticipation Cardiovascular Screening. Journal of Athletic Training, 2001, 36, 197-204.	1.8	20
1470	Role of implantable cardioverter defibrillators in the treatment of hypertrophic cardiomyopathy. Indian Pacing and Electrophysiology Journal, 2005, 5, 72-5.	0.6	1
1471	Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. Journal of Medical Genetics, 1999, 36, 542-5.	3.2	52
1472	Recommendations and cardiological evaluation of athletes with arrhythmias: Part 1. Netherlands Heart Journal, 2004, 12, 157-164.	0.8	5
1473	Hypertrophic cardiomyopathy in daily practice: an introduction on diagnosis, prognosis and treatment. Netherlands Heart Journal, 2005, 13, 452-460.	0.8	1
1474	Contemporary treatment of hypertrophic cardiomyopathy. Texas Heart Institute Journal, 2009, 36, 194-204.	0.3	37
1477	Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Medica, 2001, 92, 435-51.	0.9	38
1478	Reoperative myectomy via the left ventricular apex in a patient with hypertrophic obstructive cardiomyopathy. Texas Heart Institute Journal, 2010, 37, 576-8.	0.3	0
1479	Genetic variations of Î±-cardiac actin and cardiac muscle LIM protein in hypertrophic cardiomyopathy in South India. Experimental and Clinical Cardiology, 2012, 17, 26-9.	1.3	5
1480	Cardiac MRI in a patient with coincident left ventricular non-compaction and hypertrophic cardiomyopathy. Journal of Tehran University Heart Center, 2011, 6, 214-6.	0.2	2
1481	Prevalence of aortic dilation in hypertrophic cardiomyopathy. American Journal of Cardiovascular Disease, 2013, 3, 79-84.	0.5	6
1482	Evaluation of left ventricular function, rotation, twist and untwist in patients with hypertrophic cardiomyopathy. Experimental and Clinical Cardiology, 2013, 18, e47-9.	1.3	7
1484	Race and gender representation of hypertrophic cardiomyopathy or long QT syndrome cases in a South African research setting. Cardiovascular Journal of Africa, 2007, 18, 312-5.	0.4	11
1485	REPRODUCIBLE AND SHAREABLE QUANTIFICATIONS OF PATHOGENICITY. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2016, 21, 231-42.	0.7	2
1486	Setting up Multiplex Panels for Genetic Testing of Familial Hypertrophic Cardiomyopathy Based on Linkage Analysis. Iranian Journal of Public Health, 2016, 45, 329-39.	0.5	0

#	Article	IF	Citations
1487	Recent advances in diagnosis and management of hypertrophic cardiomyopathy. Heart Asia, 2009, 1, 16-9.	1.1	0
1488	Predictors of Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy. Journal of Atrial Fibrillation, 2015, 7, 1200.	0.5	7
1489	A One Health Approach to Hypertrophic Cardiomyopathy. Yale Journal of Biology and Medicine, 2017, 90, 433-448.	0.2	12
1490	Coexistence of Gitelman Syndrome and Hypertrophic Cardiomyopathy in a Pregnant Woman. Acta Cardiologica Sinica, 2018, 34, 92-95.	0.2	1
1491	Fluid dynamic aspects of ejection in hypertrophic cardiomyopathy. Hellenic Journal of Cardiology, 2011, 52, 416-26.	1.0	15
1492	New insights provided by myofibril mechanics in inherited cardiomyopathies. Conditioning Medicine, 2019, 2, 213-224.	1.3	4
1493	Relationship between Left Ventricular Outflow Tract Pressure Gradient and Hemoglobin in Patients with Hypertrophic Cardiomyopathy. Acta Cardiologica Sinica, 2020, 36, 343-350.	0.2	1
1494	Factors associated with the risk of cardiac death in children with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart and Lung: Journal of Acute and Critical Care, 2022, 52, 26-36.	1.6	4
1495	A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. Biomolecules, 2021, 11, 1718.	4.0	14
1496	Acute coronary syndrome with non-obstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy. BMC Cardiovascular Disorders, 2021, 21, 556.	1.7	7
1497	Understanding the molecular basis of cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H181-H233.	3.2	14
1498	The genetic basis of sudden death in young people â€“ Cardiac and non-cardiac. Gene, 2022, 810, 146067.	2.2	3
1499	Safety and efficacy of alcohol septal ablation in adolescents and young adults with hypertrophic obstructive cardiomyopathy. Clinical Research in Cardiology, 2022, 111, 207-217.	3.3	6
1500	Clinical Characteristics for the Improvement of Cushing's Syndrome Complicated With Cardiomyopathy After Treatment With a Literature Review. Frontiers in Cardiovascular Medicine, 2021, 8, 777964.	2.4	3
1501	Commentary: The Value of the ECG in the Preparticipation Sports Physical Examination: The Italian Experience. Pediatrics in Review, 2006, 27, e75-e76.	0.4	0
1502	Molekulare Prinzipien in der Kardiologie: Genetik bei hypertropher Kardiomyopathie. , 0, , .		0
1503	Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy. CJC Open, 2022, 4, 406-415.	1.5	6
1505	Cellular models and therapeutic perspectives in hypertrophic cardiomyopathy. Medizinische Genetik, 2021, 33, 235-243.	0.2	0

#	Article	IF	Citations
1506	Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annual Review of Medicine, 2022, 73, 363-375.	12.2	14
1507	The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy. Diagnostics, 2022, 12, 314.	2.6	7
1508	Assessment of Exercise Function in Children and Young Adults with Hypertrophic Cardiomyopathy and Correlation with Transthoracic Echocardiographic Parameters. Pediatric Cardiology, 2022, , .	1.3	2
1509	Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era. Frontiers in Cardiovascular Medicine, 2021, 8, 765876.	2.4	7
1510	Management of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 390-414.	2.8	129
1511	Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning. JMIR Medical Informatics, 2022, 10, e30483.	2.6	5
1512	Modern genomic techniques in the identification of genetic causes of cardiomyopathy. Heart, 2022, , heartjnl-2021-320424.	2.9	3
1513	South Asian-Specific MYBPC3Î”25bp Deletion Carriers Display Hypercontraction and Impaired Diastolic Function Under Exercise Stress. Frontiers in Cardiovascular Medicine, 2021, 8, 766339.	2.4	1
1515	Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study. Heart, 2022, 108, 1383-1391.	2.9	11
1516	Ventricular Tachycardia Unveiling an Obstructive Cardiomyopathy Complicated with an Apical Aneurysm. World Journal of Cardiovascular Diseases, 2022, 12, 111-117.	0.2	0
1517	AQUA Mutant Protein Quantification of Endomyocardial Biopsy-Sized Samples From a Patient With Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2022, 9, 816330.	2.4	0
1518	Exploring the Communal Pathogenesis, Ferroptosis Mechanism, and Potential Therapeutic Targets of Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy via a Microarray Data Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 824756.	2.4	10
1519	Familial Hypertrophic Cardiomyopathy With Fasciculoventricular AccessoryÂPathway. JACC: Case Reports, 2022, 4, 198-204.	0.6	1
1520	Percutaneous Septal Reduction Therapy in a Patient with Severely Symptomatic Hypertrophic Obstructive Cardiomyopathy. Sultan Qaboos University Medical Journal, 0, , .	1.0	0
1521	Left atrial dysfunction may precede left atrial enlargement and abnormal left ventricular longitudinal function: a cardiac MR feature tracking study. BMC Cardiovascular Disorders, 2022, 22, 99.	1.7	21
1522	Small Angle X-ray Diffraction as a Tool for Structural Characterization of Muscle Disease. International Journal of Molecular Sciences, 2022, 23, 3052.	4.1	28
1523	Emergency department utilization in patients with hypertrophic cardiomyopathy: a nationwide population-based study. Scientific Reports, 2022, 12, 3534.	3.3	1
1524	From Takotsubo to Yamaguchi. Cureus, 2022, 14, e23561.	0.5	0

#	Article	IF	Citations
1525	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. Cardiology and Therapy, 2022, 11, 249-267.	2.6	5
1526	Basic life support, a necessary inclusion in the medical curriculum: a cross-sectional survey of knowledge and attitude in Uganda. BMC Medical Education, 2022, 22, 140.	2.4	3
1527	Unique Medical Considerations for the Athlete Undergoing Anesthesia. Clinics in Sports Medicine, 2022, 41, 185-201.	1.8	0
1528	Cardiovascular evaluation of pregnant women with hypertrophic cardiomyopathy. Herz, 2022, , 1.	1.1	0
1529	Use of Photovoice to Explore Pediatric Patients with Hypertrophic Cardiomyopathy and their Parents' Perceptions of a Heartâ€Healthy Lifestyle. Journal of the American Heart Association, 2022, 11, e023572.	3.7	3
1530	Ageâ€related survival after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. ESC Heart Failure, 2022, 9, 327-336.	3.1	8
1531	Ventricular arrhythmia management in patients with genetic cardiomyopathies. Heart Rhythm O2, 2021, 2, 819-831.	1.7	1
1532	A complex unit for a complex disease: the HCM-Family Unit. Monaldi Archives for Chest Disease, 2021, , .	0.6	0
1533	Radiomics Analysis Derived From LGE-MRI Predict Sudden Cardiac Death in Participants With Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 766287.	2.4	6
1534	Mechanisms of Arrhythmogenicity of Hypertrophic Cardiomyopathy-Associated Troponin T (TNNT2) Variant I79N. Frontiers in Cell and Developmental Biology, 2021, 9, 787581.	3.7	13
1535	Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 2573-2579.	2.8	17
1536	Factors associated with excess female mortality in obstructive hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 1545-1556.	1.8	4
1537	Catheter ablation of ventricular tachycardia in dilatedâ€phase hypertrophic cardiomyopathy: Substrate characterization and ablation outcome. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 773-785.	1.2	3
1538	Outcomes of pregnancy in women with hypertrophic cardiomyopathy: A systematic review. International Journal of Cardiology, 2022, 359, 54-60.	1.7	7
1539	What Aspects of Phenotype Determine Risk for Sudden Cardiac Death in Pediatric Hypertrophic Cardiomyopathy?. Journal of Cardiovascular Development and Disease, 2022, 9, 124.	1.6	1
1546	Phenotypic Expression and Clinical Course of Hypertrophic Cardiomyopathy. , 0, , 1-36.		0
1547	Genetic Mutations that Remodel the Heart in Hypertrophic Cardiomyopathy. , 0, , 37-66.		0
1548	Role of Septal Ablation in a Surgical Center. , 0, , 297-306.		0

#	Article	IF	Citations
1549	Molecular and Clinical Tools for Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy. , 0, , 307-318.		0
1550	Cardiovascular Causes of Sudden Death, Preparticipation Screening, and Criteria for Disqualification in Young Athletes. , 0, , 404-431.		0
1552	CrossRef Listing of Deleted DOIs. , 2008, 1, 93-9.		3
1554	Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: a systematic review and meta-analysis. Open Heart, 2022, 9, e001815.	2.3	5
1559	Right Ventricular Enlargement and Dysfunction Are Associated With Increased All-Cause Mortality in Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2022, , .	3.0	0
1560	A Case Series of Hypertrophic Cardiomyopathy Conducted in Vietnam Revealing a Novel Pathogenic Variant of the TNNT2 Gene. Open Cardiovascular Medicine Journal, 2022, 16, .	0.3	0
1561	The Genetic Architecture of Hypertrophic Cardiomyopathy in Hungary: Analysis of 242 Patients with a Panel of 98 Genes. Diagnostics, 2022, 12, 1132.	2.6	4
1562	Differential Diagnosis of Thick Myocardium according to Histologic Features Revealed by Multiparametric Cardiac Magnetic Resonance Imaging. Korean Journal of Radiology, 2022, 23, 581.	3.4	3
1563	Atrial fibrillation in hypertrophic cardiomyopathy â€“ A contemporary mini-review. Hellenic Journal of Cardiology, 2022, 67, 66-72.	1.0	9
1566	Temporal Changes in Cardiac Morphology and Its Relationship with Clinical Characteristics and Outcomes in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2022, 176, 125-131.	1.6	1
1567	Advances in hypertrophic cardiomyopathy: What the cardiologist needs to know. Revista Portuguesa De Cardiologia, 2022, 41, 499-509.	0.5	4
1568	Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging. Journal of Cardiovascular Development and Disease, 2022, 9, 169.	1.6	5
1569	Identification of Novel Genetic Variants and Comorbidities Associated With ICD-10-Based Diagnosis of Hypertrophic Cardiomyopathy Using the UK Biobank Cohort. Frontiers in Genetics, 0, 13, .	2.3	5
1570	Association of the Genetic Variation in the Long Non-Coding RNA FENDRR with the Risk of Developing Hypertrophic Cardiomyopathy. Life, 2022, 12, 818.	2.4	3
1571	Uncovering hypertrophic cardiomyopathy pathophysiology â€“ the unsolved role of microvascular dysfunction. Revista Portuguesa De Cardiologia, 2022, , .	0.5	0
1572	Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. Journal of the American Society of Echocardiography, 2022, 35, 533-569.	2.8	46
1574	Clinical Features of Heart Failure in Patients With Hypertrophic Cardiomyopathy in a Regional Japanese Cohortã€€â€• Results From the Kochi RYOMA Study â€•. Circulation Journal, 2022, 86, 1934-1940.	1.6	2
1575	Exercise training during childhood and adolescence is associated with favorable diastolic function in hypertrophic cardiomyopathy. International Journal of Cardiology, 2022, 364, 65-71.	1.7	8

#	Article	IF	Citations
1577	Hypertrophic Cardiomyopathy in the Elderly: A Case Identified With Genetic Screening. Journal of Investigative Medicine High Impact Case Reports, 2022, 10, 232470962211092.	0.6	0
1579	Molecular Diagnosis of Primary Cardiomyopathy in 231 Unrelated Pediatric Cases by Panel-Based Next-Generation Sequencing: A Major Focus on Five Carriers of Biallelic TNNI3 Pathogenic Variants. Molecular Diagnosis and Therapy, 2022, 26, 551-560.	3.8	4
1580	Coexistent Diabetes Is Associated With the Presence of Adverse Phenotypic Features in Patients With Hypertrophic Cardiomyopathy. Diabetes Care, 0, , .	8.6	4
1581	Mavacamten: First Approval. Drugs, 2022, 82, 1127-1135.	10.9	32
1582	The effect of Mg²⁺ on Ca²⁺ binding to cardiac troponin C in hypertrophic cardiomyopathy associated <scp>TNNC1</scp> variants. FEBS Journal, 2022, 289, 7446-7465.	4.7	4
1583	Homozygous Pro1066Arg MYBPC3 Pathogenic Variant in a 26Mb Region of Homozygosity Associated with Severe Hypertrophic Cardiomyopathy in a Patient of an Apparent Non-Consanguineous Family. Life, 2022, 12, 1035.	2.4	1
1584	The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathyâ€"A systematic review and metaâ€analysis. Journal of Genetic Counseling, 2022, 31, 1290-1305.	1.6	5
1585	Could echocardiographic left atrial characterization have additive value for detecting risks of atrial arrhythmias and stroke in patients with hypertrophic cardiomyopathy?. European Heart Journal Cardiovascular Imaging, 0, , .	1.2	4
1586	Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review. Revista Portuguesa De Cardiologia, 2022, 41, 693-703.	0.5	3
1587	Double heterozygosity for mutations in the Î²-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. Journal of Medical Genetics, 1999, 36, 542-545.	3.2	54
1588	Resonancia magnÃ©tica cardÃaca en la miocardiopatÃa hipertrÃ³ficaca: un paso mÃ¡s allÃ¡ del diagnÃ³stico. Revista De EcocardiografÃa PrÃ¡ctica Y Otras TÃ©cnicas De Imagen CardÃaca, 2016, , 11-18.	0.0	0
1589	Identification of key genes for hypertrophic cardiomyopathy using integrated network analysis of differential lncRNA and gene expression. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	7
1590	Transcriptome Profile Identifies Actin as an Essential Regulator of Cardiac Myosin Binding Protein C3 Hypertrophic Cardiomyopathy in a Zebrafish Model. International Journal of Molecular Sciences, 2022, 23, 8840.	4.1	1
1591	Clinical significance of genetic variation in hypertrophic cardiomyopathy: comparison of computational tools to prioritize missense variants. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
1592	Transcriptional bursts and heterogeneity among cardiomyocytes in hypertrophic cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2
1593	A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants. JACC Basic To Translational Science, 2022, 7, 763-775.	4.1	14
1594	Cardiovascular causes of complex breathlessness. , 2022, , 153-172.		0
1595	MicroRNA targeted therapy in cardiovascular disease. , 2022, , 521-547.		0

#	Article	IF	Citations
1596	Circular RNAs: New Players in Cardiomyopathy. Genes, 2022, 13, 1537.	2.4	2
1597	The initial experience of left bundle branch area pacing in patients with hypertrophic cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 1065-1074.	1.2	8
1598	Interactions Between Body Mass Index and Glomerular Filtration Rate Increase the Identification Ability of Obstructive Sleep Apnea in Patients with Hypertrophic Cardiomyopathy. Nature and Science of Sleep, 0, Volume 14, 1699-1708.	2.7	0
1599	Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. Archives of Cardiovascular Diseases, 2022, 115, 529-537.	1.6	11
1600	Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	0
1601	Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: A nationwide medical claims database study. Journal of Cardiology, 2023, 81, 316-322.	1.9	1
1602	RNAâ€seq profiling reveals different pathways between remodelled vessels and myocardium in Hypertrophic Cardiomyopathy. Microcirculation, 0, , .	1.8	2
1603	Current therapies for hypertrophic cardiomyopathy: a systematic review and metaâ€analysis of the literature. ESC Heart Failure, 0, , .	3.1	2
1604	School-Based Cardiovascular Screening and Sudden Cardiac Deaths: Emphasis on Arrhythmias Associated with Hypertrophic Cardiomyopathy. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2021, 37, 255-264.	0.0	0
1605	Hypertrophic Cardiomyopathy and Pregnancy: A Retrospective Analysis From a Tertiary Care Hospital. Texas Heart Institute Journal, 2022, 49, .	0.3	1
1606	Different mechanisms of mitral regurgitation in hypertrophic cardiomyopathy: A clinical case and literature review. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2
1608	Tandem deep learning and logistic regression models to optimize hypertrophic cardiomyopathy detection in routine clinical practice. Cardiovascular Digital Health Journal, 2022, 3, 289-296.	1.3	1
1609	Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR). Acta Cardiologica, 2022, 77, 836-845.	0.9	6
1610	Myocardial mechanics of percutaneous intramyocardial septal radiofrequency ablation. Heart, 2023, 109, 289-296.	2.9	5
1611	Genetics of familial cardiomyopathies and arrhythmias. Swiss Medical Weekly, 0, , .	1.6	5
1612	Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211360.	2.5	1
1613	Liquidâ€“liquid phase separation, membrane-less organelles, and biomolecular condensates in cardiovascular disease. , 2023, , 663-679.		0
1614	Circulating Biomarkers in Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2022, 11, .	3.7	16

#	Article	IF	Citations
1615	Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China. Scientific Reports, 2022, 12, .	3.3	13
1617	First-in-man application of Liwen RFâ„¢ ablation system in the treatment of drug-resistant hypertrophic obstructive cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2
1618	Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy. Hellenic Journal of Cardiology, 2023, 70, 65-74.	1.0	3
1619	Hypertrophic Obstructive Cardiomyopathy with SAM Phenomenon: A Case Report and Literature Review. Cardiology and Cardiovascular Medicine, 2022, 06, .	0.2	0
1620	Quality of life and societal costs in hypertrophic cardiomyopathy: protocol of the AFFECT-HCM study. Netherlands Heart Journal, 0, , .	0.8	2
1621	Diastolic dysfunction assessed by cardiac magnetic resonance imaging tissue tracking on normal-thickness wall segments in hypertrophic cardiomyopathy. BMC Medical Imaging, 2023, 23, .	2.7	1
1622	Molecular Diagnosis of Hypertrophic Cardiomyopathy (HCM): In the Heart of Cardiac Disease. Journal of Clinical Medicine, 2023, 12, 225.	2.4	6
1623	A Case Report on the Atypical Presentation of Hypertrophic Cardiomyopathy (HOCM) in a 19-Year-Old Female. Cureus, 2022, , .	0.5	0
1624	A Cardiac Magnetic Resonance Study: Comparison of Biventricular Longitudinal Function in Hypertrophic Cardiomyopathy Patients and Normal Individuals. Cureus, 2023, , .	0.5	0
1625	Diretriz Brasileira de Dispositivos CardÃacos EletrÃ´nicos ImplantÃ¡veis â€“ 2023. Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.8	1
1626	A novel Loss-of-function Mutation in MYBPC3 Causes familial hypertrophic cardiomyopathy with extreme intrafamilial phenotypic heterogeneity. Balkan Journal of Medical Genetics, 2023, 25, 71-78.	0.5	0
1627	Left Bundle Branch Pacing for Bradycardia in Non-obstructive Hypertrophic Cardiomyopathy Patients: Feasibility, Safety, and Effect. Cardiovascular Drugs and Therapy, 0, , .	2.6	0
1628	Familial Hypertrophic Cardiomyopathy: Diagnosis and Management. Vascular Health and Risk Management, 0, Volume 19, 211-221.	2.3	4
1629	DNA methylome and transcriptome profiling reveal key electrophysiology and immune dysregulation in hypertrophic cardiomyopathy. Epigenetics, 2023, 18, .	2.7	2
1630	Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective. Journal of Clinical Medicine, 2023, 12, 2810.	2.4	6
1632	Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. American Journal of Cardiology, 2023, 192, 16-23.	1.6	2
1633	Hypertrophic cardiomyopathy is associated with dilated sinus of Valsalva: A case-control study. IJC Heart and Vasculature, 2023, 45, 101180.	1.1	0
1634	Prevalence, characteristics, and natural history of apical phenotype in a large cohort of patients with hypertrophic cardiomyopathy. Hellenic Journal of Cardiology, 2023, 73, 8-15.	1.0	1

#	Article	IF	Citations
1635	Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2023, 63, .	1.4	4
1636	Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers. International Journal of Molecular Sciences, 2023, 24, 3881.	4.1	0
1637	Genetic analysis of patients with hypertrophic cardiomyopathy. Genes and Cells, 2020, 15, 68-73.	0.2	6
1638	Prevalence and Clinical Burden of Idiopathic Dilated Cardiomyopathy in the United States. , 2023, 10, 100038.		1
1639	Novel filamin C (FLNC) variant causes a severe form of familial mixed <scp>hypertrophicâ€restrictive</scp> cardiomyopathy. American Journal of Medical Genetics, Part A, 2023, 191, 1508-1517.	1.2	2
1640	Biomechanical Impact of Pathogenic MYBPC3 Truncation Variant Revealed by Dynamically Tuning In Vitro Afterload. Journal of Cardiovascular Translational Research, 2023, 16, 828-841.	2.4	1
1641	Feline myocardial transcriptome in health and in hypertrophic cardiomyopathyâ€"A translational animal model for human disease. PLoS ONE, 2023, 18, e0283244.	2.5	1
1642	Sport and exercise in genotype positive (+) phenotype negative (â˜) individuals: current dilemmas and future perspectives. European Journal of Preventive Cardiology, 2023, 30, 871-883.	1.8	4
1645	Identification of circRNA-miRNA-mRNA regulatory network and its role in cardiac hypertrophy. PLoS ONE, 2023, 18, e0279638.	2.5	3
1646	Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain. Genes, 2023, 14, 840.	2.4	1
1647	How common is hypertrophic cardiomyopathyâ€¦ really?: Disease prevalence revisited 27Âyears after CARDIA. International Journal of Cardiology, 2023, 382, 64-67.	1.7	7
1648	Novel insights on GTPBP3â€associated hypertrophic cardiomyopathy. American Journal of Medical Genetics, Part A, 2023, 191, 1804-1813.	1.2	1
1649	A convolutional attention mapping deep neural network for classification and localization of cardiomegaly on chest X-rays. Scientific Reports, 2023, 13, .	3.3	5
1650	Prevalence of different echocardiographic abnormalities in a large Turkish workers population. Echocardiography, 2023, 40, 408-416.	0.9	0
1651	MYH7 in cardiomyopathy and skeletal muscle myopathy. Molecular and Cellular Biochemistry, 2024, 479, 393-417.	3.1	4
1652	Diagnosis and Treatment of Obstructive Hypertrophic Cardiomyopathy. Neurology International, 2023, 13, 75-91.	0.5	2
1653	mAKAPÎ² signalosome: A potential target for cardiac hypertrophy. Drug Development Research, 2023, 84, 1072-1084.	2.9	0
1654	Aborted sudden cardiac death and a severe form of hypertrophic cardiomyopathy in a 2-year-old. Cardiology in the Young, 0, , 1-4.	0.8	0

#	Article	IF	Citations
1657	Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. Journal of Medical Economics, 2023, 26, 682-690.	2.1	2
1659	Transcriptome data analysis of primary cardiomyopathies reveals perturbations in arachidonic acid metabolism. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
1660	Cardiomyopathy-associated variants alter the structure and function of the Î±-actinin-2 actin-binding domain. Biochemical and Biophysical Research Communications, 2023, 670, 12-18.	2.1	1
1661	Clinical Significance of Physical Examination for Hypertrophic Cardiomyopathy. Circulation Journal, 2023, 87, 1068-1074.	1.6	1
1662	Cardiac imaging and biomarkers for assessing myocardial fibrosis in children with hypertrophic cardiomyopathy. American Heart Journal, 2023, 264, 153-162.	2.7	2
1663	A Pharmacologic Update. Nursing Clinics of North America, 2023, , .	1.5	0
1664	Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management. Annals of Pharmacotherapy, 2024, 58, 273-285.	1.9	0
1665	Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan. Cardiac Electrophysiology Clinics, 2023, , .	1.7	0
1666	Magnetic resonance myocardial T1Ï•mapping. Journal of Cardiovascular Magnetic Resonance, 2023, 25, .	3.3	6
1667	Should young athletes be screened for cardiomyopathies to reduce the burden of sudden cardiac death in athletes?. Biophysical Reviews, 2023, 15, 321-327.	3.2	0
1668	Hypertrophic cardiomyopathy in an adult patient with Noonan syndrome with multiple lentigines. Clinical Case Reports (discontinued), 2023, 11, .	0.5	0
1669	Beneficial effects of exercise initiated before development of hypertrophic cardiomyopathy in genotype-positive mice. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 324, H881-H892.	3.2	0
1670	Prognostic value of left ventricular global longitudinal strain in patients with hypertrophic cardiomyopathy. Actual Problems of Modern Medicine, 2022, , 39-49.	0.1	0
1671	Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy: Volume Still Matters for Septal Myectomy. Journal of the American Heart Association, 2023, 12, .	3.7	0
1672	Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy. Heart International, 2023, 17, 2.	1.4	0
1674	Cardiac Myosin Inhibitors for ManagingÂObstructive HypertrophicÂCardiomyopathy. JACC: Heart Failure, 2023, 11, 735-748.	4.1	1
1675	The Role of Personalized Medicine in Companion Animal Cardiology. Veterinary Clinics of North America - Small Animal Practice, 2023, , .	1.5	0
1676	Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy. European Heart Journal, 2023, 44, 5146-5158.	2.2	4

#	Article	IF	Citations
1677	Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions. Journal of Clinical Medicine, 2023, 12, 4706.	2.4	0
1678	Advanced searching for hypertrophic cardiomyopathy heritability in real practice tomorrow. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
1679	Identification and analysis of key hypoxia- and immune-related genes in hypertrophic cardiomyopathy. Biological Research, 2023, 56, .	3.4	1
1680	Cardiomyopathy in Asian Cohorts: Genetic and Epigenetic Insights. Circulation Genomic and Precision Medicine, 2023, 16, 496-506.	3.6	0
1682	2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal, 2023, 44, 3503-3626.	2.2	177
1683	Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction. JAMA Cardiology, 2023, 8, 968.	6.1	10
1684	Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement. International Journal of Molecular Sciences, 2023, 24, 13239.	4.1	1
1685	Historical and modern aspects of surgical treatment of hypertrophic cardiomyopathy in children (literature review). Sibirskij Â¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 0, , .	0.4	0
1686	Invasive therapies for symptomatic obstructive hypertrophic cardiomyopathy. Progress in Cardiovascular Diseases, 2023, , .	3.1	0
1687	The penetrance of rare variants in cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for secondary findings. American Journal of Human Genetics, 2023, 110, 1482-1495.	6.2	1
1688	Left ventricular global longitudinal strain as a prognosticator in hypertrophic cardiomyopathy with a low-normal left ventricular ejection fraction. European Heart Journal Cardiovascular Imaging, 2023, 24, 1374-1383.	1.2	0
1689	Energetics of Cardiac Blood Flow in Hypertrophic Cardiomyopathy through Individualized Computational Modeling. Journal of Cardiovascular Development and Disease, 2023, 10, 411.	1.6	0
1690	Exercise and Sports Participation in Children with Cardiomyopathy: A Review. Current Treatment Options in Cardiovascular Medicine, 2023, 25, 543-559.	0.9	0
1691	Accurate Classification of Non-ischemic Cardiomyopathy. Current Cardiology Reports, 0, , .	2.9	1
1692	Medical therapies for hypertrophic cardiomyopathy: Current state of the art. Progress in Cardiovascular Diseases, 2023, 80, 32-37.	3.1	1
1693	Novel Mutation Glu98Lys in Cardiac Tropomyosin Alters Its Structure and Impairs Myocardial Relaxation. International Journal of Molecular Sciences, 2023, 24, 12359.	4.1	0
1694	Major Cardiac Events in Patients andÂRelatives With Hereditary HypertrophicÂCardiomyopathy. , 2023, 2, 100604.		0
1695	Association of duration and intensity of exercise with phenotypic expression in hypertrophic cardiomyopathy. International Journal of Cardiology, 2023, 392, 131253.	1.7	0

#	Article	IF	Citations
1696	Multimodality Imaging in Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation. Diagnostics, 2023, 13, 3049.	2.6	0
1697	Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents. Expert Opinion on Investigational Drugs, 2023, 32, 849-853.	4.1	0
1698	ECG Abnormalities Preceding Structural Changes of Apical Hypertrophic Cardiomyopathy by up to 10 Years. Cureus, 2023, , .	0.5	0
1699	The evolving paradigm and current perception of hypertrophic cardiomyopathy: Implications for management. Progress in Cardiovascular Diseases, 2023, 80, 8-13.	3.1	1
1700	Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study. Frontiers in Pharmacology, 0, 14, .	3.5	1
1701	Prevalence and Risk Factors of Cardiovascular Diseases among the Nigerian Population: A New Trend among Adolescents and Youths. , 0, , .		1
1702	Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. European Heart Journal, 2023, 44, 4622-4633.	2.2	4
1703	Electrocardiographic Findings in Genotype-Positive and Non-sarcomeric Children with Definite Hypertrophic Cardiomyopathy and Subclinical Variant Carriers. Pediatric Cardiology, 0, , .	1.3	0
1704	Inherited Cardiomyopathies. , 2023, , 251-272.		0
1705	ERRÎ³ agonist under mechanical stretching manifests hypertrophic cardiomyopathy phenotypes of engineered cardiac tissue through maturation. Stem Cell Reports, 2023, 18, 2108-2122.	4.8	2
1706	Should We Be Looking at the Forest or the Trees? Postoperative Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2023, 39, 1938-1940.	1.7	1
1707	Gender-Based Outcome Discrepancies in Patients Who Underwent Alcohol Septal Ablation or Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy: A Systematic Review andÂMeta-Analysis. American Journal of Cardiology, 2023, 208, 134-142.	1.6	1
1708	Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Nonâ€“Î²-Blocking R-Enantiomer Carvedilol. Circulation, 0, , .	1.6	0
1709	Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2023, 12, 6628.	2.4	0
1710	Reversed Septal Curvature Is Associated With Nonsustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2024, 210, 195-200.	1.6	1
1711	Hypertrophic Cardiomyopathy in Underrepresented Populations: Clinical and Genetic Landscape Based on a Russian Single-Center Cohort Study. Genes, 2023, 14, 2042.	2.4	0
1712	Therapeutic Approaches Targeting Ferroptosis in Cardiomyopathy. Cardiovascular Drugs and Therapy, 0, , .	2.6	0
1713	The Autosomal Short Tandem Repeat Polymorphisms Are Potentially Associated with Cardiovascular Disease Predisposition in the Latin American Population: A Mini Review. BioMed Research International, 2023, 2023, 1-9.	1.9	0

#	Article	IF	Citations
1714	Lack of Evidence for the Role of the p.(Ser96Ala) Polymorphism in Histidine-Rich Calcium Binding Protein as a Secondary Hit in Cardiomyopathies. International Journal of Molecular Sciences, 2023, 24, 15931.	4.1	0
1715	Complications of Implantable Cardioverter Defibrillator and Their Potential Risk Factors in Patients with Hypertrophic Cardiomyopathy. Cardiology Research and Practice, 2023, 2023, 1-7.	1.1	0
1716	Screening UFMylation-associated genes in heart tissues of Ufm1-transgenic mice. BMC Cardiovascular Disorders, 2023, 23, .	1.7	0
1717	Case Report: Integrated echocardiographic assessment guided Liwen procedure for treating obstructive hypertrophic cardiomyopathy with ventricular aneurysm. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
1719	Perioperative outcomes of hypertrophic cardiomyopathy: An insight from the National Readmission Database. International Journal of Cardiology, 2024, 398, 131601.	1.7	0
1720	Validation of the HCM Riskâ€SCD model in patients with hypertrophic cardiomyopathy and future perspectives. PACE - Pacing and Clinical Electrophysiology, 2023, 46, 1519-1525.	1.2	0
1721	Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling. , 2023, 6, 100056.		1
1722	Effect of beta-blockers and exercise restriction on the prevention of sudden cardiac death in pediatric hypertrophic cardiomyopathy. Journal of Cardiology, 2023, , .	1.9	1
1723	History of diagnosis and treatment of hypertrophic cardiomyopathy. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2023, 16, 634.	0.3	0
1724	Model for classification of heart failure severity in patients with hypertrophic cardiomyopathy using a deep neural network algorithm with a 12-lead electrocardiogram. Open Heart, 2023, 10, e002414.	2.3	0
1725	Athlete Screening and Sudden Cardiac Death. Pediatrics in Review, 2023, 44, 669-681.	0.4	0
1726	Transapical beating-heart septal myectomy for hypertrophic cardiomyopathy with latent obstruction. European Journal of Cardio-thoracic Surgery, 0, , .	1.4	0
1727	The Neonatal QRS Complex and Its Association with Left Ventricular Mass. Pediatric Cardiology, 2024, 45, 248-256.	1.3	0
1728	Septal Perforator Artery Doppler Flow in Hypertrophic Cardiomyopathy: Searching for Clinical Applicability. Journal of the American Society of Echocardiography, 2024, 37, 352-355.	2.8	0
1729	Hypertrophic cardiomyopathy in MYBPC3 carriers in aging. , 0, 4, .		0
1730	A 3D-0D Computational Model of the Left Ventricle for Investigating Blood Flow Patterns for Cases of Systolic Anterior Motion and after Anterior Mitral Leaflet Splitting. Applied Sciences (Switzerland), 2024, 14, 466.	2.5	0
1731	Morphological and Genetic Aspects for Post-Mortem Diagnosis of Hypertrophic Cardiomyopathy: A Systematic Review. International Journal of Molecular Sciences, 2024, 25, 1275.	4.1	1
1732	The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation. Thrombosis Journal, 2024, 22, .	2.1	0

#	Article	IF	Citations
1733	Electrocardiographic and genetic characteristics in first degree relatives of hypertrophic cardiomyopathy probands: A descriptive cross-sectional study from Vietnam. JRSM Cardiovascular Disease, 2024, 13, .	0.7	0
1734	Clinical to Population Prevalence of Hypertrophic Cardiomyopathy Phenotype: Insights From the National Echo Database Australia. Heart Lung and Circulation, 2024, 33, 212-221.	0.4	0
1735	ECG changes and their prognostic value for the development of sudden cardiac death in HCM patients. Emergency Medicine, 2023, 19, 537-546.	0.2	0
1736	Hypertrophic Cardiomyopathy with Rheumatic Mitral Stenosis: A Rare Association of an Inherited Cardiomyopathy with Acquired Heart Disease. Journal of Clinical and Preventive Cardiology, 2023, 12, 124-126.	0.1	0
1737	Beating-Heart Septal Myectomy. JACC Asia, 2024, 4, 166-168.	1.5	0
1738	The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2024, , .	1.7	1
1739	Current RNA strategies in treating cardiovascular diseases. Molecular Therapy, 2024, 32, 580-608.	8.2	0
1740	Medical Treatment Strategies for Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2024, 212, S33-S41.	1.6	0
1741	Heart-on-a-chip systems: disease modeling and drug screening applications. Lab on A Chip, 2024, 24, 1494-1528.	6.0	0
1742	Re-evaluating the Incidence and Prevalence of Clinical Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2024, 99, 362-374.	3.0	1
1743	Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center. Progress in Cardiovascular Diseases, 2024, , .	3.1	0
1744	Trends of hypertrophic cardiomyopathy-related mortality in United States young adults: a nationwide 20-year analysis. Journal of Cardiovascular Medicine, 2024, 25, 303-310.	1.5	0
1745	Homologous mutations in human Î², embryonic, and perinatal muscle myosins have divergent effects on molecular power generation. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.1	0
1746	Longâ€term postâ€transplantation outcomes in patients with hypertrophic cardiomyopathy: Singleâ€center 35â€year experience. Clinical Transplantation, 2024, 38, .	1.6	0
1747	The Majority of Participants With Suspected Hypertrophic Cardiomyopathy Documented During Screening Echocardiography Have a Normal Electrocardiogram. Critical Pathways in Cardiology, 2024, 23, 20-25.	0.5	0
1748	Comparative Evaluation of Alcohol Septal Ablation: Left Anterior Descending Versus Non-left Anterior Descending Artery Approaches. American Journal of Cardiology, 2024, 216, 54-62.	1.6	0
1749	Heart Failure and Hypertrophic Cardiomyopathyâ€"Looking Back on Decades of Remarkable Progress. Mayo Clinic Proceedings, 2024, 99, 352-354.	3.0	0
1750	Circular RNAs: Biogenesis, Functions, and Role in Myocardial Hypertrophy. Biochemistry (Moscow), 2024, 89, S1-S13.	1.5	0

#	Article	IF	Citations
1751	Is there still a place for disopyramide in the management of obstructive hypertrophic cardiomyopathy?. CJC Open, 2024, , .	1.5	0
1752	The role of fibrosis in cardiomyopathies: An opportunity to develop novel biomarkers of disease activity. Matrix Biology, 2024, 128, 65-78.	3.6	0